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ABSTRACT
Background
Radial artery spasm is the most common cause of patient discomfort and reduces 
the procedural success rates during transradial coronary artery procedures. The 
impact of transradial procedures on the vascular function of the radial artery is 
unknown.
Hypothesis
Hydrophilic coating of the introducer sheath will reduce radial artery spasm and 
the TR Band compression device will reduce patient discomfort and time taken 
to achieve haemostasis. Transradial procedures cause impairment of vascular 
function.
Methods
790 patients were randomly assigned in a factorial design to receive long (23 cm) 
hydrophilic, long uncoated, short (13 cm) hydrophilic and short uncoated 
introducer sheaths during transradial procedures. The primary end point was 
radial artery spasm and secondary end points were patient’s discomfort and local 
vascular complications. Similarly, patients were randomly assigned to receive 
either TR band or Radistop and the outcome measures evaluated were patient 
tolerance of the device, local vascular complications and the time taken to 
achieve haemostasis. Radial artery endothelium-dependent and endothelium- 
independent functions were assessed in 35 patients.
Results
Procedural success was achieved in 96% of the cases and radial artery spasm 
accounted for 2.2% of failed cases. There was significantly less radial artery 
spasm observed and patient-reported discomfort in patients receiving a 
hydrophilic coated sheath. No difference was observed between long and short 
sheaths. Radial artery occlusion was observed in 9.5% of the patients and was 
not influenced by sheath length or coating. Younger age, female sex, diabetes, 
and lower body mass index were identified as independent predictors of clinical 
radial artery spasm. Patients in the Radistop group reported significantly more 
pain across all categories of severity and time taken to achieve haemostasis was 
significantly longer in the TR Band group. Endothelium dependent dilatation in 
the catheterized ami decreased significantly in the coated and uncoated groups, 
respectively. These values returned towards baseline levels 3 months later. GTN 
induced vasodilatation decreased significantly in both groups. Values returned to 
baseline at 3months.
Conclusions
Hydrophilic coating of the introducer sheath reduces the incidence of radial 
artery spasm. Sheath length did not influence this effect. Both TR Band and 
Radistop devices are safe and effective as haemostatic compression devices 
following transradial procedures. However, more patients felt discomfort with 
the Radistop device and the time taken to achieve haemostasis was longer with 
the TR band. Placement of a catheter sheath inside the radial artery dismpts 
endothelium-dependent and independent vasodilator function, which largely 
recovers after 3 months. No differences were evident between hydrophilic-coated 
and uncoated sheaths or long and short sheaths.
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Chapter 1 Introduction
1.1 General Introduction
The transradial approach for coronary angiography was first described by 
Campeau in 1989(1) and the technique was extended to percutaneous 
transluminal coronary angioplasty and stenting by Kiemeneij and Laarman (2). 
Since then a widespread proliferation of coronaiy procedures via the radial artery 
has taken place (3-8).
The safety of the radial approach, compared to the conventional femoral 
approach for coronary procedures, is mainly due to favourable anatomic relations 
of the radial artery. No major veins or nerves are located near the radial artery at 
the wrist, minimising the chance of neurological or vascular injury. Haemostasis 
is easily achieved because of the superficial course of the radial artery. 
Thrombotic or traumatic radial arterial occlusion does not endanger the viability 
of the hand if an adequate collateral blood supply from the ulnar artery is present.
A meta-analysis by Hamon et al. (9) of twelve randomised trials, 
including 3,224 patients, comparing radial and femoral approaches for coronaiy 
procedures has shown similar major adverse cardiac events with radial and 
femoral approach (2.1% vs. 2.4%). However, radial access was associated with a 
significantly lower rate of entry site complications (0.3% vs. 2.8%). There was 
higher rate of procedural failure with radial approach in the earlier studies but 
there was the trend towards equalization of the rate of procedural success over 
the years.
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Figure 1-1 Annual increase in coronary catheterisation procedures 
performed via the radial artery in the United Kingdom from 2004-2008.
/-------------
28.1
10.2
15.7
21.3
The proportion of coronary procedures being performed via a radial approach in 
the United Kingdom have been steadily increasing and about one third of the 
total number of cases were performed via a radial approach in the United 
Kingdom in the year 2008 (British Cardiovascular Intervention Audit 2008) 
(Figure 1.1). This percentage ranges from 10% to 90% of the total procedures 
performed via radial approach at each centre (Figure 1.2). The radial approach is 
used at similar rates in various clinical syndromes (Figure 1.3).
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Figure 1-2 Rates of cases performed via a transradial approach at 
individual centres across the United Kingdom from 2006-2008.
Figure 1-3 Rates of coronary catheterisation cases performed via 
transradial access by different clinical settings in United Kingdom during 
year 2008
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Failure to complete the procedure via the radial approach occurs for several 
reasons: firstly, there may be failure to successfully puncture and camiulate the 
radial artery because of the small size of the vessel, a tortuous course, or radial 
artery spasm. Secondly, it may be difficult to intubate the coronary ostia due to 
difficulty in manipulating the catheter due to radial artery spasm or excessive 
tortuousity of the vasculature. Thirdly, the procedure may fail because of 
inadequate catheter support, 
hi this introductory chapter I aim to:
1) Provide an overview of literature on the various problems encountered during 
transradial coronary procedures, and their impact on the procedural success and 
complications.
2) Outline our current understanding of the factors playing role in the 
pathogenesis of radial artery spasm, and local vascular complications.
3) Review the studies to date that have examined various mechanistic and 
pharmacological approaches to ameliorate the incidences of radial artery spasm, 
and local vascular complications
4) Outline the studies and methods evaluating the vascular function 
(endothelium-dependent and endothelium-independent) of the radial artery, and 
the impact of transradial catheterisation.
1.2 Radial artery spasm
1.2.1 Mechanisms and incidence of radial artery spasm
Much of the discomfort and difficulty of transradial procedures is related to 
vasospasm induced by the introduction of a sheath or catheter into the radial
16
artery (11, 12, and 13). Circulating levels of catecholamine play a role in radial 
artery spasm (147); therefore local anaesthesia and adequate sedation to control 
anxiety should reduce circulating catecholamines during catheter insertion and 
may be important preventative measures. The incidence of radial artery spasm 
has been reported to be around 10-20%, and in about 2-5% of the patients this 
prevents the successful completion of the procedure by the radial route (11, 12, 
and 13). Radial artery spasm has been mainly defined in the literature as patient 
discomfort encountered during manipulation of the arterial sheath or catheter in 
the radial artery and can be associated with considerable difficulty in moving the 
sheath or catheter. This friction is mainly due to mismatch between the outer 
diameter of the radial sheath or catheter and the inner diameter of the radial 
artery.
This mismatch can occur because of a smaller radial artery diameter compared to 
the radial sheath size or due to radial artery spasm reducing the effective 
diameter. There are several other factors that can also play a role in this 
mismatch, such as fixed atherosclerotic lesions, vessel tortuousity and entry into 
the smaller aberrant arteries.
The occurrence of radial artery spasm during transradial coronary procedure 
could play a role in patient’s and/or physician’s preference when choosing 
between the transradial and the transfemoral approach.
1.2.2 Measurement of radial artery spasm
In clinical practice, radial artery spasm is mainly described as increased 
resistance during manipulation of the intra-arterial equipment and may or may 
not be associated with the patient complaining of pain in the forearm.
17
Researchers have used combination of operator’s and patient’s questionnaires to 
measure the extent of radial artery spasm. There have also been attempts to 
quantify the radial artery spasm objectively by the use of an automatic pull-back 
device for removal of the arterial sheath (14). This device consists of a motorized 
trolley that railroad over a fixed platform. The trolley houses a digital force 
gauge and a controller unit, which are connected to personal computer for system 
control and data collection. The controller unit guides the movement of the 
trolley according to the commands set by the operator and the digital force gauge 
makes multiple instantaneous recordings during the pull-back. With the use of 
this device researchers have shown in 50 consecutive patients a mean maximal 
pull-back force of 0.53±0.52 kgf (range 0.1 to 3.0 kgf). In 48 patients the 
maximal pull-back force was reached within the first five seconds of the pull­
back. All patients with clinical radial artery spasm, as assessed by a combination 
of operator’s and patient’s questionnaires and defined as pain perceived by the 
patient and/or difficulty perceived by the operator during sheath insertion, 
removal or catheter manipulation, had a maximum pull-back force greater than 
1.0 kgf, while the remaining patients had a maximum pull-back force less than 
1.0 kgf. .
Thus there are quantitative and qualitative methods of assessing radial artery 
spasm during transradial procedures. However, the quantitative methods can 
only measure the spasm during sheath withdrawal, but this is not the clinical 
spasm that may prevent completion of the procedure. The clinical spasm during 
the procedure and the pull-back force needed to remove the sheath may be 
related. There is no recognised way of quantifying the spasm that grips the 
catheter and makes torsion difficult during the procedure. Therefore, there is a
18
need to use a qualitative definition of spasm for our study. A qualitative 
definition of spasm has been used widely by several researchers to assess the 
efficacy of different drugs and equipment used during transradial procedures, 
and their impact on radial artery spasm (12, 13, and 14).
1.2.3 The impact of vasodilator agents on radial artery spasm
It has been demonstrated, in isolated radial artery ring segments, that nitro­
glycerine and verapamil are effective agents in preventing arterial spasm (15). A 
study using the automatic pull back device has shown that an intra-arterial 
cocktail of verapamil and nitro-glycerine reduces the incidence of pain from 14% 
to 34%. The mean pull-back force was also significantly lower (0.53±0.52 kgf vs. 
0.76±0.45 kgf) compared to the patients not receiving any vasodilating drug (12). 
Clinically-impoitant radial artery spasm in this study was seen in 8% of patients 
receiving a spasmolytic cocktail compared with 22% in the control group 
(p=0.029).
Salmeron et al have shown, in a randomised controlled trial, that verapamil is 
more effective in preventing radial artery spasm than phentolamine (13). Both 
vasodilator agents induced a significant increase in radial artery diameter 
(2.22±0.53 to 2.48±0.57mm for verapamil and 2.20±0.53 to 2.45±0.53mm for 
phentolamine). However, verapamil was more effective in preventing radial 
artery spasm (13.2% vs. 23.2% in phentolamine treated patients), assessed 
qualitatively.
The SPASM study (16) group randomised patients to placebo, molsidomine, 
verapamil or a combination of both verapamil and molsidomine, administered 
via the radial sheath. They concluded that the incidence of radial artery spasm 
was lowest in patients receiving verapamil and molsidomine (4.9%), compared
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to verapamil 2.5mg or 5mg (8.3 and 7.9%), or molsidomine Img (13.3%) or 
placebo (22.2%, pO.OOOl). Jose Ronaldo et al (17) have also shown, in a 
randomised double blind trial of 50 patients, that the use of diltiazem as an 
adjunctive drug to isosorbide mononitrate, administered through the transradial 
sheath decreased the rate of vascular complications. The complications (spasm, 
occlusion and partial obstruction) occurred in four patients (17.4%) in the control 
group and did not occur in diltiazem group. They also demonstrated an increased 
radial artery diameter after 30 minutes in the diltiazem group. Coppola et al (18) 
have shown that the addition of nitroprusside to nitroglycerine did not further 
reduce the incidence of spasm. However, after multivariate analysis, the 
following variables were found to be independent predictors of radial artery 
spasm: radial artery diameter (RD)/height index, RD/body surface area (BSA) 
index, and sheath outer diameter (OD)/RD index. The sex of the patient, 
presence of diabetes, body surface area and smoking history did not play any 
role in predicting the occurrence of radial artery spasm.
Similarly, Chen et al (19) have shown the effectiveness of a heparin and 
nitroglycerine combination in preventing radial artery spasm. In this study there 
was no difference seen in the incidence of radial artery spasm between patients 
treated with heparin, nitroglycerine and verapamil and those treated with heparin 
and nitroglycerine only.
Recently, Kim et al (20) have shown the effectiveness of nicorandil in preventing 
radial artery spasm. In a randomised study comparing 4mg of nicorandil and 
200pg of nitroglycerine, the authors concluded that both agents induced 
significant radial artery vasodilatation. Nicorandil caused a significant increase 
in the mean radial artery diameter, compared to the cocktail, at the middle
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segment of the radial artery (0.32 mm+/- 0.23 mm for nicorandil and 0.24+/- 
0.15 mm for nitroglycerine, p<0.05). There was no significant difference in the 
rate of radial artery spasm, defined as discomfort during pull-back of the sheath 
(50.7% vs. 50.2%).
Fukuda et al (20) have examined the incidence of radial artery spasm by radial 
arteriography immediately after and five months after the procedure in 48 
patients. They quantified radial artery spasm by the degree of stenosis in the 
radial artery compared between the first (perfonned just after the transradial 
procedure) and the second arteriography (perfonned five months after the 
procedure using a transbrachial approach). The radial artery diameter soon after 
the transradial procedure may be small because of radial artery spasm, and the 
investigators compared the radial artery diameter with baseline radial artery 
diameter on arteriography few months after the procedure. In this study the 
authors defined more than 75% stenosis in the radial artery, 25-75% stenosis, 
and less than 25% stenosis as severe spasm, moderate spasm, and mild spasm, 
respectively. They concluded that some degree of radial spasm was seen in all 
patients with severe spasm seen in 50% of patients, moderate spasm in 23%, and 
mild spasm in 27% of patients. They also found a correlation between severe 
spasm and the diameter of the artery. The diameters of both the proximal and 
distal radial arteries in patients with severe spasm were significantly smaller than 
those with mild or moderate spasm (proximal site: severe group 2.39+0.70mm 
versus mild group 2.98±0.46mm, p<0.05, and moderate group 2.96±0.77mm, 
p<0.05, distal site: severe group 2.26±0.60mm versus mild group 2.73±0.47mm, 
p< 0.05, and moderate group 2.86+0.71mm, p<0.05). .
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1.2.4 The impact of the introducer sheath on radial artery 
spasm
There are several different types of transradial introducer sheaths available from 
various manufacturers. The introducer sheaths from each manufacturer differ in 
sheath design and physical properties of the sheath. The main variables are the 
length of the sheath, the material from which it is constructed and the presence or 
absence of a hydrophilic coating.
To remove an introducer sheath from the radial artery the operator must 
overcome the friction between the outer wall of the sheath and the inner radial 
artery wall and the friction between the outer wall of the sheath and the skin and 
the subcutaneous connective tissue. This latter effect is likely to be much smaller 
than the friction within the artery and can be ignored. The friction within the 
vessel depends on the ratio of the inner luminal diameter of the vessel and the 
outer diameter of the sheath and the tone of the arterial wall musculature (anxiety 
and repeated punctures increases the tone and spasm) at the time of the 
procedure. The force required to insert or remove the sheath also depends on the 
surface properties of the two surfaces (hydrophilic coating might reduce friction) 
and also the surface area of contact between the two surfaces (proportional to the 
length of sheath in contact with radial artery wall).
Therefore the potential advantage of a long sheath may be the free movement of 
the guide catheter and the guide wire in relation to the radial artery wall. This 
reduced mechanical stimulation of radial artery wall might be associated with 
less radial artery spasm and endothelial injury. However if spasm develops, it 
might be more difficult to retrieve a long sheath. The opposite may be true for 
the short length introducer sheath; they may be easier to retrieve in the event of 
spasm but could provide more substrate for the spasm because of mechanical
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stimulation of the arterial wall by guide catheters and wires. Similarly introducer 
sheaths coated with lubricious material could be easier to retrieve in the event of 
spasm because of reduced friction.
Saito et al (21) have tested in vitro the static friction resistance between the 
introducer sheath with and without a hydrophilic coating and also tested the 
durability of the lubricant. For this experiment the sheath introducers were fixed 
to a strain gauge, and a glass tube filled with water and plugged by silicon rubber 
was slowly removed. The static friction resistance between the sheath introducer 
and the silicon rubber plug was defined as the maximum force between the glass 
tube moved away from the sheath introducer. They also assessed the incidence of 
clinical radial artery spasm two groups, with and without hydrophilic coating of 
a 6F (outer diameter 2.6 mm), 16cm long sheath from Terumo, Japan. The 
hydrophilic coating caused a 70% decrease in the friction force in the in vitro 
model (1060±105 to 312±40 gram force, p= <0.0001). Dynamic friction 
resistance, measured during 200 repeated forward and backward movements of 
the sheath infroducers at a constant rate of 1,000 per minute, was highest in both 
groups at the beginning of the tests and was preserved during the tests. At all 
time points dining the tests, dynamic friction resistance was significantly lower 
in sheaths with hydrophilic coating. The easiness of sheath insertion into the 
radial artery was not different in either group. The positional stability of the 
sheath introducer was worse in the hydrophilic group (sheath easily moved 
during procedures in 70% cases in hydrophilic group as compared to 20% in 
control group, p=0.0242). The easiness of sheath removal was better in 
hydrophilic group (sheath were removed easily in 60% cases in hydrophilic 
group as compared to 20% in control group, p^0.00003). Radial artery spasm
23
occurred in one patient in the hydrophilic group and in four patients in the 
uncoated group (2.7 vs. 11%, p=0.15). They concluded that hydrophilic coating 
of the introducer sheath is useful during transradial procedures.
Jean Dery et al (22) have assessed the impact of hydrophilic coating in a 
randomised study of 90 patients. They used 6F, 19cm long hydrophilic coated 
sheaths or 6F, 21cm uncoated sheaths, both from Cook, hi. The researchers 
assessed the peak traction force by electronic traction gauge and quantification of 
pain at the time of removal of the introducer sheath. The mean±SD peak traction 
force at sheath removal was 265±167g and 865±318g in the coated and uncoated 
groups respectively (69% reduction, p<0.001). The mean maximal pain score 
was 0.6±1.2 and 4.8±2.9 in the coated and uncoated groups respectively (88% 
reduction, p<0.0001). They concluded that the use of a hydrophilic coated 
introducer sheath considerably reduces the traction force and pain experienced 
by the patient during sheath removal.
Keimeneij et al (23) also assessed the effects of hydrophilic coated sheaths on 
the incidence of the radial artery spasm. All patients received 6F 25cm long 
radial sheaths from Terumo and a vasodilator cocktail of heparin and 
nitroglycerine was used routinely. The automatic pullback device, as described 
previously (14), was used for sheath removal at the end of the procedure. Three 
patients in the coated group experienced discomfort during sheath removal 
compared to 12 patients in the uncoated group (7% vs. 27%, p=0.02). The 
maximal pull-back force was significantly lower in the coated group compared to 
the uncoated group (0.24±0.31 vs. 0.44±0.33 kgf, p=0.003). Similarly, the mean 
pullback force was significantly lower in the coated group (0.14±0.23 vs. 
0.32±0.24 kgf; p<0.001). They concluded that removal of the coated Terumo
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transradial sheath required less traction force than an identical uncoated sheath. 
The coated sheath was also associated with less discomfort for the patient.
Koga et al (24) assessed the impact of hydrophilic coated catheters on the 
incidence of radial artery spasm during transradial procedures. They concluded 
that there was a reduced incidence of radial artery spasm with the use of the 
hydrophilic coated catheters (1% vs. 11%, p=0.007).
Therefore, there are a small number of studies investigating the effect of 
hydrophilic coating on the introducer sheath in patients undergoing transradial 
coronary procedures. The available data suggests the usefulness of the 
hydrophilic coated sheaths. However, these studies are small; some of them are 
non-randomised and had routine use of vasodilator cocktail during the procedure. 
Therefore it is very difficult to assess the true impact of hydrophilic coating on 
the incidence of radial artery spasm as concomitant vasodilator use might mask 
or exaggerate the true effect of coating on the introducer sheath. There is a lack 
of data in the literature comparing the effect of different lengths of introducer 
sheath and the impact on the incidence of radial artery spasm during transradial 
coronary procedures.
1.2.5 The potential effects of radial artery spasm on other 
complications
The above studies have shown that radial artery spasm can cause discomfort to 
the patient and difficulty in retrieving the sheath at the end of the procedure. 
Spasm occurring during the procedure could cause increased friction between the 
sheath and the inner lining of the radial artery, resulting in damage to the 
endothelial lining of the radial artery. This interaction could result in the
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sustained endothelial damage and be a precursor for thrombus formation. 
Potentially, this can increase the incidence of non-occlusive and occlusive radial 
artery injury. This is a hypothesis and, although there is no proof of this, there is 
some evidence to support a link between vasospasm and subsequent neointimal 
hyperplasia, hi the coronary vasculature there is limited data supporting a 
relationship between vasospasm and neointimal hyperplasia (25, 26). Suzuki et 
al (25) have found high incidence (in 68% patients) of neointimal hyperplasia, 
thrombus formation and intimal haemorrhage at the site of spasm from coronary 
atherectomy samples. They concluded that coronary vasospasm may provoke 
vascular injury that leads to the formation of neointima in these patients similar 
to that seen with restenosis after transluminal intervention.
1.3 Radial artery occlusion
Although radial artery occlusion was a major concern of the early transradial 
operators, the consequences of the radial artery occlusion are usually benign. The 
dual arterial supply to the hand appears robust and the avoidance of ischaemic 
complications was promoted by the original recommendation by Kiemeneij that 
transradial procedures be perfonned only in patients with a documented patent 
ulnar artery and palmar arch. This has traditionally been evaluated using Allen’s 
test, but ultrasound Doppler and plethysmography prior to the procedure are 
more accurate (27).
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1.3.1 The incidence of radial artery occlusion
Several factors influence the incidence of radial artery occlusion following 
transradial catheterisation. Consistent factors which influence the frequency of 
radial artery occlusion include radial artery size at baseline, radial sheath to 
artery ratio, duration of the sheath placement, prior procedures, and the presence 
of diabetes mellitus (28, 29, 30, 13, 14, and 15).
Bedford and Wollman (31) found a 25% rate of radial artery occlusion after a 
relatively short period of radial artery cannulation (less than 20 hours), as 
opposed to a 50% rate of radial artery occlusion in cannulation lasting more than 
24 hours. In another study Bedford (32) has reported an 11% incidence of radial 
artery occlusion in cannulation lasting 1-3 days, whereas that lasting 4-10 days 
resulted in a 29% incidence of radial artery occlusion. Mandel and Douched (33) 
described the occurrence of partial or complete thrombosis of the radial artery as 
19.7% in the cannulation lasting from 0-12 hr, while the incidence of occlusion 
rose to 48.8% in cannulation lasting more than 48 hrs. All these reports were in 
the setting of long term hemodynamic monitoring of the arterial pressure in 
Intensive Care Units, using short cannulae of much smaller diameter than used in 
cardiac catheterisation procedures. Much lower rates of radial artery occlusions 
are seen following transradial coronary procedures, probably because radial 
sheaths are removed immediately following the procedure and the patients often 
receive periprocedural anti-thrombotic treatment.
Stella et al (28) have shown radial artery occlusion rates of 5.3% demonstrated 
by ultrasonography at discharge and, at 1 month, persistent occlusion was found 
in 2.8% of patients undergoing coronary angioplasty using 6F guide catheters. 
They studied 563 patients prospectively undergoing coronary procedures via the
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transradial route. None of the patients with radial artery occlusion manifested 
signs of compromised perfusion of the hand. In this study the incidence of radial 
artery occlusion was numerically lower in females (2.9% vs. 6% in males, 
p=0.09). This finding does not support the hypothesis that a smaller vessel 
diameter, as found in females, is more prone to occlusion after camiulation than 
larger vessels found in males. Nagai et al (35) have shown early (2±2 days after 
catheterisation) radial artery occlusion rates of 9% with spontaneous 
recannalisation noted late after procedure (95±29 days after catheterisation) in 
60% of the cases assessed for absent forward flow by Doppler ultrasound.
1.3.2 The effect of antithrombotic therapy
Transradial procedures can result in radial artery spasm, endothelial damage and 
arterial dissections. Severe radial artery spasm causing blood stagnation and 
endothelial injury could potentially cause thrombus formation and result in radial 
artery occlusion. Antithrombotic agents are often given during transradial 
procedures to reduce the thrombotic complications of transradial coronary 
procedures.
Adequate anticoagulation is shown to be of significance in the patients 
undergoing transradial procedures. Many operators have shown radial artery 
occlusion rates varying from 3-10% in anti coagulated patients undergoing 
transradial procedures (28, 29, 30). In contrast, the incidence of radial artery 
occlusion was as high as 30% in patients receiving 1,000 units of heparin during 
diagnostic catheterisation as compared to 5000 units of heparin (34).
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1.3.3 The effects of catheter and radial artery size
Catheter size has also been shown to be a predictor of radial artery occlusion. 
One study has shown that the ratio between the diameter of the arterial sheath 
and the radial artery has an impact on the rate of radial artery occlusion (29). The 
incidence of occlusion was 4% in patients with a ratio of greater than one, as 
compared to 13% in those with a ratio of less than one.
1.4 Non-occlusive radial artery injury
Recent studies have demonstrated that permanent radial artery injury without 
occlusion may occur following transradial intervention in some patients. The 
mean radial artery internal diameter, as measured by ultrasound, was smaller in 
patients undergoing repeat transradial interventional procedures compared to 
those undergoing a first time procedure (30). These investigators found the mean 
radial arterial diameter was significantly decreased from 2.63±0.35 to 
2.51 ±0.29mm during follow at one to four months (p=0.01). However there was 
no significant difference in the vascular access times of the initial and repeated 
procedures (2.9±3.1 vs. 3.3±3.6 minutes, p=0.08), and success rate of repeat 
procedures was similar to those of the initial procedure. The incidence of radial 
artery occlusion was higher for repeat procedures. The investigators used 5F 
sheaths in the majority of the patients undergoing diagnostic angiography.
Nagai et al evaluated vascular complications following transradial coronary 
procedures by two-dimensional echo and colour Doppler ultrasound studies 
before, early (1 to 8 days, mean 2±2 days), and late (37-182 days, mean 95±29 
days) after catheterisation (35). Early after the procedure, segmental stenosis was 
noted in 22% and no flow in 9% of the patients. Late after the procedure,
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segmental stenosis was seen in 1%, diffuse stenosis in 22% and no flow in 5% of 
the patients. They also examined the risk factors for vascular complications 
using multivariate analysis and found that radial artery diameter before the 
procedure was one of the significant and independent determinants of no flow 
both early and late after the procedure. The difference in the radial artery 
diameter and the sheath size was related to the occurrence of diffuse stenosis late 
after the procedure, diabetes mellitus was related to no flow or diffuse stenosis. 
The rate of vascular complications late after the procedure was correlated with 
the difference in size between the radial artery and the sheath size. When the 
sheath diameter was larger than the radial artery diameter, vascular 
complications increased significantly from 14% to 38% (p<0.01). The authors 
have suggested that early stenotic events relate to haematoma or thrombosis at 
the puncture site and diffuse stenosis represents intimal thickening related to a 
catheter-induced intimal injury. As patients with ischaemic heart disease may 
require repeated coronary procedures, the role of the introducer sheath in causing 
local complications is important. It is advisable, wherever possible, to choose the 
sheath smaller than radial artery diameter or a sheath that causes fewer vascular 
complications.
Further studies have shown that this progressive narrowing is due to intimal 
hyperplasia. Wakeyama et al (36) assessed the extent and nature of radial artery 
injury following transradial intervention using intravascular ultrasound. In 100 
consecutive patients undergoing transradial intervention (TRI) they found that in 
patients having a second transradial procedure the lumen area (LA) and minimal 
luminal diameter (MLD) were smaller than in those having a first transradial 
intervention (LA of 5.05± 1.26mm2 in the repeat-TRI group vs. LA of
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5.62±1.35mm2 in the first-TRI group, p~0.032 and MLD of 2.37±0.31mm in the 
repeat-TRI group vs. MLD of 2.51±0.33mm in the first-TRI group, p=0.028), 
whereas the intima-media cross sectional area (IMcsa) and intima-media 
thickness (IMT) were significantly greater than those in first-TRI patients (IMcsa 
2.24±0.65mm2 in the first-TRI group vs. 2.89±0.68mm2 in the repeat-TRI group, 
p<0.0001; IMT of 0.31±0.007mm in the first-TRI group vs. 0.46±0.10mm in the 
repeat-TRI group, p< 0.0001). In the proximal radial artery there was no 
significant difference in the vessel area, LA, IMcsa, or MLD between the two 
groups.
Edmunds on and Mann (37) have also shown that non-occlusive radial artery 
injury is common after transradial interventional procedures. Intravascular 
ultrasound evaluation revealed a variable degree of intima-media hyperplasia in 
all patients who had had a previous transradial procedure. The luminal cross 
sectional diameter and area were significantly smaller in the repeat procedure 
group than in a control group (6.7±0.8mm2 vs. 5.0±0.7mm2, p<0.01). They found 
that vasoreactivity to nitroglycerine was maintained in both groups of patients. 
However, the sample size in this study was small and the results may have been 
affected by a preponderance of females in one group and diabetics in the other. 
The above-mentioned observational studies, involving small number of patients 
in cross-sectional fashion, have shown that injury to the radial artery is common 
after transradial procedures. They have identified several factors such as radial 
artery diameter, introducer sheath diameter, sex of the patient and diabetes as 
playing a significant role in predicting radial artery injury following transradial 
procedures. The ramifications of radial artery occlusion and injury are important 
not only in patients undergoing repeat interventional procedures, but also in
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patients in whom the radial artery may be used as a conduit for coronary artery 
bypass surgery or for the creation of arteriovenous fistulae for haemodialysis.
1.5 Haemostasis after transradial procedures
The transradial approach has become an attractive alternative to the femoral and 
the brachial routes for coronary angiography and angioplasty. Because of the 
superficial course of the radial artery, haemostasis can be obtained easily by 
local compression. Mechanical compression devices are favoured over manual 
compression as this allows immediate removal of the intra-arterial devices when 
the concomitant use of aggressive antiplatelet and antithrombotic therapies 
require prolonged pressure to achieve secure haemostasis. There are several 
devices available for mechanical compression of radial artery following 
transradial procedures.
1.5.1 Currently-available devices
1.5.1.1 Tourniquets
Among mechanical compression devices, tourniquets are widely used with good 
results and low complication rates. However, a simple tourniquet has the main 
disadvantage of being uncomfortable for the patient because of non-selective 
delivery of pressure around the wrist. This can induce venous congestion of the 
hand, which can be extremely unpleasant and painful.
32
1.5.1.2 The Radistop radial compression system
The Radistop radial compression system is manufactured by RADI Medical 
Systems AB, Uppsala, Sweden. This device was developed with following 
objectives:
1) Application of immediate and sustained haemostasis after sheath removal in 
spite of anticoagulant and antiplatelet therapy.
2) Safety during and after arterial compression.
3) Delivery of haemostatic pressure locally on the puncture site with sustained 
arterial and venous residual flow.
4) Patient comfort allowing painless prolonged compression and immediate 
ambulation.
5) No increase in the incidence of chronic radial artery occlusion compared to 
other techniques.
Chatelain et al (38) tested the efficacy of this device in 159 patients (130 male, 
age 60±11 years). Haemostasis after sheath removal was considered difficult to 
achieve in four patients (2.5%), requiring repositioning of the compression pad 
with application of higher pressure. The device was considered uncomfortable 
and painful by 28 patients (18%), but in no patient was it necessary to interrupt 
compression for that reason. The mean compression time with the Radistop 
system was 151±82 minutes (114±64 minutes in the angiography group and 
223±64 minutes in the angioplasty group, p=0.001). This difference was related 
to a smaller sheath size and no use of antithrombotic medication in patients 
undergoing angiography alone. There were 23 (15%) local complications 
reported: in seven patients (4.4%), the radial pulse was absent but no patient had 
clinical evidence of hand ischemia, one patient had chronic radial artery
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occlusion and one patient had recurrent bleeding after two hours. In 15 patients 
(9%), a small haematoma was observed around the puncture site after 
compression. All patients in this study were given an intra-arterial bolus of 
heparin and the sheath was removed immediately after the procedure. There was 
no mention of the length or type of radial sheath used in these cases.
1.5.1.3 The TR Band
This compression device was launched by Terumo (Terumo Corporation, Tokyo, 
Japan) with the advantage of directed radial artery compression. This is 
performed with the help of two separate inflatable balloons. A large balloon 
compresses the entire puncture site and the small balloon gives it an angled 
direction point compression. The transparent band allows full visualisation of the 
puncture site during the post-procedure period and the balloon can be deflated 
slowly over a period of time. The presence of a valve allows precise control of 
the volume of air in the compression balloon.
This device was tested by Pancholy et al (118) in a randomised study comparing 
the TR Band with conventional pressure haemostasis in 436 patients. They 
reported a significantly lower incidence of early (at 24 hours) radial artery 
occlusion compared to conventional pressure compression (11.2% vs. 4.4%, 
p<0.005) and also late (at 30 days) radial artery occlusions (7.2% vs. 3.2%, 
p<0,05). They introduced the concept of “patent haemostasis,,; prevention of 
bleeding while maintaining luminal flow, achieved by the TR band and 
speculated that this was responsible for better outcomes.
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1.5.1.4 Hydrophilic wound dressings
A non-compressive, soft, non-woven hydrophilic wound dressing device called 
Closure Pad (Scion Cardio-Vascular, Miami, Florida) is available. This 
haemostatic device is constructed from polypropyl acetate, a hydrophilic, 
naturally-occurring biopolymer. Once it comes in contact with blood it causes it 
to coagulate and achieves haemostasis. This device was developed because there 
are a few disadvantages of compression devices, such as restriction of wrist 
movement with the Radistop, the necessity of prolonged application of device, 
and the risk of late occlusion. This Closure Pad device is applied immediately 
after removal of the sheath, over the puncture site, allowing a small amount of 
blood to come in contact with the dressing. Pressure is maintained for 30 seconds 
and the site is covered with a sterile dressing. Choi et al (39) compared this 
device with a modified tourniquet in a randomised study of 80 patients. The 
mean haemostasis time for the hydrophilic wound dressing group was 58.7±32.6 
minutes and for the compression device group was 131.3±59.1 minutes 
(p<0.001). Local haematomas were reported in one patient (2.5%) in the 
compression device group and two patients (5%) in HWD group. These data 
have shown that the Closure Pad can decrease haemostasis time without any 
increase in local complications. However, the sample size was small and only 
included patients undergoing diagnostic coronary catheterisation.
1.5.1.5 Adapty
The Adapty (Medikit, Tokyo, Japan) (Figure 1-4) device consists of a pad fixed 
to a transparent plastic plate, to which a self-adhesive strap can be applied.
Ochiai et al (40) tested the safety and efficacy of this device in 200 patients and
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found this device was effective in achieving haemostasis in 99.5% of patients. 
However they did not report compression times, vascular complications or 
discomfort level with this device.
Figure 1-4 The Adapty haemostatic compression device
1.5.2 The effect of compression on radial artery flow and 
complications
There is some data available to assess the effect of compression of the radial 
artery to achieve haemostasis following transradial procedures. This interruption 
of blood flow by compression devices might also influence the incidence of 
radial artery occlusion and other vascular complications. Recently, Samartin et al 
(41) have analysed the possible relationship between compression after 
transradial procedures and radial artery occlusion. In this study of 275 
consecutive patients, arterial sheaths were removed immediately after the 
procedure and a conventional compression dressing using a tourniquet was 
applied for two hours. The pulse oximeter signal in the index finger during 
ipsilateral ulnar compression was used as the assessment of the radial artery flow. 
Radial artery flow was absent in 174 cases (62%) immediately after access site 
compression. After two hours of conventional haemostasis, radial artery flow 
was absent in 162 cases (58%) before bandage removal. At seven-day follow-up
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12 patients (4.4%) had absent pulsations and radial artery flow was absent in 29 
cases (10.5%). Logistic regression analysis showed that absent flow before 
compressive bandage removal was the only independent predictor of radial artery 
occlusion at follow up (OR=6.7, 95% Cl 1.95-22.9; P=0.002). Flow-limiting 
compression was frequently seen in this study and the absent radial artery flow 
during compression was found to be a predictor of radial artery occlusion. 
Therefore there are several different compression and non-compression devices 
available to achieve haemostasis following transradial procedures. Transradial 
procedures are gaining popularity because of the ease of achieving haemostasis 
and thereby reducing the risk of major entry site complications, hospital staff 
workload and cost. There is limited data available in the literature comparing 
these different devices and also assessing the patient comfort level, haemostasis 
time, vascular complications and radial artery occlusion rates.
1.6 The importance of hand collateral arteries via the 
ulnopalmar arches
Traditionally the modified Allen’s test has been used widely to evaluate the 
patency of ulnopalmar arches and collateral supply (Figure 1-5). This is a 
subjective test and assessed as the time taken for hand to blush after compression 
over both arteries then release of the ulnar artery compression. Up to 5-10 
seconds are considered satisfactoiy for collateral supply. More objective tests 
like plethysmography and pulse oximetery, which are more sensitive in assessing 
the collateral circulation are described in the section below.
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Figure 1-5 Superficial and deep palmar arch and collateral supply of the 
hand.
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1.6.1 Methods of assessing ulno-palmar circulation
The modified Allen’s test is performed as follows: after firm compression of 
both radial and ulnar arteries, the patient is asked to forcefully clinch their hand 
several times to expel blood from the hand. The hand is then opened, avoiding 
hyperextension of the wrist and fingers, before release of the ulnar artery 
compression. The amount of time taken to achieve a maximal palmar blush after
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release of the ulnar artery while maintaining occlusive pressure of the radial 
artery is measured.
Plethysmography (PL) and oximetery (OX) tests are recorded with a pulse 
oximeter with a clamp sensor applied to the thumb. PL readings are recorded 
before and immediately after radial artery compression for as long as two 
minutes. PL readings were divided into four types: A, no damping of pulse 
tracing immediately after radial artery compression; B, damping of the pulse 
tracing; C, loss of the pulse tracing followed by recovery within two minutes; D, 
loss of pulse tracing without recovery within two minutes. OX results were either 
positive (oximetery signal present) or negative (oximetery signal absent) during 
radial artery compression,
Barbeau et al (42) have compared these two methods in 1010 consecutive 
patients undergoing a transradial approach. In men the mean time to maximal 
blushing was 4.7±2.7 seconds for both the left and right hands, compared with 
4.1±2.3 seconds and 4.0±2.1 seconds for the left and right hands respectively in 
women. Overall, an Allen’s test result of less than nine seconds was found in 
86.5%, 87.8%, 80.8% and 93.6% of patients on the right side, left side, both 
sides, or any side, respectively. In multivariate analysis including age, height, 
weight, sex, and the presence of diabetes mellitus or previous bypass grafting, 
the only predictors of failure to achieve an Allen’s test result of less than nine 
seconds were increased age and male sex. Plethysinography and oxymetery type 
A or B pattern was found in 90.8%, 89.5%, 83.9%, and 96.3% of patients on the 
right side, left side, both sides, or any side, respectively. Increasing age and male 
sex was found to be predictor of failure to achieve PL and OX type A, B, or C. 
On the basis of an Allen’s test result of nine seconds or more, 6.3% of patients
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were excluded from the transradial approach, whereas with PL and OX types A, 
B, and C, only 1.5% of patients were excluded.
Doppler ultrasonography can also be used to assess the hand collateral 
circulation. Ruengsakulrach et al (43) have evaluated the hand circulation of 71 
patients by means of the Allen’s test and ultrasound in patients scheduled for 
coronary artery bypass grafting. Among 71 hands, four (5.6%) had an abnormal 
Allen’s test result (more than 10 seconds) and two (2.8%) of dorsal digital 
arteries in the thumb showed no flow during radial artery compression, as 
measured by ultrasonography. They concluded that the absence of flow in the 
dorsal digital thumb artery with radial artery compression should be considered 
an absolute contraindication to the radial artery harvesting.
1.6.2 The relation between tests of collateral circulation and 
ischaemic complications
There are no studies demonstrating a relationship between the time to maximal 
blushing using the Allen’s test and ischaemic symptoms and complications to the 
hand. Some authors, however, because of an absence of complications after 
radial artery cannulation for monitoring even in patients with abnormal Allen’s 
test results, have suggested that the Allen’s test is not predictive of ischaemic 
complications and therefore probably not necessary (44, 45, and 46). Collateral 
recruitment may explain in part the paucity of ischaemic hand complications 
reported in the literature despite the widespread use of the radial artery for 
monitoring and coronary interventions.
Greenwood et al (47) assessed the accuracy of the modified Allen’s test in 
predicting hand ischaemia in patients undergoing transradial coronary
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angiography. These investigators, over a period of four months involving 55 
patients, measured the Allen’s test time, circulation in the radial artery (RA), 
ulnar artery (UA), principal artery of thumb (PAT), and thumb capillary lactate 
levels before and after 30 minutes of radial artery occlusion. Patients with an 
abnormal Allen’s test were all men, had a larger radial artery (3.4 vs. 2.8mm, 
p<0.001), and a smaller ulnar artery (1.9 vs. 2.5mm, p< 0.001), compared to 
patients with a normal Allen’s test. After 30 minutes of radial artery occlusion in 
patients with abnormal Allen’s test, the blood flow velocity to the principal 
artery of thumb improved from 3.2 to 7.7cm/s (p<0.001) yet remained reduced 
relative to the patients with a normal Allen’s test (7.7 vs. 21.4cm/s, pO.OOl). 
The thumb capillary lactate levels were elevated in patients with an abnormal 
Allen’s test (2.0 vs. 1.5mmol/l, p=0.019). They concluded that after 30 min of 
radial artery occlusion, patients with an abnormal Allen’s test showed 
significantly reduced blood flow and increased thumb capillary lactate, 
suggestive of ischaemia.
Debate persists about the necessity of doing Allen’s test prior to transradial 
procedures and denies the benefits of transradial procedures to patients with an 
abnormal Allen’s test (5-10%). The radial artery approach has been widely used 
for last 15 years and there are no cases of hand ischaemia reported in literature. 
Therefore many high-volume operators and cardiac cenfres have stopped using 
the Allen’s test prior to transradial procedures.
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1.7 Physiological changes in the radial artery following 
transradial procedures
The radial artery is a muscular artery and therefore more prone to spasm. As the 
size of the radial artery is small, and similar to the dimensions of the catheter and 
sheath used for transradial procedures, this predisposes the injury to the vessel 
wall during transradial procedures. These procedures can result in disruption and 
damage to endothelium and potentially cause injury to internal elastic laminae 
and tunica media resulting in neointimal proliferation and arterial remodelling.
A small study has examined by ultrasound both endothelium-mediated and non­
endothelium-mediated vasodilatation of the radial artery before and after 
transradial catheterisation (117). The study group consisted of 18 patients and a 
short sheath (7-12cm) with no hydrophilic coating used. They found that, at 
baseline, the mean radial artery diameter was 2.56±0.45mm. The mean diameter 
significantly increased to 2.86±0.48mm at 24 hours (p=0,001). At one week it 
was 2.75±0.44mm (p=0.03 compared to baseline). At one month the radial artery 
diameter was similar to baseline (2.60±0.27mm, p=0.95). The maximum 
diameter achieved after 0.4mg sublingual nitroglycerine was similar throughout 
the study period. Overall, there was a small vasodilatory response to post- 
ischaemic hyperaemia (flow-mediated dilatation; change in radial artery diameter 
in response to hyperaemia, 2.7±4,7% from baseline), suggesting a high 
prevalence of endothelial dysfunction in this population. The response did not 
change significantly throughout the study period (3.4±3.7; 3.5±3.9; 4.8 ±4.7 % at 
one, seven and 30 days respectively). Nitroglycerine- induced vasodilatation 
decreased significantly at 24 hours with a return to baseline at seven days 
(14.1±7.9% at baseline and 6.6±8.4% at one day, 9.8±8.5% at seven days and 
13.0±8.9% at 30 days). This study showed that hyperaemia-induced
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vasodilatation did not change significantly whereas nitroglycerine-induced 
vasodilatation was significantly attenuated at 24 hours, but had improved at one 
week and one month. This is probably related to local trauma provoked by the 
sheath and catheters. The study was performed on a mixed group of patients 
using different diameter sheaths (ranging from 4F to 6F) and the majority of 
patients were males. The radial artery diameter was measured with ECG-gated 
ultrasound measurements and there is a potential for error and intra-observer 
variability. The exact extent of endothelial damage and its impact on radial artery 
physiology in the long term are not known.
More recently, Burstein et al (49) assessed the impact of radial artery cannulation 
for coronary angiography and angioplasty on radial artery function. They studied 
22 patients using a 6F short length sheath with routine use of a vasodilator 
cocktail. Baseline radial artery diameters were 2.36±0.9 mm in the cannulated 
arm and 2.38±1.1 mm in the non-cannulated ami. There were no significant 
changes in the non-cannulated aim immediately after the procedure and at nine 
week follow up, whereas radial artery diameter in the cannulated ami increased 
after the procedure (2.89±0.9 mm, p<0.01) and returned to its original size nine 
weeks after the procedure (2.46±0.9 mm, p = 0.51). The average flow-mediated 
dilatation (FMD) of the cannulated ann before the procedure was 13.2%. The 
average FMD of the cannulated ami immediately after the procedure was 
significantly decreased at 3.6% (p <0.01). The average FMD of the cannulated 
arm at follow up remained blunted at 0.2% and was significantly decreased 
compared with that before the procedure (p<0.01). In comparison there was no 
difference in the non-cannulated arm across the study periods.
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Nitrate-responsiveness (increase in diameter in response to nitrate) in the 
cannulated arm before the procedure was 18.9%. This was significantly 
decreased immediately after the procedure (3.7%, p <0.01) and at follow-up 
(8.6%, p <0.05). No changes were seen in nitrate-responsiveness in the non- 
cannulated arm. They concluded that there was impaired vascular function of the 
radial artery for up to nine weeks following transradial procedures.
These studies show conflicting effects on FMD and nitrate-responsiveness of the 
radial artery in the cannulated arm following transradial procedures. The 
impaired FMD is probably as a result of endothelial damage and disruption 
during introducer sheath and catheter exchanges. However, the endothelial 
function should improve over time with endothelial repair. The impaired nitrate- 
responsiveness could be explained by impairment of smooth muscle function of 
the radial artery.
This impairment of vascular function as a result of injury sustained to the radial 
artery could theoretically be different with different diameter and length 
introducer sheaths. These sheaths will cause different extents of injury to the 
radial artery and therefore could have different effects on the vascular function of 
the radial artery. Long sheaths will be in contact with a larger area of radial 
artery endothelium and therefore there is potential for more endothelial injuiy. 
Catheters that are smaller in size than radial artery may induce less damage 
because they are not in contact with the arterial wall. Similarly, shorter sheaths 
will be in contact with a smaller area of radial artery endothelium and will cause 
less injury. However, in smaller sized radial arteries, where the catheter is in 
contact with the artery proximal to the sheath there will be more radial artery
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irritation at the time of catheter manipulation or exchange with the use of a 
shorter length introducer sheath.
These physiological changes in the radial artery might have important 
implications for the patients. The radial artery is an important bypass conduit and 
may also be needed for the formation of an arterio-venous fistula in patients 
requiring haemodialysis. Further research into reducing the extent of vascular 
impairment of the radial artery following transradial procedures will help this 
group of patients.
1.8 Vascular function and the use of the radial artery as a 
graft conduit
The use of the radial artery as a conduit for coronary artery bypass surgery was 
first introduced in 1972. However, the use of this conduit was almost completely 
abandoned after 1976 because of high failure rates. These high failure rates were 
mainly due to intimal hyperplasia and hyperspasticity seen in radial artery grafts. 
In the early 1990’s interest in the use of radial artery was revived because of 
improved harvesting procedures and the use of aspirin and vasodilators. As there 
has been increasing interest in total arterial revascularisation in coronary surgery, 
there has been resurgence in the use of the radial artery as an alternative arterial 
conduit (51). With increasing use of the radial artery as the access site for 
percutaneous coronary intervention there have been concerns raised and 
reluctance by cardiac surgeons to use the radial artery after transradial 
procedures as a bypass conduit. There is little scientific data to support or 
examine this issue.
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Kamiya et al reported that there was significant intimal hyperplasia (68% vs. 
39%, p=0.046)) and reduced early graft patency (77% vs. 98%) in patients in 
whom the radial artery had previously been used as an access route (48). This 
was a retrospective cohort of 67 consecutive patients who underwent isolated 
coronary artery bypass grafting using the radial arteries. They performed a 
further analysis on 18 patients to investigate the relationship between the 
occurrence of graft stenosis or occlusion and preoperative transradial 
catheterisation. Among introducer size, number, and the interval since previous 
catheterisation, the number of previous transradial catheterisations was the most 
significant factor affecting graft patency (p=0.07). This study also demonstrated 
that distal sites of the radial artery suffered from greater intimal hyperplasia after 
preoperative transradial catheterisation compared with those without transradial 
catheterisation. They concluded that preoperative transradial catheterisation 
decreased early graft patency and caused intimal hyperplasia in the radial artery. 
However, this did not affect early clinical outcomes. The authors concluded that 
use of the radial artery as a bypass conduit after transradial catheterisation should 
be undertaken cautiously, particularly when multiple previous procedures have 
been performed. The impact of endothelial damage and long term outcome 
following the use of radial artery as a bypass conduit is not yet known in 
prospective studies.
There is some data from surgical literature which examines the anatomy, 
pathology and physiological changes in radial artery in the context of its use as a 
bypass conduit. It is well known that the radial artery is a thick-walled muscular 
artery and is more prone to suffering from intimal hyperplasia and 
arteriosclerotic change than the internal mammary artery, which is an elastic
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artery (51). Oshima et al (52) examined the intravascular ultrasound images of 
the radial artery in patients undergoing coronary artery bypass surgery. In a study 
of 58 patients, the mean luminal diameter was 3.28±0.69mm and 3.00±0.70mm 
at the proximal and distal segments respectively, with a minimal diameter of 
2.58 ±0.73mm, A plaque area greater than 50% was seen in five radial arteries 
(8.6%), whose average plaque length was 26.4 ±3 0.8mm. Five of these radial 
arteries showed calcification and were considered unsuitable for grafting. This 
study shows that the radial arteries in patients with coronary artery disease are 
not normal and could influence the results of transradial procedures.
1.9 Sterile inflammation associated with transradial 
catheterisation and hydrophilic sheaths
There are a few reports in the literature of sterile inflammation at the site of 
radial artery access following transradial coronary procedures. These are mainly 
reported after the use of hydrophilic coated sheaths. Kozak et al (62) reported 33 
cases out of total 2038 cases over a 3 year period. They also reported that radial 
abscesses occurred in 30 patients out of the 1063 cases (2.8%) in whom they 
could confirm the use of a hydrophilic coated sheath, but in no patient in whom 
they could document that an uncoated sheath was used. Typically the 
inflammatory lesion was noted 20 weeks after the procedure (range three days to 
three months). The lesion usually presented as violaceous tender nodule at the 
exact site of radial cannulation. Punch biopsy was perfonned in some of these 
lesions and all showed varying degrees of acute and chronic inflammation. None 
showed evidence of infectious organisms including bacteria, mycobacteria or 
fungi. Many patients received empirical antibiotic therapy without any benefit.
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Several biopsy specimens showing a suppurative and granulomatous reaction 
also demonstrated an extracellular blue grey substance after staining. 
Macrophages were seen engulfing the substance, suspected of being the gel- 
hydrophilic coating of the catheter and the cause of this reaction.
The vascular sheath associated with these reactions was a hydrophilic polymer 
coated catheter. The hydrophilic polymer coating is composed of polyacrylamide 
and polyvinylpyrrolidone. Investigators mentioned that standard para-marketing 
animal studies were performed by the manufacturer and did not show any 
adverse reaction.
This complication is likely to be a sterile abscess (foreign body-type reaction) at 
the site of the sheath insertion caused by the shedding of the coating during the 
insertion or removal of hydrophilic coated sheath. None of these reactions have 
been shown to have any long term sequelae.
1.10 Historical Introduction
1.10.1 Anatomical aspects of the radial artery
The radial artery arises from the brachial artery bifurcation, below the elbow, at 
the radial tuberosity, and is the straighter continuation of the brachial artery. The 
other branch of the brachial artery, the ulnar artery, is usually of greater size and 
takes off at almost a right angle from the parent vessel (Figure 1.4).
The proximal radial artery course underneath the belly of the brachioradialis 
muscle and then progressively leaves the lower surface of the muscle, running 
beneath the antebrachial fascia, between the brachioradialis muscle and the 
flexor caipi radialis muscle. The medial portion of radial artery lies close to the 
superficial branch of the radial nerve. Near the wrist, the radial artery becomes
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superficial, lying anterior to the radius and the pronator quadratus muscle, 
between the tendons of the brachioradialis and the flexor carpi radialis muscles 
(Figure 1.5).
From its more distal portion, the radial artery has many branches which 
anastomose with ulnar artery, providing the vascularisation of the hand. In about 
15% of cases, the radial artery may show a high origin, between the axilla and 
the elbow (54).
The internal diameter of radial artery varies between 2-3 mm (55, 56, and 57).
Figure 1-6 The course of the radial and brachial artery
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Figure 1-7 Anatomy of the radial artery.
(Taken from Anatomy of the Human Body by Henry Gray, [197])
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1.10.2 Pathological aspects of the radial artery
The radial artery is a thick-walled muscular artery. The intima has one layer of 
endothelial cells beneath which multiple layers of subendothelial cells and a 
small number of myocytes are present. The internal elastic lamina has multiple 
fenestrations, and the media is constituted by many leiomyocytes, elastic and
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collagen fibres, fibroblasts, and rare macrophages. The external elastic laminae is 
less individualised than the internal lamina. There is some evidence that the vaso 
vasomm, nerves, and lymphatic vessels are confined to the adventitia, and do not 
join the medial layer within the structure of the adventitia (58).
The radial artery has a thick wall compared to other arteries and has higher 
density of muscle cells with the same amount of elastic tissue in its media (56) 
(Figure 1.8). Moreover, in the radial artery the myocytes are organised into 
multiple tight layers and this, together with the wider thickness of the media, 
may at least in part explain the propensity of the radial artery to spasm (58). 
Kaufer and colleagues (58) investigated the pathology of radial artery in 102 
patients prospectively in the patients undergoing coronary artery bypass grafting 
using radial artery grafts. In their study an intima to media ratio of more than 
0.25 was noted in 54% of the patients as compared to 23 % of left internal 
mammary artery (LIMA) specimens. They analysed the correlation between the 
degree of atherosclerosis and the various demographic factors. They found weak 
but statistically significant correlation between degree of atherosclerosis and 
diabetes (r=0.2061; p= 0.038), male sex (r=0.3224; p=0.001), and advanced age 
(r=0.3262; p= 0.001). Atherosclerotic involvement of the radial artery reduces 
the lumen of the artery and could be one factor predisposing to spasm and 
endothelial dysfunction.
A similar study from Vonson et al (57) has also shown that the radial artery is a 
muscular artery and the intima plus media thickness is around 529+7-52 pm, 
which may predispose radial artery to spasm causing occlusion and ischemia in 
patients undergoing bypass surgery. The radial artery is prone to accelerated
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intimal hyperplasia following endothelial injury or focal damage to the intima 
(35,36,37, 48, 50, and 51).
Figure 1-8 Cross-section of the radial artery
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1.10.3 Physiological function of the radial artery
According to the functional classification of the arterial grafts (60), the radial 
artery belongs to type 3, a type of graft that is more spastic than type 1 arteries. 
To further investigate the tendency to spasm of radial arteries, He et al (61) 
investigated the sub-type of adrenal-receptors found in the human radial artery in 
an ex-vivo study. They, for the first time, were able to demonstrate that the radial 
artery is an alpha-adrenoceptor dominant artery with little beta-adrenoceptor 
function and the alpha-1-adrenoceptor is dominant although alpha2 functions
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also exist. Therefore, circulating catecholamines will primarily contract the 
radial arteries through the alpha-1 mechanism and the use of beta-blockers will 
be unlikely to evoke radial artery contraction or spasm during or after coronary 
artery bypass surgery. Radial artery spasm can result in the occlusion of radial 
artery in some cases. This understanding of radial artery physiology is important 
in the pathophysiology of radial artery spasm and occlusion, and their avoidance 
and treatment.
1.11 The physiological basis of radial artery vascular 
function and endothelial function
The endothelium is a single layer of cell lining covering the internal surface of 
blood vessels, cardiac valves, and numerous body cavities (Figure 1-9). The 
location of the endothelium exposes it to changes in the haemodynamic forces 
and blood-borne signals and allows it to respond by releasing vasoactive 
substances. A critical balance between endothelium-derived relaxation and 
contracting factors maintains vascular haemostasis. When this balance is 
disrupted it predisposes the vasculature to vasoconstriction, leucocyte adherence, 
platelet activation, mitogenesis, pro-oxidation, thrombosis, impaired coagulation, 
vascular inflammation, and atherosclerosis.
A transradial procedure has the potential to cause endothelial injury to the radial 
artery and result in endothelial dysfunction. Radial sheaths cause a mechanical 
insult to the lining and the muscular wall of the radial artery, cascading the above 
mentioned effects as seen by other stimuli like haemodynamic forces and blood- 
borne signals. Moreover, different lengths and coatings of the sheath might cause
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different degrees of endothelial injury and there are several patient-related 
factors playing a significant role in causing radial artery injury.
Figure 1-9 Layers of the radial artery
1.11.1 Discovery of endothelium-derived relaxing factor 
and the L-arginine nitric oxide pathway
The era of endothelial biology was brought to the forefront by work from Dr 
Furchgott (63). He and his colleagues observed that in a ring preparation from a 
rabbit thoracic aorta, acetylcholine produced marked relaxation at a 
concentration lower than that required to produce contraction (64, 65, and 66). In 
investigating this apparent discrepancy they discovered that the loss of the 
relaxation response to acetylcholine could occur as a result of the unintentional 
rubbing of its intimal surface against foreign surfaces during its preparation. If 
care was taken to avoid rubbing of the intimal surface during preparation, the
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tissue always exhibited relaxation to acetylcholine, and the possibility was 
considered that rubbing of the intimal surface had removed endothelial cells.
They went on to demonstrate that relaxation of blood vessels by acetylcoline 
requires the presence of endothelial cells, and that acetylcholine, acting on 
muscarinic receptors of these cells, stimulates release of a substance that causes 
relaxation of vascular smooth muscle.
Following this discovery of endothelium-dependent vasodilatation by Furchgott 
and Zawadzki, vascular endothelium has been recognised as an important 
functional unit involved in the regulation of vascular smooth muscle tone. It was 
then hypothesised, when stimulated by vasoactive agents such as acetylcholine 
and bradykinin, endothelial cells secrete short-lived endothelium-derived 
relaxing factor(s) (EDRF), causing relaxation of the underlying smooth muscle 
cells. One EDRF was identified as nitric oxide or a closely related substance (67). 
Vasoconstriction dependent on or enhanced by intact endothelium was also 
observed in response to the various chemical and physical stimuli, such as 
noradrenaline (68), thrombin (68), hypoxia (69, 70), increased transmural 
pressure (71) and mechanical stretch (72).
The discovery that mammalian cells generate nitric oxide, a gas previously 
considered to be merely an atmospheric pollutant, has provided important 
information about many biologic processes. The quest to identify so-called 
EDRF led to the discovery in the vasculature of an enzyme called nitric oxide 
synthase that generates nitric oxide from the amino acid L-arginine (67, 74, 75, 
76, 77, 78, 79, 80, and 81). This enzyme is constitutive, is calcium- and 
calmodulin-dependent, and releases picomoles of nitric oxide in response to 
receptor stimulation (82). The identification of a competitive inhibitor of this
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enzyme, the methylated L-arginine analogue NG-monomethyl-L-arginine, has 
provided an important tool to investigate the relevance of nitric oxide in the 
biological process.
NG-monomethyl-L-arginine (L-NMMA) is a potent vasoconstrictor in vitro. It 
constricts vascular beds, produces a hypertensive response in animals and causes 
vasoconstriction of the forearm arterial circulation in humans (82). This action is 
completely endothelial-dependent, and its vasoconstrictor properties result from 
the inhibition of an endogenous vasodilator mechanism. These discoveries led to 
the conclusion for the first time that there is a physiological, nitric oxide- 
dependent vasodilator tone that is essential for the regulation of blood flow and 
pressure and indicated that the traditional concept of the cardiovascular system 
as a resistance network should be reassessed. The nitric oxide-dependent 
vasodilator tone seems to be maintained through the physical activation of 
endothelial cells by stimuli such as pulsatile flow and shear stress (82). Nitric 
oxide released from noradrenergic, non-cholinergic terminals may also 
contribute to the regulation of blood flow and pressure (83).
Several invasive and non-invasive techniques have been developed during the 
last few years to evaluate endothelial function. There are invasive studies which 
require the administration of intracoronary or intrabrachial infusions of 
vasoactive agents. These are still considered the gold standard for early detection 
of endothelial dysfunction, hi addition, several non-invasive techniques have 
been developed, with comparable results and good reproducibility.
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1.11.2 Flow-mediated dilatation
Peripheral arteries respond to physical and chemical stimuli by adjusting 
vascular tone and regulating blood flow (83). Increased blood flow in peripheral 
arteries leads to increased shear stress, increased nitric oxide production and 
vasodilatation (83). The vasodilatory response of the brachial artery to increased 
shear stress is called flow-mediated dilatation (FMD) and reflects the ability of 
vascular endothelium to produce nitric oxide (83).
That there has been an abundance of FMD studies in the cardiovascular literature 
in the past decade is attributable to the idea that it provides a functional bioassay 
for in vivo endothelium-derived nitric oxide (NO) bioactivity in humans. In 1992 
Celermaejer and colleagues (84) introduced the idea of using cuff occlusion to 
examine endothelial function by inducing arterial shear stress. It was known at 
that time that human conduit arteries dilated in response to increased blood flow 
(85, 86, 87) and that, in animals, this response was dependent on intact 
endothelium (88, 89).
Joannides and colleagues (90) published the first study involving L-NMMA 
infusion to block NO production after cuff occlusion in humans. They imaged 
the radial artery for diameter and flow at rest and after three minutes of 
ischaemia induced by a wrist cuff placed distal to the ultrasound probe. L- 
NMMA, infused into the brachial artery up stream, converted the radial artery 
FMD response (3.6%) to a constriction (-2.8%). This abolition of FMD by NO 
blockade in the absence of the changes in peak radial artery flow, although, L- 
NMMA decreased the duration of hyperaemia, raising the possibility of a 
confounding non-specific vasoconstrictor-mediated decrease in radial artery 
shear stress. This study provides strong evidence that FMD is an endothelium-
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dependent process, mediated by nitric oxide. Doshi et al (90) have shown that the 
FMD response was abolished by an infusion of L-NMMA and was more 
effective if the occlusion cuff was placed distal to the ultrasound probe. Mullen 
et al (92) showed that a brachial artery infusion of L-NMMA decreased the 
radial artery diameter response to five minutes of distal wrist cuff occlusion from 
5.3% to 0.7%. The L-NMMA infusion had no effect on either the peak or 
prolonged flow response after cuff deflation. Conversely, after 15 minutes of 
wrist cuff inflation, FMD was 9.6% but L-NMMA had no impact on radial artery 
dilatation. This physiologic study provided further evidence that the widely-used 
FMD approach in humans, involving a response to five minutes of occlusion is 
almost entirely abolished by L-NMMA. These studies reinforce the methodology 
of FMD used and this is essentially abolished by NO blockade.
The above-mentioned studies prove that FMD reflects the NO-mediated 
mechanism if the described protocol is followed. However, other internal 
molecules, such as endothelium derived prostanoids or endothelium derived 
hyperpolarising factor, may also contribute to the degree of flow-mediated 
vasodilatation (93).
The procedure of testing FMD is mainly as initially described by Celermajer et al 
(84) and then described by Corretti et al (97) in the report of the International 
Brachial Artery Reactivity Task Force. Vasoactive drugs must be discontinued at 
least 12 hours before the study, and the patient must refrain from cigarette 
smoking for at least six hours. The subject is positioned in a supine position, in a 
quiet room under constant room temperature. The brachial artery is imaged in the 
longitudinal plane using a linear array transducer (frequency 7-12Hz). The 
baseline diameter of the brachial artery is measured at rest and blood flow is
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estimated. The diameter of the brachial artery is determined manually with 
electronic callipers or automatically using edge-detection software.
After baseline brachial artery diameter determination, ischaemia is produced by 
inflating a cuff placed at the distal forearm, at a pressure 50mmHg greater than 
systolic blood pressure. The release of the ischaemia cuff after five minutes leads 
to an increase in forearm blood flow, resulting in a vasodilatory effect on the 
brachial artery. The maximum blood flow velocity is detected by analysing mid­
artery pulsed Doppler signals immediately or up to 15 seconds after cuff release, 
while the maximum diameter of the brachial artery is detennined approximately 
60 seconds after release or 45-60 seconds after the peak hyperaemia flow.
This method of FMD is reproducible, with a coefficient of variation for repeated 
measurements of brachial artery diameter in a good laboratory of about 3-4% in 
short term (two hour interval) and long term (three week interval) repeated 
measurements (98).This method is safer and faster than invasive methods, while 
its results are closely correlated with endothelial function in coronary arteries. 
However, it seems to be highly operator dependent, requires excellent patient co­
operation, and has relatively poor resolution relative to arterial size.
1.11.3 Strain gauge plethysmography
This is another currently-used method for non-invasive evaluation of endothelial 
function in the brachial artery. This involves evaluation of the changes in 
forearm blood flow during reactive hyperaemia, by the use of strain gauge 
plethysmography (95, 96). This technique is non-invasive, simple and 
reproducible since its results are less observer-dependent than ultrasound. The 
technique evaluates the change of flow from baseline to the maximum flow
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during reactive hyperaemia following five minutes of ischaemia in the distal 
forearm. Several studies have suggested that endogenous nitric oxide plays only 
a minor role in vasodilation during reactive hyperaemia, and that reactive 
hyperaemia is largely caused by endothelium-related mechanisms other than 
nitric oxide, such as adenosine, prostaglandins, and endothelium-derived 
hyperpolarising factor (96). Although this technique leads to less specific results 
than FMD, it is preferred by many centres because it is easily applied, does not 
require highly trained personnel, and its results are less observer-dependent. 
Forearm blood flow is measured using a mercury-filled silastic strain gauge 
plethysmograph. The strain gauge is attached to the upper forearm, at the 
position of maximum diameter. It is supported above the level of the right atrium 
and it is connected to a plethysmograph device. The upper arm congesting cuff is 
inflated to 40 mmHg for seven seconds in each 15 second cycle to occlude 
venous outflow from the ami, using a rapid cuff inflator. The FBF is estimated 
by the gradient of the tangent to the curve during the first cardiac cycles, and is 
expressed in ml/100ml of forearm tissue volume/minute. The final FBF is 
calculated as the mean of ten consecutive measurements, and always by two 
independent observers.
1.11.4 Intrabrachial infusion of vasoactive agents
After brachial artery cannulation and baseline infusion of saline for 30 minutes, 
acetylcholine is infused in the brachial artery with a gradually increasing 
infusion rate (e.g. 3,12, 24, and 48pg per minute). Each infusion rate remains 
constant for five minutes. Forearm blood flow is measured for each infusion 
period. The same protocol is usually repeated with sodium nitroprusside infusion
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for evaluation of endothelium-independent dilatation. The FBF during 
acetylcholine and nitropmsside infusions represents indices of endothelium- 
dependent and endothelium-independent dilatation respectively. To evaluate 
nitric oxide availability, acetylcholine infusion is repeated during simultaneous 
constant intra-arterial infusion of L-NMMA, a nitric oxide synthase inhibitor. 
This method is highly reproducible, since previous studies have shown a 
variation of 5-8% in the short term evaluation (two hour interval) as well as in 
the longer term (three week interval) (98). The method of intrabrachial 
vasodilator infusion, although reliable, reproducible, and easily applied, remains 
an invasive method with potential side effects such as injuries to the median 
nerve or the brachial artery (100).
1.12 Anatomical variations of the radial artery
The anatomy of the radial artery branching, anomalies and the diameter of the 
radial artery could play a significant role during a transradial approach for 
coronary intervention. Anomalies resulting in excessive tortuosity or sheath- 
artery diameter mismatch could lead to radial artery spasm and a failed 
procedure. There are some studies evaluating the anatomic features of the radial 
artery in patients undergoing transradial procedures. Valsecchi et al (119) have 
shown that in a prospective series of 2,211 patients undergoing transradial 
cardiac catheterisation, anatomic variations were noted in 22.8% patients on 
angiography. This included tortuous configurations (3.8%), stenosis (1.7%), 
hypoplasias (7.7%), radio-ulnar loop (0.8%), abnormal origin of the radial artery 
(8.3%) and lusoria subclavian artery (0.45%).Patients with anatomical variations 
had a significantly lower puncture (96.2% vs. 99.7%, p=0.001) and procedural
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success (93.1% vs. 98.8%, pO.OOOl). Recently, Lo et al (165) have reported an 
incidence of radial artery anomaly of 13.8% patients in a series of 1540 patients 
on angiography. This included high-bifurcating radial artery (7.0%), radial loop 
(2.3%), radial artery tortuousity (2.0%) and other miscellaneous anomalies 
including accessory branches (2.5%). Procedural failure was significantly higher 
in this group with radial artery anomalies than those wth normal anatomy (14.2% 
vs. 0.9%, p<0.001)
Yoo and colleagues (193) evaluated the anatomy and diameter of the radial 
artery using two-dimensional ultrasound in 1191 cases undergoing transradial 
cardiac catheterisation. They reported a mean radial artery diameter of 2.60±0.41 
mm (2.69±0.40mm in men and 2.43±0.38mm in women, p<0.001). They found 
anomalous branching of the upper extremity artery (3.2%), high origin of the 
radial artery (2.4%), and tortuousity of the radial or the brachial artery (4.2%). 
The most common site of radial artery tortuousity was the proximal third of ante- 
cubital fossa.
1,13Aims and scope of this study
It is clear from the literature to date that there is an increasing use of the 
transradial approach for coronary procedures and this is being applied in all 
clinical situations and patient subsets. However, there are complications 
specifically related to transradial approach, such as radial artery spasm, vascular 
injury to the radial artery, and radial artery occlusion. These complications could 
result in procedural failure, patient discomfort, or sustained vascular injury to the 
radial artery. Several technical advancements of the equipment and adjuvant 
pharmacotherapy have been shown to reduce these complications. There is
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growing evidence that hydrophilic coating of the introducer sheath could reduce 
the incidence of radial artery spasm and thereby reduce the patient’s discomfort. 
However, the impact of introducer sheath length on clinical outcomes is 
unknown. Similarly, there are not many data comparing various haemostatic 
compression devices.
In this study, I have investigated the impact of length and coating of the 
introducer sheath and compression devices on the incidences of procedural 
success, radial artery spasm, and local vascular complications. I have also 
studied the impact of introducer sheath coating on vascular function.
1.13.1 Hypotheses
This randomised trial will test the following three hypotheses:
1. We hypothesized that the use of a hydrophilic coating on the introducer sheath 
would reduce friction resistance between the sheath and the arterial wall. This 
would reduce traction force during sheath insertion or removal and the 
discomfort experienced by patients compared to similar uncoated introducer 
sheaths.
2. That long length introducer sheaths (23 cm) could cause more friction 
resistance and thereby cause more radial artery spasm and patient discomfort 
compared to short length (13cm) introducer sheaths.
3. Both TR Band and Radistop haemostatic devices are safe and effective to 
achieve haemostasis after transradial coronary procedures. We hypothesised that 
the TR Band would cause less discomfort to the patient and reduce the time 
needed to achieve haemostasis when compared to the Radistop.
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4. In a subgroup study, we would also test the hypothesis that hydrophilic 
coating of the introducer sheath would play a role in reducing endothelial 
damage and subsequent disturbance of endothelial function of the radial artery.
Randomised controlled trials provide the best quality evidence in medical 
research, (148) but they require a large commitment of time and effort, certainly 
from the investigators and often from participants. As a result, testing several 
hypotheses in parallel trials can be expensive and time consuming. For these 
reasons, we have tested these hypotheses in a factorial design, where participants 
are allocated to receive combinations of different treatments. A factorial design 
provides a cost-effective way of conducting trial of two or more interventions, 
each with its own primary outcome in one group of participants.
Factorial designs are relatively common in clinical trials. McAlister et al (149) 
examined the quality of the analysis and reporting of factorial trials published 
between January 2000 and July 2002 and identified 29 trials, including some of 
major importance (194, 195, 196). A factorial clinical trial has two or more 
treatments or interventions. For each intervention, the experiment may be 
whether the intervention is used, different intensities of the intervention or 
comparisons between mutually exclusive types of intervention. In a complete 
factorial design a participant can be randomised to any possible combination of 
the levels of the factors being considered (150).
hr our study, we will be testing the coating and length of the introducer sheath 
and the type of haemostatic device used in study participants in different 
combinations. In order to realise the above-mentioned advantages, however, 
factorial trials require some special considerations, particularly at the design and
64
analysis stages (151). These considerations will be discussed in the next chapter 
in the sample size and statistical analysis sections.
1.13.2 The scope of this study
To examine the hypotheses posed, we investigated the impact of different length 
and coating of introducer sheaths from the same manufacturer on various clinical 
outcomes. We also studied comparative effects of two commonly used 
haemostatic compression devices.
In a sub-study we have investigated the impact of introducer sheath coating on 
endothelium-dependent and endothelium-independent vascular function.
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Chapter 2 Methods: Clinical study
2.1 Aims and objectives of the study
To assess the impact of length and hydrophilic coating of the transradial 
introducer sheath on the incidence of radial artery spasm, radial artery 
occlusion, local inflammatory reaction and other vascular complications.
- To compare the impact of the TR band and Radistop compression 
haemostatic devices on the time taken to achieve haemostasis, radial 
artery occlusion rates, local vascular complications and patient tolerance 
of the device.
2.2 Study design
This was a prospective, randomised, single-blind, single-centre study. All 
patients attending The Cardiothoracic Centre, Liveipool (now Liveipool Heart 
and Chest Hospital) for coronary angiography or coronary intervention by the 
transradial approach were screened and invited to participate in the study. Those 
giving consent to participate were randomised by computer-generated random 
numbers. The randomisation was perfonned in blocks of eight and the patients 
were randomised into eight groups. Each treatment group consisted of one type 
of the radial introducer sheath and one type of haemostatic compression device to 
be used during the transradial procedure. The eight randomised group are as 
following:
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1. Long hydrophilic sheath (23 cm) + TR band
2. Long hydrophilic sheath + Radistop
3. Long uncoated sheath + TR band
4. Long uncoated sheath + Radistop
5. Short hydrophilic sheath (13 cm) + TR band
6. Short hydrophilic sheath + Radistop
7. Short uncoated sheath + TR band
8. Short uncoated sheath + Radistop
2.3 Study outline
Patients were screened in the pre-assessment clinic (elective procedures) or ward 
(urgent procedures). All eligible patients were approached and informed about 
the nature and purpose of the study. Those agreeing to participate were entered 
into the study after giving informed consent (Figure 2-1).
2.4 Inclusion and Exclusion Criteria
2.4.1 Inclusion criteria
1. Intended procedure via the radial route.
2. Patient more than 18 years of age and able to give informed consent.
2.4.2 Exclusion criteria
1. Unable or unwilling to give informed consent.
2. Haemodynamically unstable patient.
3. Patients with forearm A-V fistula or patients with chronic renal failure.
4. Previous ipsilateral transradial procedure.
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Figure 2-1 Study procedures
Information sheet and consent fonn given
I
Consent obtained on the day of procedure
i
Randomisation
I
Clinical procedure
I
Questionnaire completed by operator (to comment on clinical radial artery 
spasm) immediately after the procedure, and other procedural details collected
i
Questionnaire completed by patient (to comment on the level of discomfort
during procedure)
I
Patient assessed before discharge for radial artery patency [hand held Doppler 
and modified Allen’s test] and local vascular complications by the investigator
(SR)
l
Long term radial artery patency and late vascular complications assessed at
4-6 month follow up visit
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2.5 Study Outcomes
2.5.1 Primary end-point
1. The incidence of clinical radial artery spasm, as assessed by the operator.
2.5.2 Secondary end-points
1. The incidence of radial artery occlusion.
2. The incidence of local vascular complications.
3. Procedural success rates via the radial route.
4. Time taken to achieve haemostasis.
5. Patient tolerance of the haemostatic device.
6. The incidence of radial artery occlusion at follow-up.
7. The incidence of late vascular complications.
2.6 Sample size
We have tested three interventions, in a factorial design, in our patient population. 
Special emphasis is needed at the design stage to calculate the sample size of a 
factorial trial. The most commonly suggested procedure is to perform separate 
calculations based on the target effect sizes for each of the interventions. The 
trial sample size is then simply the largest of these, and the trial is said to be 
powered to detect the main effects of each intervention (152, 153). However, this 
sample size is based on the crucial assumption that there is no interaction 
between the interventions. If the trial is to have adequate power to detect an 
interaction, then the sample size generally needs to be increased. It has been 
suggested that if the interaction is of primary interest then it is essential that the
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trial is powered to detect a reasonable target interaction effect. We have 
calculated the sample size with this pretext.
The incidence of clinical radial artery spasm is between 20 and 30% in studies in 
the literature, using several qualitative and quantitative definitions. We assumed 
that a 50% reduction in the incidence of radial artery spasm would be clinically 
significant. A factorial design was used to compare hydrophilic-coated and 
uncoated sheaths and short and long sheaths. This design allowed us to evaluate 
two factors (coating and length of introducer sheath) simultaneously and their 
impact on radial artery spasm without compromising the power of the study. The 
sample size was calculated for both hydrophilic-coated and long introducer 
sheaths and considering the primary end-point of clinical radial artery spasm.
The sample size for both coating and length of sheath independently was 
calculated as following:
p 1 = incidence of radial artery spasm from literature (20%) 
p 2= incidence of radial artery spasm with the intervention (10%)
50% relative reduction in the incidence of radial artery spasm 
a = 0.02 
P = 0.05
n= pi X aoo-pl) + P2 X (100- d2) xf(a, p)
(p2- pi)2
F(a, P) = 15
We calculated that we would need 375 patients in each ami of different 
introducer sheath types to detect a difference of this magnitude with statistical
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confidence in the result. We decided to recruit 400 patients in each ann to 
compensate for missing data. This is with significance level of 0.02 (alpha error), 
and power of 95% (beta error 0.05). We have calculated this sample size to keep 
the chance of type II error low and also to adjust for a potential interaction effect. 
Therefore, our aim was to recmit 800 patients in total thus comparing 400 
patients with long sheaths against 400 patients with short sheaths, 400 patients 
with coated sheaths against 400 patients with uncoated sheaths and 400 patients 
with each of the two different haemostatic compression devices.
2.7 Randomisation
Randomisation was performed by computer-generated random numbers from a 
proprietary database. The randomisation was performed in the blocks of eight to 
keep similar numbers of patients in each group throughout the study period. The 
person responsible for patient’s registration and randomisation (SR) was not in 
any way concerned or involved in the treatment of the patient. The treating 
doctor was informed of the treatment allocation prior to the procedure by the 
investigator (SR).
2.8 Recruitment
All patients scheduled to undergo transradial procedure at our centre (Liverpool 
Heart and Chest Hospital, formerly The Cardiothoracic Centre, Liverpool, UK) 
were contacted either at the pre-assessment clinic or inpatient cardiology wards. 
Five of the consultant cardiologists (JLM, RAP, RHS, NDP and JDM), who 
routinely use the radial artery for coronary procedures, agreed for their patients
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to be entered into the study. During the study period all patients were screened to 
see which met the inclusion and exclusion criteria. Those suitable were asked to 
participate in the study. Willing patients were provided with the patient 
information sheet (Appendix 1) and informed consent (Appendix 2) obtained. 
The patient information sheet and consent form were approved by local research 
ethics committee and hospital academic committee (06/Q1502/94)
After consent was obtained, patients were randomised to treatment strategies as 
previously described. Following randomisation the operator of the case was 
informed of the type of sheath and compression device to be used.
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Figure 2-2 Study outline diagram
Excluded (n= 120)
Not meeting inclusion criteria (n= 100)
Refused to participate (n= 20)
4 Patients underwent a femoral 
approach (protocol violation)
Short Uncoated 
n=197 (24.9%)
Short sheath 
n= 394
Long sheath 
n= 396
Coated sheath 
n= 397
Long Uncoated 
n=196 (24.8%)
Uncoated sheath 
n= 393
Randomisation (n=794)
Enrolment
Short Hydrophilic 
n=197 (24.9%)
Long Hydrophilic 
n= 200 (25.3%)
Follow up n= 625(79.1%)
Received allocated treatment (n= 790)
Assessed for eligibility in two phases 
Phase 1: November 2006-March 2007 (n= 570)
Phase 2: July 2007-January 2008 (n= 344)
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2.9 Data Collection
2.9.1 Demographics
Baseline characteristics were measured including age, sex, height, weight, and 
wrist circumference. The indication and urgency for the transradial procedure 
was identified. The indications were grouped as stable angina, acute coronary 
syndrome and acute myocardial infarction. The procedure was classified as 
routine, urgent or emergent depending on the clinical situation.
2.9.2 Ulno-palmar circulation
Each patient had ulno-palmar collateral circulation assessed before the procedure 
and documented, although patients were not excluded from the study on the basis 
of these tests. Each patient had a modified Allen’s test and a ‘plethysmography 
and oximetry’ test performed, as described below.
The modified Allen’s test:
The modified Allen’s test was performed according to the following protocol.
The examiner faces the patient, whose hand is supinated and the test is performed 
in well lit room. The radial artery and ulnar artery are located by their pulses.
The examiner’s thumbs are placed over the radial artery and ulnar artery 
simultaneously, with the four fingers of each hand placed behind the patient’s 
wrist and pressure is applied, sufficient to block the flow in the arteries. The 
patient is then asked to close his fist tightly several times to expel blood from the 
hand. The patient is then asked to relax the hand and extend the fingers into a 
slightly flexed position with the examiner maintaining the pressure on the radial
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and ulnar arteries. The hand at this point should appear blanched. The examiner 
then releases the pressure on the ulnar artery and continues applying pressure to 
the radial artery. The return of colour to the hand and fingers to its normal colour 
is noted and recovery time in seconds is noted to document patent ulnar collateral 
circulation. One experienced observer [SR] performed these tests in the majority 
of the patients. In the remaining patients these tests were performed by 
experienced operators as per protocol. The time taken to achieve normal colour 
of the hand is categorised in following five groups: less than 5 seconds, 5-10 
seconds, 10-15 seconds, 15-20 seconds, more than 20 seconds, and not at all.
The ‘plethysmography and oximetry test:
The spectrophotometric principles of the plethysmography and oximetry (PL & 
OX) tests are well known (26). The PL & OX tests were carried out as described 
by Barbeau et al (27). These were undertaken with a pulse oximeter with a clamp 
sensor applied to thumb. After the pulse oximeter is applied to the thumb, the 
wave form on plethysmography and oxygen saturations are observed before 
compression is applied to the radial artery. Following this, the radial artery is 
occluded to block any forward flow for two minutes and the above measurements 
are repeated while pressure on the radial artery is maintained. Plethysmography 
readings are divided into four types: A; no damping of pulse tracing immediately 
after radial artery compression and after two minutes, B; damping or reduced 
amplitude of pulse tracing immediately after radial artery compression but 
recovering to normal at two minutes, C; loss of pulse tracing followed by 
recovery of pulse tracing within two minutes, D; loss of pulse tracing without 
recovery within two minutes. Oximetiy results (SpOa) were either positive
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(reading present and constant) or negative during radial artery compression 
(Figure 2-3).
Figure 2-3 Plethysmography (PL) traces and oximetery (OX) recordings assessing ulno- 
palmar collateral circulation
Typ» Start After 2 min.
2.10 Procedural Details
2.10.1 Radial artery cannulation
In the standard fashion, with the arm supported with the wrist in mild 
hyperextension, local anaesthesia was achieved with 2% lignocaine, after 
disinfection. The radial artery was punctured using a 21-gauge arterial needle 
through which a 0.018 inch platinum-tipped nitinol guidewire was introduced. 
Following this the needle was withdrawn and a 6F introducer sheath with dilator 
taper length of 2.5 cm was introduced. All introducer sheaths and other kit used
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were from the same manufacturer (Cook, Incorporated) (Figure 2-4, Figure 2-5).
Long sheaths were 23cm in length and short sheaths were 13cm in length, with
and without a hydrophilic coating. After introducer sheath insertion, a weight-
adjusted dose of heparin, when required, was administered into the central
circulation. The routine use of a vasodilator cocktail was avoided and
vasodilators were only used in the event of radial artery spasm. In the event of
spasm 100 to 200pg of nitro-glycerine and/ or 2.5 to 5mg of verapamil were
administered via the radial artery sheath, at the operator’s discretion. The rest of
the procedure was performed according to the operator’s preference.
Procedural success via the radial route was defined as successful radial artery
puncture and completion of the intended coronary procedure.
Figure 2-4 The hydrophilic-coated short (13 cm) introducer sheath with dilator and guide 
wire.
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Figure 2-5 The uncoated long (23 cm) introducer sheath with dilator.
2.10.2 Introducer sheath removal and haemostasis
All introducer sheaths were removed immediately after the procedure and 
haemostasis achieved in the catheterisation laboratory using either a TR band or 
a Radistop according to randomisation. Only enough pressure was applied to just 
stop the bleeding and maintain forward flow in the radial artery. The TR band 
and Radistop devices were removed using the following protocols.
2.10.2.1 TR Band application and removal
On completion of the procedure introducer sheath is withdrawn by 2-3cm and the 
green marker on the TR Band is positioned over the arterial puncture site, 
approximately 0.5-1.0cm above the skin incision. Thereafter, the Velcro® strap
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is wrapped around the wrist and 15-18ml of air is injected through the valve to 
inflate the compression pad. The introducer sheath is then removed, observing 
for any bleeding. The syringe is then re-attached to the valve and air is slowly 
removed, watching for any bleeding. When bleeding occurs 2-3ml of air is re­
injected and the syringe removed. At this stage radial pulsation distal to the 
device should be detectable.
On return to the ward, air is slowly removed from the device, 2ml at a 
time, starting one hour after the procedure. Evidence of bleeding is watched for 
at all times and, if bleeding occurs, the device is re-inflated with l-2ml of air. 
Further air is removed every thirty minutes until the pad is completely deflated 
and the band is then removed. (Appendix 3) (Figure 2-6)
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Figure 2-6 The TR Band compression device
Showing the band, and syringe used to inflate and deflate compression pad, top panel. Bottom 
panel shows its application on the wrist at the radial artery puncture site.
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2.10.2.2 Radistop application and removal
The hand and the wrist are placed in the support plate and the distal and proximal 
Velcro® straps are fixed. Then centre of the compression pad is placed directly 
over the radial artery puncture site, continually applying pressure while removing 
the introducer sheath. The compression pad is secured with the third Velcro® 
strap while continual pressure is applied. The radial pulse should be palpable 
after the application of the device.
After one hour of return to ward, pressure is reduced gradually, observing 
for haemostasis and checking this every thirty minutes until the device can be 
removed completely (Appendix 4, Figure 2-7).
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Figure 2-7 Radistop application over the radial artery puncture site after a transradial 
procedure.
The procedure time was considered as the period ranging from sheath 
insertion to sheath withdrawal. The time taken to achieve haemostasis was 
defined as the period from application of the compression device to its complete
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removal. The results of time taken to achieve haemostasis are recorded as the
time to which the device was removed, in units of 0.5 hours as the devices are 
only checked every 30 minutes.
2.10.3 The assessment of radial artery spasm (Operator)
Clinical radial artery spasm was defined as pain reported by the patient to the 
operator and /or advanced difficulty perceived by the operator during insertion, 
manipulation, and/or withdrawal of the introducer sheath and catheter.
This was assessed by a questionnaire completed by the operator.
Operators were asked to report the presence of radial artery spasm on the 
following criteria:
1. The patient reported presence of continuous forearm pain.
2. The patient reported forearm pain only during catheter manipulation.
3. The patient reported forearm pain during sheath retrieval.
4. Finn grip of the catheter during manipulation.
5. Augmented resistance to sheath retrieval.
The operators were allowed to score on multiple criteria. This scoring system 
excludes cases of difficult manipulation due to severely tortuous radial or 
subclavian arteries, therefore only identifying those patients in whom difficulty 
was likely to be due to radial artery spasm.
Clinical radial artery spasm was defined as meeting at least two criteria from the 
above scoring or, only one criterion and the need for intra-arterial vasodilators. 
This qualitative definition has been used by other investigators in the past and 
correlates well with quantitative measures of radial artery spasm.
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2.10.4 The assessment of discomfort experienced by the 
patient
Each patient was approached soon after the procedure and asked to complete a 
questionnaire on their experience during the procedure. They were requested to 
comment on degree of discomfort felt, if any, during introduction of the sheath at 
the beginning and pull-back at the end of procedure.
The pain score denotes the patient’s assessment of pain during the pullback of 
sheath:
1. Nothing felt during procedure.
2. Noticeable sensation but no pain.
3. Mild pain.
4. Significant pain (Moderate)
5. Unbearable pain (Severe)
Radial artery spasm was defined as any moderate or severe discomfort during the 
manipulation of the introducer sheath reported following the procedure.
2.10.5 Assessment of the compression devices
Each patient included in the study was randomised to either a TR band or a 
Radistop device to achieve haemostasis. The compression device is applied at the 
end of procedure and the removed over time as per protocol. All patients were 
assessed by investigator (SR) to evaluate the discomfort, if any, caused by the 
use of the haemostatic device. Patients were asked to describe the level of 
discomfort as none, mild, moderate, or severe while the compression device was 
in situ. If the randomised compression device was changed to the other 
compression device, the reason for this was documented.
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2.10.6 Assessment of radial artery patency
Each patient included in study was examined by investigator (SR) or another 
experienced physician to assess the patency of the radial artery after removal of 
haemostatic compression device and before the patient was discharged. Pulsation 
of the radial artery was examined by palpation proximal and distal to the original 
entry site. When equivocal, patency was confirmed by using a hand held Doppler 
device (10MHz) to detect flow proximal and distal to the original entry site. Each 
patient also had a reverse Allen’s test performed to assess the patency of radial 
artery. A reverse Allen’s test is performed in a similar way to an Allen’s test but 
after compression of both arteries at the wrist, the pressure over the radial artery 
is released first to demonstrate patency of the radial artery. In equivocal cases a 
PL & OX test was performed to assess the patency of the radial artery by 
applying pressure on ulnar artery and measming PL & OX from the patient’s 
thumb.
Radial artery occlusion was defined as the absence of palpable radial pulsation 
distal to the puncture site, confirmed by an abnormal reverse Allen’s test and/or 
absent Doppler flow signals. When patency of the radial artery was assessed by 
measuring PL and OX, and radial artery was considered occluded when the 
oxygen saturation and pulse pressure tracing during ulnar artery compression 
were absent.
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2.10.7 Assessment of local complications
Local vascular complications were assessed after removal of the compression 
device. Vascular complications were defined as following:
1. Oozing from the puncture site was defined as any leakage of blood from 
the puncture site requiring re-application of pressure.
2. Ecchymosis was defined as bleeding into the subcutaneous tissue planes 
causing bluish-purple discoloration of more than 4cm in diameter without 
visible swelling.
3. Local haematomas were classified as small if they were less than 2cm in 
their largest diameter.
4. Local haematomas were classified as large if they were 2cm or more in 
any diameter.
5. Any evidence of access site inflammation or infection at discharge was 
also noted.
6. Radial, brachial or subclavian artery dissection was documented if proven 
by angiography.
Patients were advised to contact the investigator or the on-call doctor 
immediately if any late complication occurred and were reviewed by the 
investigator [SR].
2.10.8 Follow-up
The majority of patients undergoing transradial PCI were routinely reviewed in 
the outpatient clinic after four to six months. In those attending, the patency of 
the radial artery and any late access site complications were assessed. Follow-up
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assessment was performed as per protocol and in the majority of cases by the 
investigator (SR).
Radial artery patency at follow up was assessed using the same techniques as the 
assessment before discharge.
A history of late access-related complication, particularly any evidence of local 
allergic reactions, was sought and documented. Any access site vascular 
complications were documented and evidence of functional impairment was 
recorded.
2.11 Analysis of Data
2.11.1 Computers and software
All data was collected on a case record form (Appendix 5) and subsequently 
transferred on to a Microsoft Access database for storage and analysis.
2.11.2 Statistical analysis
Continuous variables are expressed as percentages and described as mean ± 
standard deviation and comparisons were made using Student’s t test.
Categorical variables are expressed as frequencies and compared using the chi- 
squared test or Fisher’s exact test where appropriate. The comparison was done 
between long introducer sheaths and short introducer sheaths and between coated 
and uncoated introducer sheaths in the factorial design. Multivariate analysis was 
performed using logistic regression analysis to assess predictors of clinical radial 
artery spasm and radial artery occlusion rates. A secondary analysis was
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performed as an extension to the multivariate regression analysis, by introducing 
a term for interaction. Analysis of variance (ANOVA) was applied to detect any 
interaction between coating and length of the introducer sheaths for the primary 
outcome of radial artery spasm. Similarly, there was a comparison done between 
the two different compression devices. All analysis was performed using SPSS 
Version 15. hi all tests p values of less than 0.05 were considered significant.
2.11.3 Presentation of results from a factorial trial
Interaction tests were not applied for the secondary outcomes as the sample size 
was powered to test the primary outcome. The results are presented as the 
primary outcome analysis relating to the main interventions (hydrophilic coating 
and length of introducer sheath) investigated in the trial, A common 
misunderstanding is that outcome measures should be analysed and presented 
separately for each of the four factorial cells (long coated, long uncoated, short 
coated, and short uncoated in our study), but to do so would fail to realise the full 
efficiency and purpose of the factorial design (152). Even in trials powered for 
main effects, a test for the interaction should be provided (152, 154). Going with 
this guidance, we have presented our primary outcome results comparing all 
patients receiving coated versus uncoated sheath and long versus short sheath.
Chapter 3 Methods: Physiological study
3.1 Aims and objectives of the study
- Assessment of changes in the vascular function of the radial artery following a 
transradial coronary procedure.
- Assessment of the impact of the length and coating of the transradial introducer 
sheath on changes in the vascular function of the radial artery.
3.2 Study design
Patients in this study were a selected subgroup of patients enrolled in the larger 
prospective randomised study, where patients were assigned to one of two 
different introducer sheaths: a hydrophilic coated (coated sheath) or a sheath 
without coating (uncoated sheath).
Patients were tested on three occasions: the day of the transradial procedure 
(immediately before the catheterization, “pre”), the day after catheterization 
(“post”) and approximately three months after catheterization (“recov”). 
Volunteers were requested to abstain from alcohol or caffeinated beverages and 
cigarettes for 12 hours prior to each testing session. Assessments were taken in a 
quiet, temperature-controlled room. Patients rested in a supine position for a 
minimum of 20 minutes to ensure that all hemodynamic variables had stabilized. 
The radial artery was assessed with the aim extended and supported at an angle 
of approximately 80° from the torso. A rapid inflation/deflation pneumatic cuff 
was positioned on the imaged arm around the wrist. A standard catheter sheath 
was then used to mark the length of the catheter on the surface of the aim, from
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the scaphoid process. Care was taken to image the same section of the artery 
during repeat measurements. We assessed both amis to determine whether 
changes as a consequence of catheterization were specific, or more generalized, 
throughout the vascular system. On each occasion flow-mediated [endothelial- 
dependent] dilatation (FMD) was assessed over a distal section of the radial 
artery, within the zone that would contain the sheath. A minimum of 20 minutes 
rest was observed between repeated FMD assessments in the same arm. 
Endothelium-independent function was assessed as the vascular response to a 
sublingual dose of glyceryl trinitrate (GTN). A minimum of 30 minutes elapsed 
between repeat doses of glyceryl trinitrate.
3.3 Study outline
Visit 1 (pre-assessment clinic)
1. Information sheet provided (Appendix 6) and infonned consent obtained.
Visit 2 (On the day of the procedure)
1. Baseline demographics were recorded and Allen’s test perfomied.
2. Vascular function of the radial artery was assessed before the transradial 
procedure. Endothelium-dependent and endothelium-independent vasodilatation 
was measured on both radial arteries as described in section 3.9.
3. Following assessment of vascular function, the transradial procedure was 
performed.
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Visit 3 (24 hours after the procedure)
1. Patients were invited for repeat assessment of vascular function of the radial 
artery one day after the procedure
Visit 4 (Follow-up after three to four months)
1. Patients were reviewed and followed-up to repeat the assessment of vascular 
function of the radial artery.
3.4 Inclusion and exclusion criteria
3.4.1 Inclusion criteria
1. Intended transradial coronary procedure
2. Patient at least 18 years old and able to give informed consent.
3.4.2 Exclusion criteria
1. Previous ipsilateral or contralateral transradial procedure or coronary 
artery bypass surgery.
2. Myocardial infarction during the previous three months.
3. Valvular heart disease.
4. Left ventricular ejection fraction less than 40%.
5. Chronic obstructive lung disease.
6. Renal or hepatic dysfunction.
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3.5 End-points
The end-points were the change in flow-mediated and GTN-mediated 
vasodilatation between the initial assessment (“pre”) and the assessments the day 
after (“post”) and at follow-up (“recov”) stages. The sample size was calculated 
considering the change in endothelium-dependent vasodilatation between “pre 
and “post” stages as a primary end-point..
3.6 Sample size
The sample size estimation was based on historical studies performed by 
Woodman and Green et al (128), using a novel computerised edge-detection and 
wall-tracking software system. We have used this software to reliably and 
reproducibly measure the change in radial artery diameter in our study subjects.
In this study (128) the standard deviation (SD) for determining sample size was 
calculated by using the SD of the mean of visits 1 and 2 (between-subject 
variance) for parallel design. Sample size was then calculated using the following 
formula:
For a paired t-test; sample size = .
Woodman and Greens study (128) showed the mean absolute difference between 
visits was 1.6±1.0% in the flow-mediated dilatation (FMD) measurement in 
normal subjects. Similarly there was a between-visit difference in the GTN- 
mediated dilatation of 3.8±3.3%. Based on this study we assumed that detection 
of 2.0% change in FMD will be clinically relevant. Therefore, assuming a power 
of 90% (alpha= 0.05), a parallel design study would require 16 patients in each
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arm. We recruited 40 patients to account for loss in follow-up and completing all 
three visits.
3.7 Randomisation
The patients for this sub-study were recruited form main clinical study 
randomisation and after thorough discussion with the patients. Consecutive 
patients fulfilling inclusion and exclusion criteria that agreed and gave consent to 
attend for all three visits to undergo vascular function testing were included in 
the physiology sub-study.
3.8 Radial artery access and transradial procedural 
details
The radial artery was approached with the aim extended and supported with the 
wrist in mild hyperextension. Local anesthesia was achieved with 2% lignocaine 
after disinfection at the puncture site. The radial artery was punctured with a 21 
gauge arterial needle through which a 0.118 inch platinum-tipped nitinol 
guidewire was introduced. Following this, the needle was withdrawn and a small 
skin incision was made. A 6 F introducer sheath (13 or 23 cm in length, external 
diameter 2.6 mm, Cook Medical Inc. Bloomington, IN, U.S.A) with a dilator tip 
length of 2.5 cm was inserted. Routine use of vasodilator cocktail (arterial 
vasodilators like, nitroglycerine, verapamil, or diltiazem) was avoided and a 
weight-adjusted dose of heparin was introduced into the central circulation 
following the introduction of the first catheter. All introducer sheaths were 
removed at the end of the procedure and haemostasis achieved in the
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catheterization laboratory by a compression device. The patients were mobilized 
immediately and the compression device was removed after two to four hours.
3.9 Experimental procedural details 
3.9.1 Experimental design
All studies were performed under standardized conditions and preferably at the 
same time of day. All measurements were performed by one experienced 
investigator (ED), who is a post-doctoral fellow (Research Institute for Sports 
and Exercise Sciences, Liverpool John Moore’s University, Liverpool) with 
experience in performing vascular function studies. This operator was blinded to 
the randomisation data. All procedures were performed after six hours of fasting 
and patients were asked to abstain from caffeine or alcohol for 12 hours before 
the assessment. Patients were advised to continue with their medications as 
normal. Each patient had flow-mediated dilatation (FMD) and glyceryl trinitrate- 
mediated dilatation assessed using high resolution B-mode ultrasound imaging of 
the radial artery. There were six examinations performed during each visit, in the 
following order:
1. Flow-mediated dilatation (FMD) distally on the ipsilateral forearm (a few 
cm above the flexor retinaculum): Distal FMD, treatment arm.
2. Flow-mediated dilatation (FMD) distally on the contralateral forearm, 
similar in location to the treatment arm: Distal FMD, control arm.
3. Flow-mediated dilatation (FMD) at least 13 cm above the intended radial 
puncture site on the ipsilateral forearm: Proximal FMD, treatment ann.
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4. Flow-mediated dilatation (FMD) similar in location on the contralateral 
forearm: Proximal FMD, control arm.
5. Glyceryl trinitrate (GTN)-mediated dilatation distally on the ipsilateral 
forearm: GTN-mediated dilatation, treatment arm.
6. Glyceryl trinitrate (GTN)-mediated dilatation distally on the contralateral 
forearm: GTN-mediated dilatation, control arm.
Two different lengths (23cm and 13cm) of introducer sheaths were used to assess 
their impact on vascular function of the radial artery. With the use of the 13 cm 
length introducer sheath guide, catheters used during procedure come into 
contact with the radial artery beyond the sheath. Therefore there is the potential 
for radial artery injury and an effect on vascular function of the proximal radial 
artery. In contrast, the 23 cm long sheath comes into contact with a large area of 
the radial artery and reduces guide catheter irritation of the proximal portion. 
These two lengths can potentially have different effects on the vascular function. 
Therefore, to test the effect of different length, the vascular function is tested at 
two different points, the distal being covered by the sheath in all cases. The 
proximal area assessed would be covered by the sheath when the long sheath was 
used, but would be exposed to catheter movements in patients receiving the short 
sheath.
3.9.2 Vascular measurements
Patients were rested supine with the test arm extended and immobilised with the 
foam supports at an angle of approximately 80 to 90 degrees from the torso. 
Heart rate (HR) and mean arterial blood pressure (MAP) were determined from
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an automated sphygmomanometer (Dinamap; GE Pro 300V2, Tampa, Florida) 
on the contralateral arm. A rapid inflation/deflation paediatric pneumatic cuff 
was positioned on the imaged forearm at the level of the wrist to provide the 
stimulus to hand ischaemia. A 12MHz multi-frequency linear array probe 
attached to a high resolution ultrasound machine (T3000, Terason, Burlington, 
MA) was used to image the radial artery in the forearm. The radial artery was 
imaged just above the inflator cuff and at a second point which was around 13cm 
above first measurement. These measurements were performed on both forearms 
in the order described in section 3.9.1. Ultrasound parameters were set to 
optimise longitudinal B- mode images of the lumen/arterial wall interface. 
Continuous pulsed wave Doppler velocities were obtained using the ultrasound 
machine, and data were collected using the lowest possible isonation angle 
(always less than 60 degrees), which did not vary during each study.
After adjusting for gain and compression settings, the images were acquired and 
archived for later measurements.
3.9.3 Flow-mediated dilatation (endothelium- 
dependent NO-mediated function).
To examine the radial artery FMD response, a rapid inflation/deflation paediatric 
pneumatic cuff was used to provide the ischaemic stimulus. After an initial 15 
minute resting period, baseline scans assessing resting vessel diameter and flow 
were recorded over one minute. The cuff was then inflated to > 200 mm Hg for 
five minutes. Diameter and flow recordings resumed 30 seconds before cuff 
deflation and continued for five minutes thereafter as described by Black et al
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(198). Peak artery diameter and flow, and the time taken to reach these peaks 
after release of the occlusion, were recorded.
These measurements were repeated after 20 minutes on the contralateral arm at a 
similar location on the forearm. Following this a repeat measurement is 
perfonned on the test aim at a higher point on the foreami to measure the FMD, 
and also repeated a higher point on the contralateral arm after a wait of 20 
minutes. This whole process gave FMD measurements at two locations 
(proximal and distal) on each foreann.
3.9.4 Glyceryl trinitrate-mediated dilatation
(endothelium-independent NO-mediated function)
Following a further 15 minute recovery period, 400 jig of GTN was administered 
sublingually and the diameter of the radial artery and the peak blood flow were 
measured for the following five minutes. Blood pressure and pulse rate were 
measured simultaneously on the contralateral foreami before and after the 
administration of GTN. The ultrasound measurements were perfonned on the test 
arm at the distal point at the wrist corresponding to the FMD site measurements. 
Following a further 20 minute recovery period, GTN-mediated dilatation 
measurement was performed at a similar location on the contralateral forearm.
3.9.5 Radial artery diameter measurement and blood 
flow analysis
Post-test analysis of radial or brachial artery diameter was perfonned using 
custom-designed edge detection and wall-tracking software, which is 
independent of investigator bias as shown by Woodman et al (128). This study
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has shown a significantly lower (6.7%) mean intra-observer coefficient of 
variation compared to traditional manual measurements using the intima-lumen 
interfaces (32.5%, p<0.05) and intima-media interfaces (32.5%, p<0.05). This 
study also shows significantly lower coefficients of variation for between-visit 
reproducibility of FMD and GTN-mediated dilatation of 14.7% and 17.6% 
respectively. Assuming 80% power and an alpha of 0.05, eight subjects with 
matched controls would be required, in a parallel design study, to detect an 
absolute change of 2.5% in flow-mediated dilatation.
In this technique the video signal is taken directly from the ultrasound machine, 
and, using an IMAQ-PCI-1407 card, is encoded and stored as a DICOM (Digital 
Images and Communication in Medicine) file on a personal computer. 
Subsequent software analyses of this data were performed at 30Hz using an icon- 
based graphical programming language and toolkit (Lab VIEW 6.02, National 
Instruments). The initial phase of image analysis involved the identification of 
regions of interest (ROI) on the first frame of every individual study (Figure 3-1). 
These ROTs allowed automated calibration for diameter on the B-mode image 
and velocity on the Doppler strip. An ROI was then drawn around the optimal 
area of the B-mode image. Within this ROI a pixel density algorithm 
automatically identified the angle-corrected near and far wall e-lines for every 
pixel column within the ROI. The algorithm begins by dividing the ROI into the 
upper half, containing the near wall himen-mtima interface, and the lower half 
containing the far wall interfaces. The near wall intimal edge is identified by a 
rake routine that scans from the bottom to the top of the upper half of the ROI. 
The position of the edge is established by determining the point where the pixel 
intensity changes most rapidly. Typical B-mode ROIs therefore contained
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approximately 200 to 300 diameter measures per frame, the average of which 
was calculated and stored. This process occurred at 30 frames per second. We 
did not use the R-wave gating function in our software because of previous 
observations that at 30MHz the continuous assessments of diameter yields 
similar results.
Figure 3-1 Still frame of B- mode ultrasound image acquisition software.
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A final ROI was drawn around the Doppler waveform and the peak of the 
waveform was automatically detected (Figure 3.1). The mean diameter measure 
derived from within the B-mode ROI (above) was synchronized with the velocity 
measure derived from the Doppler ROI at 30 frames per second. Ultimately, 
from this synchronized diameter and velocity data, blood flow (the product of 
cross sectional area and Doppler velocity [v]) and shear rate (four times velocity
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divided by diameter) were calculated at 30Hz. All data were written to file and 
retrieved for analysis in a custom-designed analysis package (Figure 3-2). Our 
method of blood flow assessment is closely correlated with actual flow through a 
“phantom” arterial flow system (129).
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Figure 3-2 Upper panel, The flow-mediated dilatation (FMD) edge detection 
and wall tracking software “output screen”.
Lower panel, still frame of B-mode ultrasound data “Display” software.
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3.10 Data analysis
Baseline diameter, flow and shear rate were calculated as the mean of data 
acquired across the one minute preceding the cuff inflation period (Figure 3.2). 
Each dot in upper panel represents the mean of of 200 to 300 diameter measures 
for a given frame, with a frame rate of 30 Hz. The vertical cursors are placed at 
times corresponding to baseline or FMD periods. The peak responses after FMD 
are calculated by applying a smoothing algorithm which determines the median 
value of a moving window of consecutive data points. The “peak” of the 
smoothed median values detected in this way is then used to calculate %FMD via 
comparison to the preceding baseline. Lower panel in Fig 3-2 shows continuous 
traces of radial artery diameter (white), velocity (red), and flow (yellow) against 
time. Vertical “begin” and “end” cursors are placed to zoom in on selected data 
and, ultimately, calculate mean (MBF) blood flows, area under the flow curve, 
and similar data foe shear rate. After cuff deflation, a custom-designed software 
program was used to determine peak diameter from the 30Hz of mean diameter 
data derived according to the methods described above. Peak diameter after cuff 
deflation was automatically detected according to an algorithm which identified 
the maximum bracket of data subsequent to performance of a moving window 
smoothing function. This smoothing routine calculates the median value from 
100 consecutive samples, before the window shifts to the next bracket of data 
which shares 20% overlap with the preceding bracket. The maximum value of all 
the calculated median values is then automatically detected and chosen to 
represent the peak of the diameter curve (Figure 3.2).
Flow-mediated dilatation was calculated as the percentage rise of this peak 
diameter from the preceding baseline diameter. The time to peak diameter (in
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seconds) was calculated from the point of cuff deflation to the maximum post­
deflation diameter. Calculation of FMD and time to peak were therefore 
observer-independent and based on standard algorithms applied to data which 
had undergone automated edge detection and wall tracking. In accordance with 
recent findings (130), we expressed FMD data normalised to the shear rate 
stimulus responsible for endothelium-dependent FMD. The post-deflation shear 
rate data, derived from simultaneously acquired velocity and diameter measures 
at 30Hz (Figure), was exported to a spreadsheet and the area under the shear rate 
curve (AUC) calculated for data up to the point of maximal post deflation 
diameter (FMD) for each individual. In this way an individual’s FMD was 
normalised to the area under their own shear rate curve between the point of 
deflation and maximal dilatation for that individual.
Similarly the GTN-mediated vasodilatation is measured as the percentage rise in 
the peak diameter from the preceding baseline diameter.
3.11 Statistical analysis
The responses initially were assessed using 3-way ANOVAs with linear mixed 
models. This was followed-up using 2-way repeated measures ANOVAs on the 
coated or uncoated groups compared over time and between anus. The 
differences between coated and uncoated groups were compared using a 2-way 
ANOVA on time and coating in either the catheterized or non-catheterized arms 
separately. Post-hoc analysis was carried out using paired t-tests. The effects of 
the FMD test or GTN administration on blood pressure were assessed using a 1- 
way ANOVA. Baseline characteristic differences were determined using t tests
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or chi-square tests. Results are expressed as means ± SD. A p value <0.05 was 
considered significant.
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Chapter 4 Results: Clinical study
4.1 Summary of the results
The success rate of the clinical procedure was high at 96% and was not affected 
by different introducer sheaths. Radial artery spasm prevented the completion of 
the procedure in 2.2% of cases.
Operator-defined radial artery spasm was observed in 29.4% patients and 21.8% 
patients reported discomfort of moderate or severe intensity during the procedure. 
There was significantly less radial artery spasm and patient-reported discomfort 
observed in patients receiving a hydrophilic sheath. No significant difference was 
observed between the groups receiving long and short sheaths.
Radial artery occlusion at the time of discharge was observed in 9% of the 
patients, similar in the two groups. A large local haematoma or arterial dissection 
was seen in 2.2%. Minor complications, such as a small haematoma, ecchymosis, 
or oozing were observed in about 20% of the patients in each group.
There were significantly more patients reporting no discomfort in the TR band 
group compared to the Radistop group. Patients in the Radistop group reported 
significantly more pain across all levels of severity. Local vascular complications 
were similar in both groups. The time taken to achieve haemostasis was 
significantly longer in the TR Band group compared to the Radistop group.
4.2 Study population
Between November 2006 and January 2008, 794 patients were included in the 
study. During the initial five months, 570 patients were screened and 505 patients
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were included in the study. The most common reason for exclusion was previous 
ipsilateral transradial procedure (60 patients) and five patients refused to consent. 
The recruitment for the remaining patients was slow due to an interim analysis 
and recruitment of patients for the vascular function sub-study. During this 
period 350 patients were screened and 295 patients were included in the study. 
Forty patients were excluded because they had had a previous ipsilateral 
transradial procedure, 10 patients refused to participate in the study and another 
five patients were not included because the treating physician excluded them 
from the trial. Out of these 794 patients, four patients underwent a femoral 
approach without an attempt at radial artery cannulation (protocol violation) and 
the results from 790 patients are included in this analysis on an intention-to-treat 
basis.
4.3 Baseline characteristics of the study population
Baseline characteristics of the whole population are shown in Table 4-1 and are 
typical for a population with ischaemic heart disease. The mean age of the 
patients included in the study was about 63. Approximately three quarters of the 
patient in the study were male and one quarter female. Nearly 70% of the 
patients were hypertensive and 91.0% were hyperlipidaemic on treatment, as 
expected in patients with coronary artery disease. About a fifth of the patients 
were diabetic and about 75% of the patients were either ex-smokers or current 
smokers.
We measured other physical parameters in our study population such as height, 
weight and wrist circumference. Body mass index (BMI) and wrist/BMI ratio 
were calculated, as shown in Table 4-1.
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Table 4-1 Baseline and procedural characteristics of the study patients.
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
Study population 
n=790
Age (years) 62.9±11.1
Male 586 (74.2%)
Hypertension 547 (69.2%)
Hyperlipidaemia 719(91.0%)
Diabetes mellitus 155(19.6%)
Current smoker 188 (23.8%)
Allen’s test: ‘not at all’ 46 (5.8%)
PL+OX test: type D 56 (7.1%)
Clinical presentation:
Stable angina 549 (69.5%)
Acute coronary syndrome 241 (30.5%)
Wrist circumference (cm) 17.2±1.2
Height (cm) 168.8±9.8
Weight (kg) 83.7±16.4
BMI (kg/m2) 29.2T4.9
Number of catheters used 1.6±0.9
Time sheath in situ (minutes) 50.4±28.3
Procedure:
Diagnostic 61 (7.7%)
Intervention 729 (92.3%)
4.4 Ulno-palmar Circulation
The ulno-palmar collateral circulation was assessed in each patient at the 
baseline prior to the procedure. Each patient underwent an Allen’s test and a 
plethysmography and oximetry (PL&OX) test, the results of which are shown in 
Table 4-2, Figure 4-land Figure 4-2.
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Figure 4-1 Allen’s test results
Frequency
<5s 5-10s 10-20s >20s Not at all
Figure 4-2 Plethysmography and oximetry test results
90%
80%
70%
60%
Frequency 50%
40%
30%
20%
10%
0%
Type A Type B Type C Type D
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Table 4-3 The correlation between the Allen’s test and the PL&OX test
Allen’s test PL+ OX TEST Total
Type A Type B Type C Type D
< 5s 278 3 1 0 282
5-10s 343 5 0 0 348
10-20s 46 22 3 1 72
>20s 8 10 10 14 42
Not at all 1 0 4 41 46
Total 676 40 18 56 790
Figure 4-3 Correlation between Allen’s test and PL&OX Test
<5s 5-1 Os 10-20s >20s Not at all
The correlation between the Allen’s test and the PL&OX test is shown in Table 
4-3and Figure 4-3. As shown in the table the majority of patients with an Allen’s 
test up to 20s have a PL&OX test type A, B or C, which reflects physiologically 
normal ulno-palmar collateral circulation. On the other hand the majority of 
patients with a negative Allen’s test have a PL&OX test type D showing 
inadequate ulno-palmar circulation. However, up to two thirds of patients with an 
Allen’s test of more than 20s show a PL&OX test of type A, B or C, reflecting
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adequate ulno-palmar circulation and only one third of the patients show 
inadequate ulno-palmar circulation by the PL&OX test. Patients were not 
excluded from our study or deemed unsuitable for a procedure via the radial 
artery on the basis of the ulno-palmar circulation test results.
4.5 Clinical presentation of the study patients
The majority of the patients included in our study presented with stable angina 
with 549 (69.5%) of the patients undergoing a procedure for stable angina 
pectoris and 241(30.5%) patients undergoing a procedure for the investigation 
and treatment of an acute coronary syndrome. This reflects the standard 
percutaneous coronary intervention activity at a tertiary cardiac centre.
Ill
4.6 Treatment allocation
Table 4-4 Treatment allocation of the study patients.
Treatment allocation Number of 
patients
%
Sheath+compression device
1 .Long hydrophilic + TR band (LH+TR) 101 12.8
2.Long hydrophilic + Radistop (LH+RADI) 99 12.5
3.Long uncoated + TR band (LU+TR) 98 12.4
4.Long uncoated + Radistop (LU+RADI) 98 12.4
5.Short hydrophilic + TR band (SH+TR) 97 12.3
6.Short hydrophilic + Radistop (SH+RADI) 100 12.6
7.Short uncoated + TR band (SU+TR) 99 12.6
8.Short uncoated + Radistop (SU+RADI) 98 12.4
Length
Long 396 50.1
Short 394 49.9
Coating
Coated 397 50.3
Uncoated 393 49.7
Compression Device
TR Band 395 50
Radistop 395 50
4.7 Procedural characteristics
4.7.1 Operators
All the procedures were performed by consultant interventional cardiologists 
(41%) or specialist registrars in the advanced stage of training in coronary 
intervention under the direct supervision of a consultant (59%).
4.7.2 Procedural success
Procedural success via the ipsilateral radial route was achieved in 757 (96.0%) 
patients. The procedure could not be completed via the ipsilateral radial route in 
33 (4.0%) patients. The reasons for procedural failure in the different treatment
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amis are shown in Table 4.5. There were a higher number of procedural failures 
with short sheaths compared to long sheaths but there was no significant 
difference seen between coated and uncoated sheaths.
In the study population as a whole, radial artery spasm (RAS) was the reason for 
procedural failure in 17 (2.1%) cases, radial loop and subclavian tortuosity in two 
(0.25%) cases each, inability to pass the guide wire up the radial artery in eight 
(1.0%) cases, failure to puncture the radial artery in three (0.37%) cases, and 
poor guide catheter back up in one (0.12%) case. The majority of these 
procedures were completed without any problem from the contralateral radial 
artery. Only five cases (0.63%) crossed over to a femoral approach to complete 
the procedure.
Table 4-5 Procedural failure by study group
Long 
sheath 
n= 396
Short 
sheath 
n= 394
Coated 
sheath 
n= 397
Uncoated 
sheath 
n= 393
Radial artery spasm (17) 6 11 7 10
Radial loop (2) 0 2 1 1
Subclavian tortuosity (2) 1 1 1 1
Unable to pass sheath guide wire (8) 2 6 4 4
Unable to puncture radial artery (3) 0 3 1 2
Poor guide catheter back-up (1) 1 0 1 0
Total (33) 10 23 15 18
4.7.3 Procedure time
The procedure time ranged from 10 to 234 minutes with a median value of 45 
minutes. The mean procedure time was 50.2 minutes with a SD of 28.4 minutes.
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4.7.4 Number of catheters used
The number of catheters used during the procedure ranged from one to five with 
a median of one and a mean (SD) of 1.7(0.9)
4.7.5 Procedures performed
The total number of procedures performed via the radial approach in this study 
was 790 which included 61 diagnostic procedures (7.7%) and 729 procedures 
that involved coronary intervention (92.3%)
4.7.6 Heparin use
A weight-adjusted dose (70units/kg) of unfractionated heparin was given to 
patients undergoing coronary intervention. The administration of heparin was left 
to the operator’s discretion in patients undergoing diagnostic coronary 
procedures. A total of 60 (7.6%) procedures were performed without 
administration of heparin and one patient was given 1000 units of heparin. The 
remaining 729 (92.3%) patients received heparin ranging from 3000 units to 
14000 units during the procedure as part of our routine clinical practice.
4.8 Study end-points
The study endpoints in the whole study cohort are shown in Table 4-6, Figure 
4-4 and Figure 4-5.
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Table 4-6 Outcomes following transradial procedures
End points Number of cases, 
(%)
Operator’s assessment of spasm:
Patient-reported continuous pain (RCP)
Patient-reported pain during catheter manipulation (RPCM) 
Forearm pain during sheath retrieval (FPSR)
Firm grip of catheter (FGC)
Augmented resistance to sheath removal (ARSR) 
Operator-defined spasm
79 (10.0%)
103 (13.0%) 
250(31.6%)
93 (11.8%)
193 (24.4%)
230 (29.4%)
Use of spasmolytic drugs during procedure (SD) 81 (10.4%)
Patient assessment of pain
Nothing felt during procedure
Noticeable sensation but no pain
Mild pain
Moderate pain
Severe pain
Moderate or severe pain
366 (46.3%) 
112(14.2%)
140 (17.7%)
107 (13.6%)
65 (8.2%)
172 (21.8%)
Patient assessment of compression device
No discomfort
Mild discomfort
Moderate discomfort
Severe discomfort
Severe discomfort causing cross-over
555 (70.3%)
161 (20.4%)
51 (6.5%)
20 (2.5%)
3 (0.4%)
Radial artery patency (at hospital discharge)
Patent
Occluded
717(90.5%)
73(9.5%)
Local vascular complications
No complications
Oozing
Ecchymosis
Small haematoma
Large haematoma
588 (74.4%)
52 (6.6%) 
87(11.0%)
43 (5.4%)
17 (2.2%)
Radial or brachial artery dissection
Subclavian artery dissection
2(0.3%)
1(0.1%)
Time taken to achieve haemostasis 
(hours, median and interquartile range)
5.0 (4.0-6.0)
Radial artery patency (at follow up), n- 625
Patent
Occluded
582(93.1%)
43(6.9%)
Late access site complications, n=625
Swelling and infection
Pseudo-aneurysm
21(3.4%)
1 (0.15%)
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Figure 4-4 Operator-defined radial artery spasm scores
RCP
RCP: Reported continuous pain; RPCM: Reported pain during catheter manipulation; FPSR: 
Forearm pain during sheath retrieval; FGC: Firm grip of catheter; ARSR: Augmented resistance 
to sheath removal;
SD: Use of spasmolytic drugs during procedure; RAS: Operator-defined spasm.
Figure 4-5 Operator-defined radial artery spasm with the different sheaths.
□ Long hydrophilic 
■ Long uncoated
□ Short hydrophilic
□ Short uncoated
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4.8.1 Operator-defined radial artery spasm
Operator defined radial artery spasm was observed in 230 (29.4%) of the patients 
included in the study. Spasmolytic drugs were used in 81 (10.4%) patients to 
treat radial artery spasm. Further breakdown of the different individual scores of 
radial artery spasm as defined by the operators are shown in Figure 4-4 and 
Figure 4-5.
4.8.2 Forearm pain during the procedure
Moderate or severe discomfort during introduction or pull-back of the introducer 
sheath was observed in 172 (21.8%) patients in the study population. Nearly half 
of the patients 366 (46.3%) reported feeling nothing during the pullback or 
insertion of the introducer sheath. 112 patients (14.2%) reported noticeable 
sensation but no discomfort during the pull back or insertion of the introducer 
sheath and 140 patients (17.7%) reported mild discomfort.
Nearly one quarter of the patients (22%) reported moderate or severe 
discomfort during the pull back or insertion of the introducer sheath. Moderate 
discomfort was experienced by 107(13.6%) patients and severe discomfort was 
experienced by 65(8.2%) (Figure 4-6),
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Figure 4-6 Discomfort felt by the patient during sheath retrieval
Nothing felt Noticeable Mild pain Moderate pain Severe pain Moderate or
sensation severe pain
4.8.3 Radial artery patency
Radial artery occlusion was seen in 73 (9.2%) patients before discharge from 
hospital after removal of the compression device. In 717 (90.8%) patients the 
radial artery was patent. However, none of the patients with radial artery 
occlusion reported any symptoms of hypoperfusion or functional impairment of 
the hand.
4.8.4 Time taken to achieve haemostasis
As shown in Table 4-6, the time taken to remove the compression device ranged 
from one to 19 hours with a median and interquartile range of five and four to six 
hours respectively.
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4.8.5 Patient tolerance of the haemostatic device
As shown in Table 4-6, most patients did not report any discomfort during the 
time period when the compression device was in place. A mild or moderate 
degree of discomfort was reported by 161 (20.4%) and 51 (6.5%) patients 
respectively during the application of the compression device (Fig 4.7). Twenty 
(2.5%) patients reported severe discomfort with the application of the 
compression device and in three cases (0.4%) patients with a Radistop were 
changed over to the other available compression device (TR Band). No crossover 
from TR band to Radistop occurred.
Figure 4-7 Patient tolerance of the haemostatic device.
I
Mild discomfort Moderate discomfort Severe discomfort
4.8.6 Local vascular complications
There were no access site complications seen in 588 (74.4%) patients after the 
removal of the compression device. Oozing needing manual pressure to stop 
bleeding after removal of the compression device was seen in 52 (6.6%) patients. 
Ecchymosis was seen in 87 patients (11.0%) and small and large haematomas
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were seen in 43(5.4%) and 17(2.2%) patients respectively (Figure 4-8). Radial or 
brachial artery dissection and subclavian artery dissection was seen in two 
(0.3%) and one (0.1%) patients respectively. None of these local vascular 
complications required any further interventions or blood transfusion and they 
were all managed conservatively without adverse sequelae.
Figure 4-8 Local vascular complications
Small haematoma Large haematoma
4.8.7 Radial artery occlusion rates at follow up
Radial artery patency was assessed in 625 patients during routine follow-up 
between four and six months. The radial artery was patent in 582 (93.1%) 
patients and occluded in 43 (6.9%) patients. None of the patients reported any 
vascular compromise or functional impairment.
4.8.8 Late access site complications at follow up
Twenty-one (3.4%) patients reported late swelling or discharge following 
discharge from the hospital. Twelve patients were treated by antibiotics or
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surgical drainage. These patients usually sought treatment for their access site 
inflammation elsewhere and we do not know the quality of the diagnosis of 
infection. One patient developed a pseudo-aneurysm of the radial artery at the 
puncture site and needed surgical intervention.
4.9 Interaction between length and coating of the 
introducer sheath
We have described primary endpoints of the study for the different introducer 
sheaths in previous sections. Univariate analysis of variance (UNIANOVA) was 
applied to the data to assess any interaction between length and coating of the 
introducer sheath on operator-defined spasm and patient-reported discomfort 
during the radial procedure. There was no significant interaction observed 
between length and coating for operator-defined radial artery spasm (F=T.213, 
p= 0.108) or patient-reported discomfort (F=2.085, p= 0.631). The results of 
comparisons between long and short introducer sheaths and hydrophilic coated 
and uncoated sheaths are described in the following sections.
4.10 Comparison between long and short introducer 
sheaths
4.10.1 Baseline characteristics
As shown in Table 4-7, the baseline characteristics including risk factors and 
physical profile were well matched between long and short introducer sheath 
groups. The patients5 age and sex distribution was similar between the two 
groups. There were more patients with a negative Allen's test in patients who 
received a short introducer sheath compared to those who received a long 
introducer sheath but there was no difference seen in the PL&OX test between
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the two groups. The clinical presentation was similar in both groups, as was the 
physical profile including wrist circumference, height, weight, and body mass 
index.
Table 4-7 Baseline and procedural characteristics of the long and short 
introducer sheath groups.
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
Long
n=396
Short
n=394
p value
Age (years) 62.7±11.5 63.0±10.8 0.73
Male 293 (74.0) 293 (74.4) 0.93
Hypertension 275 (69.4) 272 (69.0) 0.94
Hyperlipidaemia 360 (90.9) 359 (91.1) 1.0
Diabetes mellitus 68 (17.2) 87(22.1) 0.09
Current smoker 95 (24.0) 93 (23.7) 1.0
Allen’s test: ‘not at all* 16(4.0) 30 (7.6) 0.03
PL&OX test: type D 25 (6.3) 31 (7.9) 0.41
Clinical presentation:
Stable angina
Acute coronary syndrome
280 (70.7) 
116(29.3)
269 (68.3)
125 (31.7)
0.49
Wrist circumference (cm) 17.2±1.2 17.3±1.2 0.82
Height (cm) 168.7±10.1 169.0±9.4 0.68
Weight (kg) 83.2±16.6 84.1±16.2 0.43
BMI (kg/m2) 29.2±4.8 29.4±5.0 0.54
Number of catheters used 1.7±0.86 1.7±0.85 0.96
Time sheath in situ (minutes) 50.2±27.7 50.6±28.9 0.88
Compression device:
Radistop
TR band
196 (49.5) 
200 (50.5)
199 (50.5)
195 (49.5)
0.83
Procedure:
Diagnostic
Intervention
32 (8.1)
364 (91.9)
29 (7.4)
365 (92.6)
0.79
4.10.2 Procedural characteristics
The majority of the patients underwent coronary intervention and the proportion 
undergoing intervention was similar between both groups. The total number of
122
catheters used during the procedure and the procedure time were similar in the 
two groups. Haemostasis following procedure was achieved by TR Band or 
RADISTOP in equal proportion (by randomisation).
4.10.3 Outcomes
Table 4-8 Outcomes with long and short introducer sheaths
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
Long Short p value
n=396 n=394
Operator-defined spasm 110(27.9) 120 (30.8) 0.39
Patient discomfort 85 (21.5) 87 (22.2) 0.41
Use of spasmolytic drugs 26 (6.6) 55 (14.1) 0.001
Local Complications 
Ecchymosis 43 (10.8) 44(11.2) 1.00
Oozing 31 (7.8) 21 (5.3) 0.20
Small haematoma 21 (5.3) 22 (5.6) 1.0
Large haematoma 8(2.1) 9 (2.3) 0.81
Dissection 0(0) 3 (0.8) 1.0
Occlusion 31 (8.0) 42 (10.9) 0.18
Late complications Long Short
n=324 n=301
Abscess or infection 11 (3.3) 10(3.3) 1.0
Pseudo-aneurysm 0(0) 1 (0.3) 0.51
Occlusion 27 (8.3) 16 (5.3) 0.12
4.9.3.1: Radial Artery Spasm
There was no difference in the rate of operator-defined radial artery spasm 
between patients receiving long and short introducer sheaths. Similarly, there 
were no differences in the patients’ discomfort level during insertion or retrieval 
of the introducer sheath between the two groups. However, there was a greater
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use of intra-arterial spasmolytic drugs in patients receiving short introducer 
sheaths (Table 4-8, Figure 4-9).
RCP: Reported continuous pain; RPCM: Reported pain during catheter manipulation; FPSR: 
Forearm pain during sheath retrieval; FGC: Firm grip of catheter; ARSR: Augmented 
resistance to sheath removal; SD: Use of spasmolytic drugs during procedure; RAS: Operator- 
defined spasm.
4.93.2: Local access site complication
There were similar rates of access site complications in both groups. Both small 
and large haematomas were infrequent and similar in incidence in patients 
receiving long and short introducer sheaths. Radial artery occlusion at the time of 
hospital discharge were seen in 8.0% and 10.9% (p=0.18) of patients receiving 
long and short sheaths respectively.
4.9.33: Late access site complications
Persistent radial artery occlusion was observed in 8.3% and 5.3% of the patients 
at the time of long term follow up in the long and short sheath groups. There 
were marginally higher rates of radial artery occlusion in patients receiving the
124
long introducer sheath, but this was not statistical significant (p=0.18). Late local 
access site swelling or infection were observed similarly in both groups (3.3% vs. 
3.3%, p=1.0).
4.11 Comparison between hydrophilic coated and 
uncoated introducer sheaths
4.11.1 Baseline characteristics
As shown in Table 4-9, the baseline characteristics including risk factors and 
biophysical profile were well matched between the coated and uncoated 
introducer sheath groups. Patient age and sex distribution were similar in both 
groups. The Allen’s test and PL&OX test results were similarly distributed in 
each group. The clinical presentation was also similar in both groups with two 
thirds of the patients presenting with stable angina. The biophysical profile, 
including wrist circumference, height, weight, and body mass index were 
comparable between patients receiving coated and uncoated sheaths.
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Table 4-9 Baseline and procedural characteristics in the coated and 
uncoated introducer sheath groups
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
Coated Uncoated P
n=397 n=393 value
Age (years) 62.7±11.2 63.1±11.1 0.57
Male 292 (73.6) 294 (74.8) 0.22
Hypertension 283 (71.3) 264 (67.2) 0.22
Hyperlipidaemia 366 (92.2) 353 (89.8) 0.26
Diabetes mellitus 79 (19.9) 76(19.3) 0.86
Current smoker 93 (23.4) 95 (23.9) 1.00
Allen’s test: ‘not at all’ 23 (5.8) 23 (5.9) 1.00
PL+OX test: type D 28 (7.1) 28 (7.1) 1.00
Clinical presentation:
Stable angina
Acute coronary syndrome
279 (70.3) 
118(29.7)
270 (68.7) 
123 (31.3)
0.64
Wrist circumference (cm) 17.2±1.3 17.2±1.1 0.98
Height (cm) 169.1±10.4 168.6±9.1 0.44
Weight (kg) 83.6±16.6 83.8±16.2 0.88
BMI (kg/m2) 29.2±4.8 29.4±4.9 0.52
Number of catheters used 1.67±0.88 1.69±0.82 0.74
Time sheath in situ (minutes) 47.4±26.0 53.6±30.2 0.003
Compression device:
Radistop
TR band
198 (49.9)
199 (50.1)
197 (50.1)
196 (49.9)
1.00
Procedure:
Diagnostic
Intervention
37 (9.3)
360 (90.7)
24 (6.1) 
369(93.9)
0.11
4.11.2 Procedural characteristics
The majority of the patients underwent coronary intervention, the rates of 
intervention and the total numbers of catheters used during the procedure were 
similar in the two groups. The procedure time was significantly higher in 
patients receiving an uncoated introducer sheath compared to patients receiving a 
hydrophilic-coated sheath. Compression device use was similar in the two groups.
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4.11.3 Outcomes
Table 4-10 Outcomes with coated and uncoated introducer sheath.
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
Coated Uncoated p value
(n=397) (n=393)
Operator-defined spasm 75 (19.0) 155 (39.9) <0.001
Patient discomfort 60(15.1) 112(28.5) <0.001
Use of spasmolytic drugs 37 (9.4) 44(11.4) 0.41
Local complications:
Ecchymosis 39 (9.8) 47(11.9) 0.30
Oozing 28 (7.1) 24 (6.1) 0.67
Small haematoma 22 (5.5) 21 (5.3) 1.0
Large haematoma 3 (0.8) 14(3.7) 0.006
Dissection 1 (0.3) 2 (0.5) 1.0
Occlusion 35 (8.9) 28 (10.0) 0.62
Late complications Coated Uncoated
(n=315) (n=310)
Abscess or infection 20 (6.3) 1(0.3) 0.0001
Pseudo-aneurysm 1 (0.3) 0(0) 0.57
Occlusion 24 (7.6) 19(6.1) 0.44
4.10.3.1: Radial artery spasm
There was less operator-defined radial artery spasm and patient-reported 
discomfort observed in patients receiving a hydrophilic-coated sheath (Figure 
4-10, Table 4-10). There was a 50% relative reduction in the occurrence of 
operator- defined radial artery spasm in patients receiving a hydrophilic-coated 
introducer sheath compared to those receiving an uncoated sheath. However, the 
use of intra-arterial spasmolytic drugs was similar in both groups.
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Figure 4-10 Operator-defined radial artery spasm scores by sheath coating
RCP: Reported continuous pain; RPCM: Reported pain during catheter manipulation; FPSR: 
Forearm pain while sheath retrieval; FGC: Firm grip of catheter; ARSR: Augmented resistance 
of sheath removal; SD: Use of spasmolytic drugs during procedure; RAS: Operator-defined 
spasm
4.10.3.2: Local access site complication
There were similar rates of small haematoma seen in the two groups but large 
haematomas were significantly more common in patients receiving uncoated 
introducer sheaths. All haematomas were managed conservatively by 
compression bandage and none needed surgical intervention. Radial artery 
occlusion rates at the time of hospital discharge were similar in patients receiving 
coated and uncoated sheaths (Table 4-10).
4.10.3.3: Late access site complications
Persistent radial artery occlusion was observed in 7.6% and 6.1% of the patients 
at the time of long term follow up in the coated and uncoated sheath groups. 
There was a higher occurrence of local swelling or infection at the arterial 
puncture site in patients receiving a hydrophilic coated sheath as compared to 
those receiving uncoated sheaths (Table 4-10).
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4.12 Comparison between different introducer 
sheaths
4.12.1 Operator-defined clinical radial artery spasm
The operators described the highest incidence of spasm in patients receiving long 
uncoated sheaths and the lowest in those receiving the long hydrophilic-coated 
sheath. Short sheaths had intermediate incidences with less spasm when the 
sheath was coated (Figure 4-11).
Figure 4-11 Radial artery spasm and patient discomfort by sheath type
45%
Long Long Short Short
hydrophilic uncoated hydrophilic uncoated
■ Spasm 
□ Discomfort
4.12.2 Forearm pain during the procedure
The patient experience of pain was similar to the operators’ definition of spasm, 
occurring most frequently when a long uncoated sheath was used and least 
frequently when a long hydrophilic-coated sheath was used (Figure 4-11).
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4.12.3 Radial artery patency
Figure 4-12 shows the incidence of radial artery occlusion early after discharge 
in the different sheath types used in study. The incidence of radial artery 
occlusion was highest when short uncoated sheaths were used and lowest with 
long uncoated sheaths. Short hydrophilic sheaths had a higher occlusion rate than 
long hydrophilic sheaths.
Figure 4-12 Radial artery occlusion rates with different sheaths
Overall LH LU SH SU
LH: Long hydrophilic sheath, LU: Long uncoated sheath, SH: Short hydrophilic sheath, SU: 
Short uncoated sheath.
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4.13 The comparison between TR Band and Radistop 
haemostatic compression devices
4.13.1 Baseline characteristics
As shown in Table 4-11, the baseline risk factors, including physical profile, are 
similar among both groups of patients who were treated with the TR Band and 
the Radistop haemostatic compression devices. Age and sex distribution was 
similar between both groups. The results of the Allen’s test and PL&OX test 
were equally represented in each group. Clinical presentation was also similar in 
the two groups and two thirds of the patients presented with stable angina. 
Biophysical profile including wrist circumference, height, weight, and body mass 
index was comparable between the patients receiving a Radistop or a TR Band.
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Table 4-11 Baseline and procedural characteristics and type of compression 
device used.
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
Radistop 
n= 395
TR Band 
n=395
p value
Age (years) 63.1±10.7 62.7±11.6 0.66
Male 290 (73.4) 298 (75.4) 0.30
Hypertension 268 (67.8) 279 (70.6) 0.44
Hyperlipidaemia 364 (92.2) 355 (89.9) 0.32
Diabetes mellitus 77(19.5) 78(19.7) 1.0
Current smoker
Ex-smoker
90 (22.8)
209 (52.9)
97 (24.5) 
196 (49.6)
0.62
0.39
Allen’s test:
Not at all 24 (6.1) 22 (5.6) 0.71
PL+ OX Test: Type D 26 (6.6) 30 (7.6) 0.82
Clinical syndrome:
Stable angina
Acute coronary 
syndrome
279 (70.6) 
116( 29.4)
276 (69.9) 
119(30.1)
0.91
0.82
Length of sheath:
Long
Short
196 (49.6)
199 (50.4)
200 (50.6) 
195 (49.4)
0.83
Coating of sheath: 
Hydrophilic
Uncoated
198 (50.1) 
197 (49.9)
199 (50.4) 
196 (49.6)
1.0
Wrist circumference (cm) 17,2±1.2 17.3±1.2 0.41
Height (cm) 168.7±9.6 169.0±10.0 0.63
Weight, (kg) 83.1±15.5 84.2±17.2 0.37
BMI (kg/n?) 29.2±5.1 29.3±4.7 0.81
Procedure time (minutes) 51.2±28.4 49.6±28.2 0.43
Number of catheters used 1.7±0.8 1.7±0.9 0.28
Heparin used during 
procedure
374 (94.7) 355 (89.9) 0.016
4.13.2 Procedural characteristics
The majority of the patients underwent coronary intervention and the rates of 
intervention were similar in the two groups. The total number of catheters used 
during the procedure and the procedure times were similar for both groups. 
Various introducer sheaths were used in similar proportions in both groups by
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randomisation. The frequency of heparin use during the procedure was lower in 
patients receiving a TR Band (Table 4-11).
4.13.3 End Points
4.11.3.1: Time taken to achieve haemostasis
As shown in Table 4-12, the time taken to achieve haemostasis was significantly 
longer in patients receiving a TR Band compression device compared to patients 
receiving a Radistop (Figure 4-13). However haemostasis was achieved in all 
patients with the designated compression device except for three patients in the 
Radistop group who crossed over to a TR Band because of severe discomfort.
Figure 4-13 Time taken to achieve haemostasis
Compression device
R T
Time taken to acheive haemostasis
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Table 4-12 Outcomes with different compression devices
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
Radistop TR Band P
n= 395 n= 395 value
Time taken to achieve 4.8±2.3 5.3±2.3 0.004
haemostasis(hours)
Patient discomfort
Moderate 34 (8.6) 17 (4.3) 0.019
Severe 18(4.6) 2 (0.5) 0.0003
Crossover to alternate 3 (0.8) 0(0) 0.25
device
Local complication
Ecchymosis 42 (10.6) 45 (11.4) 0.92
Oozing 28 (7.1) 24 (6.1) 0.57
Large haematoma 6(1.5) 11 (2.8) 0.33
Small haematoma 19 (4.8) 24 (6.1) 0.32
Occlusion at discharge 38 (9.6) 35 (8.9) 0.89
Occlusion at follow-up 25 (8.0) 18(5.6) 0.27
4.11.3.2: Patient tolerance of compression device
Overall both compression devices were well tolerated. However, significantly 
more patients complained of moderate or severe discomfort during compression 
with a Radistop device compared to the TR Band group (Figure 4-14). Three 
patients (0.4%) in Radistop group were crossed over to a TR Band because of 
severe discomfort.
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Figure 4-14 Patient tolerance of the haemostatic device
4.11.3.3: Access site complications
There were similar rates of small and large haematomas seen in each group 
( Figure 4-15). All haematomas were managed conservatively by compression 
bandage and none needed surgical intervention. Oozing of blood and ecchymosis 
after removal of compression device was seen in equal proportions in both 
groups of patients. Radial artery occlusion rates at the time of hospital discharge 
and at the time of follow-up were similar in the two groups.
Figure 4-15 Access site bleeding complications
Rad is top TR Band
□ Large Haematoma
□ Small haematoma 
■ Ecchymosis
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4.14 Predictors of Radial Artery Spasm
Table 4-13 shows the baseline and procedural characteristics in patients with and 
without operator-defined radial artery spasm during their transradial coronary 
procedure. Patients experiencing spasm were significantly younger and spasm 
was more likely in females. There were significantly more patients with diabetes 
experiencing spasm, but other risk factors were similar in the two groups.
The wrist circumference was significantly lower in patients experiencing spasm 
during the procedure. Similarly, the patients experiencing spasm were shorter, 
lighter, and had a lower body mass index.
There was a higher frequency of patients with abnormal ulno-palmar circulation 
in patients experiencing spasm. There was an equal distribution of an unstable 
clinical presentation in each group.
There was a significantly higher incidence of spasm in patients receiving 
uncoated introducer sheaths compared to those receiving coated sheaths. There 
was no significant impact of the length of the introducer sheath used on 
incidence of spasm.
The number of catheter exchanged or used during the procedure did not influence 
the incidence of spasm.
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Table 4-13 Baseline and procedural characteristics of patients with and 
without radial artery spasm
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
No Spasm 
n=553
Spasm
n=230
p value O.R/S.E* 95% C.I
Age (years) 63.7±10.9 60.9±11.5 0.001 0.87* 1.16-4.59
Females 115 (20.8) 87 (37.8) <0.001 1.75 1.41-2.16
Hypertension 383 (70.7) 159 (69.1) 1.0 1.004 0.79-1.27
Hyperlipidaemia 507 (91.7) 207 (90.0) 0.49 1.15 0.80-1.63
Diabetes mellitus 97 (17.5) 58 (25.2) 0.018 1.59 1.09-2.29
Current smoking 127 (23.0) 61 (26.5) 0.81
Allen’s test: Not at all 37 (6.7) 9 (3.9) 0.18
PL+OX:Type D 46 (8.3) 10(4.3) 0.04
Clinical syndrome:
Stable angina
Acute coronary syndrome
392 (70.9) 
161 (29.1)
156(67.8) 
74 (32.1)
0.39
Sheath length:
Long
Short
284 (51.4) 
269 (48.6)
110(47.8) 
120 (52.2)
0.39 1.15 0.84-1.56
Sheath coating:
Hydrophilic
Uncoated
320 (57.9) 
233 (42.1)
75 (32.6) 
155 (67.4)
<0.001 2.84 2.05-3.92
Height (cm) 169.6±9.7 166.8±9.5 <0.001 0.77* 1.37-4.38
Weight (kg) 85±16.2 80.3±16.3 <0.001 1.30* 2.11-7.21
BMI (kg/m2) 29.5T5.0 28.8T4.6 0.067 0.39* -0.04-1.47
Wrist circumference (cm) 17.4±1.2 16.9±1.2 <0.001 0.093* 0.27-0.64
Time sheath in situ (minutes) 51.1±28.0 48.7±29.0 0.001 0.87* 1.16-4.59
Number of catheters used 1.7±0.9 1.7T0.8 0.83 0.06* -0.11-0.14
A multivariate analysis of the independent predictors of spasm during transradial 
procedures was performed and the results are shown in Table 4-14. Female sex, 
young age, diabetes mellitus, small wrist circumference, and low BMI were 
found to be independent predictors of spasm in our study patients.
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Table 4-14 Independent predictors of radial artery spasm
Odds ratio 95% CJ. p value
Female sex 2.01 1.31-3.09 0.001
Age (years) 0.96 0.95-0.98 <0.001
Diabetes mellitus 1.84 1.22-2.76 0.003
Wrist circumference (cm) 0.86 0.72-1.02 0.096
BM1 (kg/nr) 0.96 0.92-1.00 0.059
4.15 Predictors of radial artery occlusion at the time of 
discharge
Table 4-15 shows the baseline variables, procedural characteristics and outcome 
measures associated with radial artery occlusion at the time of the patient’s 
discharge from hospital. Patients with occlusion were younger at the time of 
procedure and occlusion was more frequent in females. Other risk factors 
(hypertension, hyperlipidaemia and diabetes mellitus) did not influence this 
outcome in our study.
There was no significant influence of the length and the coating of the introducer 
sheath on the incidence of occlusion. Occlusion rates were also similar in the 
Radistop and the TR Band groups.
There was a significantly higher rate of occlusion seen in patients experiencing 
radial artery spasm during the transradial procedure. There was also a significant 
negative con-elation between the use of heparin during the procedure and the risk 
of occlusion. When heparin was used the rate of occlusion was 7.2% but when 
heparin was not used the rate was 22% (p=<0.0001).
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Wrist circumference was significantly smaller in patients who had occlusion after 
the procedure and patients with occlusion were shorter in height. There was no 
impact of weight and body mass index on the risk of occlusion.
Procedure time, or the duration that the introducer sheath remained in situ, and 
the time taken to achieve haemostasis were not related to the risk of occlusion in 
our study.
Table 4-15 Baseline correlates and procedural characteristics of patients 
with radial artery occlusion at the time of discharge.
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
Occlusion
n=73
No occlusion 
n=707
p value
Age 60.4±11.2 63.1±11.1 0.05
Female 31 (42.5) 170 (24.0) 0.001
Hypertension 48 (65.8) 492 (69.6) 0.80
Hyperlipaedemia 63 (86.3) 648 (91.7) 0.15
Diabetes mellitus 14 (19.2) 141 (19.9) 0.29
Sheath length:
Long
Short
31 (42.5)
42 (57.5)
361 (51.1) 
346 (48.9)
0.31
Sheath coating:
Coated
Uncoated
35 (47.9)
38 (52.1)
360 (50.9) 
347 (49.1)
0.14
Compression device:
Radistop
TR Band
38 (52.1)
35 (47.9)
351 (49.6) 
356 (50.4) 0.76
Operator-defined spasm 33 (45.2) 196 (27.7) 0.008
Heparin administered 53 (72.6) 666 (94.2) <0.0001
Height (cm) 167.0±8.5 169.0±9.9 0.056
Weight (kg) 82.4±17.2 83.8±16.4 0.52
Wrist circumference (cm) 16.8±1.2 17.3±1.2 0.001
BMI (kg/m2) 29.4±5.0 29.3±4,9 0.79
Time sheath in situ (minutes) 46.6±28.2 50.6±28.4 0.26
Time taken to achieve haemostasis 
(hours)
4.94±2.05 5.08±2.30 0.59
The results of a multivariate analysis showing independent predictors of 
occlusion are shown in Table 4-16. Younger age, smaller wrist size, operator
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defined spasm and failure to administer heparin were shown to be independent 
predictors of radial artery occlusion.
Table 4-16 Independent predictors of radial artery occlusion at the time of 
discharge
Variables O.R 95% C.I p value
Younger age (per year) 1.02 1.00-1.04 0.036
Smaller wrist size (per cm) 1.39 1.06-1.80 0.014
No operator-defined spasm 0.53 0.31-0.90 0,021
No heparin use 7.12 3.75-13.52 <0.0001
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Chapter 5 Results: Physiological study
5.1 Summary of the results
There was a significant reduction in flow-mediated dilatation (FMD) 
(endothelium-dependent) and glyceryl trinitrate (GTN)-mediated dilatation 
(endothelium-independent) of the radial artery in the catheterized arm with no 
change in the non-catheterized arm following a transradial procedure.
There was no significant difference in the magnitude of change in FMD between 
the use of coated and uncoated sheaths in the catheterized arm, with a significant 
effect of time, but no interaction of time and coating.
In the subjects who participated at the three month follow up, matched data 
revealed that FMD and the GTN-mediated vasodilatation decreased non- 
significantly and then returned towards baseline at three months in the coated 
sheath group and the uncoated group. There was no significant change in the 
FMD in the contralateral arm during the study period.
5.2 Study population
Thirty-five subjects (32 male) were recruited from the list of patients requiring 
radial artery catheterization for coronary angiography or coronary angioplasty. 
All were randomized in the main clinical study. The following were excluded: 
patients who had previously undergone coronary artery bypass surgery or 
coronary intervention via either radial route or had myocardial infarction during 
the previous three months, valvular heart disease, a left ventricular ejection
fraction less than 40%, chronic obstructive lung disease, and renal or hepatic 
dysfunction.
Fifteen of the patients had been randomized to a coated sheath; one patient had 
an occluded artery post-procedure that remained occluded at the three month 
recovery period. Occlusion was confinned by a reverse Allen's test and the 
existence of impaired SRauc following ischaemia (shear rate area under curve) as 
explained in methods section (Chapter 3). This subject’s data was removed from 
subsequent analysis. The other 14 subjects in the coated sheath group had FMD 
data collected pre-catheterization and post-catheterization and 12 of these had 
GTN-mediated vasodilatation at similar time points. A subgroup of six subjects 
was retested approximately three months after the procedure.
Twenty subjects were recruited in the uncoated group: all had FMD assessed 
before and after the procedure, with 19 able to complete the GTN testing. From 
this group 13 subjects were re-tested for the FMD and 12 for the GTN protocols 
approximately three months later.
5.3 Baseline and clinical characteristics of the study 
patients
Baseline and clinical characteristics of the patients who underwent assessment of 
the vascular function of the radial artery are shown in Table 5.1. Risk factors 
were standard for coronary artery disease populations. All patients in this group 
presented with chronic stable angina. All these variables were well matched in 
the coated and uncoated introducer sheath groups.
Various biophysical parameters and the procedure time, defined as the duration 
of the introducer sheath staying in the radial artery were also similar in the two 
groups.
Table 5-1 Clinical characteristics of the study patients (n=35).
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
All patients
n=35
Coated
n=15
Uncoated
n=20
p value
Age (years) 64.4±7.8 64.8±8.1 64.1±7.8 0.82
Male 32 (91.4) 13 (86.0) 19(95.0) 0.99
MAP (mmHg) 94±12 95±11 93±13 0.88
Heart rate (beats/minute) 62±12 62±13 62±13
Hypertension 25 (71.4) 10(66.7) 15 (75.0) 0.71
Hyperlipidaemia 32 (91.4) 13 (86.7) 19(95.0) 0.56
Diabetes mellitus 8 (22.8) 3 (20.0) 5 (25.0) 1.00
Height (cm) 171.0±8.6 169.5±8.7 172.1±8.5 0.37
Weight (kg) 88.2±16.0 83.6±9.5 91.6±19.0 0.23
Wrist circumference(cm) 17.1±0.9 16.3±3.9 17.1±1.0 0.36
Smoking:
Current
Ex-smoker
5 (14.3)
24 (68.6)
2(13.3)
10(66.7)
3 (15.0)
14 (70.0) 0.26
Stable angina 35 (100) 15(100) 20 (100) 1.00
5.4 Clinical outcomes of the study patients
There was significantly higher occurrence of operator-defined radial artery 
spasm and patient discomfort in patients receiving uncoated sheaths. Minor 
access site vascular complications were seen in one third of the patients and at
similar rates in the two groups. One patient had documented radial artery 
occlusion at the time of hospital discharge which remained occluded at follow up 
with no vascular compromise or functional impairment of the hand.
Table 5-2 Clinical outcomes of the study patients (n=35).
Continuous variables are presented as mean ± standard deviation, discrete 
variables as n (%)
All
patients
n=35
Coated
n=15
Uncoated
n=20
p value
Operator-defined spasm 9 (25.7) 0(0) 9 (45.0) <0.001
Patient discomfort 6(17.1) 0(0) 6(30) <0.001
Time sheath in situ (minutes) 66.4±27.3 70.4±30.3 64.2±24.0 0.54
Vascular complications:
Ecchymosis
Oozing
5 (14.3)
5 (14.3)
2(13.3)
4 (26.7)
3 (15.0)
1 (5.0) 0.18
Radial artery occlusion 1 (2.8) 1 (6.7) 0(0) 0.42
Late local infection 1 (2.8) 1 (6.7) 0(0) 0.42
Radial artery occlusion at follow up 1 (2.8) 1 (6.7) 0(0) 0.42
5.5 Baseline radial artery diameter in the catheterised 
and non-catheterised arms
The baseline radial artery diameter in the catheterized and non-catheterized arms 
is shown in figure 5.1. The radial artery diameter ranged from 1.8 to 3.5mm in 
the catheterised aim with a mean diameter of 2.79mm and standard deviation of 
0.43mm. These measurements were similar to those obtained in the control arm 
(2.65=t0. 45 mm, range: 1.9-3.5 mm).
Figure 5-1 Baseline radial artery diameter in control and catheterised arm 
Radial artery diameter on y axis (mm).
4
3.5 
3
2.5 
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1.5
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Catheterised arm Control arm
Baseline radial artery diameters were similar in the coated and uncoated groups, 
both in the catheterized and control arms. There was significant increase in the 
baseline diameter in the catheterised arm immediately after the procedure, which 
returned to baseline at follow up at three months.
^9577337
Table 5-3 Baseline and post-procedure radial artery diameters
Catheterized arm P Control arm P
Coated
n=15
Uncoated
n=20
Coated
n=15
Uncoated
n=20
Baseline radial
artery diameter
(mm)
2.68±0.50 2.88±0.37 0.20 2.62±0.50 2.68±0.42 0.73
Post-procedure
radial artery
diameter (mm)
3.01±0.44 3.10±0.42 0.56 2.59±0.46 2.89±0.42 0.23
5.6 Baseline endothelium-dependent vascular function 
(flow-mediated dilatation)
Baseline flow-mediated dilatation of the radial artery at the distal and proximal 
sites in both amis is shown in Table 5-4. There was no significant difference 
between the proximal and distal sites in the catheterized or the control amis.
Table 5-4 Baseline-flow mediated dilatation of the radial artery,
Patient number Catheterized ann FMD (%) Control arm FMD (%)
Distal Proximal Distal Proximal
1 6.99 - 16.82 -
2 10.94 9.25 11.15 11.18
3 8.62 10.86 15.11 13.25
4 9.32 11.75 7.33 7.67
5 15.00 13.40 13.30 -
6 10.59 10.22 11.62 10.33
7 6.23 5.69 7.29 8.45
8 10.16 10.67 8.53 8.14
9 4.26 4.36 7.83 6.47
10 13.36 16.20 14.36 22.17
11 9.80 4.60 14.62 3.98
12 16.90 8.23 10.53 7.73
13 6.65 9.28 6.60 7.27
14 6.85 6.40 6.20 7.21
15 7.20 8.82 8.12 10.00
16 5.96 4.01 11.11 10.55
17 8.81 7.89 9/94 10.43
18 11.81 15.47 7.97 7.92
19 9.94 10.43 10.07 10.61
20 9.12 7.18 6.25 8.96
21 7.77 8.75 7.73 7.80
22 8.84 10.76 9.65 12.73
23 6.82 4.79 8.87 6.29
24 7.01 9.97 7.01 7.09
25 16.02 8.10 10.37 11.42
26 6.23 5.69 6.72 6.84
27 11.97 10.50 10.39 11.24
28 13.02 13.17 12.87 12.15
29 5.08 5.98 6.73 -
30 10.78 12.24 10.88 8.18
31 5.56 5.45 6.59 4.83
32 5.50 5.03 5.50 4.80
33 5.09 6.15 5.21 4.54
34 7.38 5.65 7.24 7.09
35 9.13 10.50 6.25 13.13
Mean 8.98 8.74 9.33 9.07
Median 8.81 8.78 8.53 8.16
S.D 3.18 3.20 2.99 3.48
Range 4.26-16.90 4.01-16.20 5.21-16.82 3.98-22.17
Table 5-5 Baseline glyceryl trinitrate-induced dilatation of the radial artery.
Patient No Catheterized arm (%) Control arm (%)
1 21.25 15.5
2 14.95 11.6
3 13.00 10.1
4 15.61 8.7
5 16.06 13.7
6 8.90 -
7 15.50 8.5
8 9.60 8.6
9 11.04 9.9
10 - 12.7
11 6.19 7.6
12 14.37 14.9
13 15.73 11.5
14 24.64 7.6
15 11.62 7.9
16 14.23 12.2
17 11.28 14.7
18 5.98 7.3
19 14.72 12.5
20 7.21 8.6
21 10.96 13.2
22 16.94 13.3
23 11.23 13.3
24 5.36 7.3
25 24.79 18.6
26 15.50 8.0
27 15.25 17.8
28 27.06 10.1
29 10.03 10.2
30 10.43 12.8
31 8.08 13.4
32 7.07 7.6
33 7.58 9.4
34 10.86 8.3
35 29.18 19.9
Mean 13.59 11.39
Median 12.31 10.82
S.D 6.02 3.40
Range 5.36-29.18 7.3-19.9
5.7 Baseline glyceryl trinitrate-induced dilatation of the 
radial artery
Baseline GTN-mediated vasodilatation of the radial artery is shown in Table 5-5. 
The GTN-mediated dilatation of individual patients in both catheterized and 
control anns were highly variable. GTN-mediated vasodilatation of the radial 
artery was significantly higher in the catheterised aim at baseline.
5.8 The impact of transradial catheterization on 
vascular function of the radial artery
As shown in Figure 5-2, the FMD reduces significantly post-procedure in the 
catheterized arm and returns back to normal at three month follow up. These 
results were similar at the distal and proximal sites of the radial artery. Similarly, 
the GTN-mediated vasodilatation reduces significantly post-procedure in the 
catheterised arm and returns back to normal at follow-up.
FMD and GTN mediated vasodilatation remained unchanged in the control arm 
during the study period (Figure 5-3).
Figure 5-2 Flow-mediated and GTN-mediated dilatation in the catheterised 
arm (mean ± SD)
Distal site
Pre-procedure Post-procedure 3 month F/U
FMD (%) 8.98±3.18 5.19±3.45 7.80±3.74
P= <0.001 -------------------
P = 0.012
P= 0.71
Proximal site
Pre-procedure Post-procedure 3 month F/U
FMD (%) 8.74±3.20 4.86±3.38 7.90±4.50
P= <0.001 -------------------
P = 0.002
P= 0.85
Pre-procedure Post-procedure 3 month F/U
GTN (%) 13.59±6.02 8.53±4.22 13.37±6.19
P= <0.001 ---------------------
P = <0.001
P= 0.51
Figure 5-3 FMD at the distal site (a), proximal site (b), and GTN-mediated 
dilatation (c) in the control arm
(a)
Pre-procedure Post-procedure 3 month F/U
FMD (%)
Mean ± SD
9.33±2.99 8.92±3.01 9.01±3.40
P= 0.06 ------------------
P = 0.53
P= 0.32
(b)
Pre-procedure Post-procedure 3 month F/U
FMD (%)
Mean ± SD
9.07±3.48 9.19±4.21 8.99±2.57
P= 0.52 ------------------
P = 0.69
P= 0.41
(c)
Pre-procedure Post-procedure 3 month F/U
GTN (%)
Mean ± SD
11.39±3.40 12.02±4.10 11.54±4.07
P= 0.39 ------------------
P = 0.15
P= 0.61
5.9 Comparison of the baseline radial artery diameter 
and vascular function in the catheterised and control 
arms
As shown in table 5.6, the baseline radial artery diameter was significantly larger 
in the catheterised arm (right forearm in our study) both at the distal and 
proximal sites. The baseline endothelium-dependent vasodilatation was similar in 
both the catheterised and control arms, but we observed higher baseline GTN- 
induced vasodilatation in the catheterised arm.
There was a significant negative correlation between baseline radial artery 
diameters and flow-mediated dilatation (r=-0.361, p=0.033), which is abolished 
at follow up (i—-0.191, p= 0.294). Similarly, there was a significant negative 
correlation between baseline radial artery diameters and GTN-induced 
vasodilatation (r=-0.685, p<0.01).
Table 5-6 The baseline radial artery diameter and vascular function in 
catheterized and control arms
Measurements Catheterised arm Control arm p value
Artery diameter-distal (mm) 2.79±0.43 2.65±0.45 0.025
Artery diameter-proximal (mm) 3.03±0.52 2.85±0.54 0.013
FMD distal (%) 8.98±3.18 9.33±2.99 0.480
FMD proximal (%) 8.74±3.20 9.07±3.48 0.295
GTN-mediated dilatation (%) 13.59±6.02 11.39±3.40 0.020
5.10 The impact of sheath coating on endothelium- 
dependent vasodilatation
In the coated group there was a reduction in FMD in the catheterized ami with no 
change in the non-catheterized ann. The repeated measures were compared over 
time (pre, post and follow up) and between aims (catheterized and control arms)
as discussed in methods section in Chapter 3. There was a significant effect of 
time (p=0.04), ami (p=0.02) and interaction between ann and time (p=0.003). 
The FMD changed significantly with time after catheterization in catheterized 
aim.
In the uncoated group there was also a significant reduction in the FMD with no 
change in the non-catheterized ami. There was a significant effect of time 
(p=0.005), aim (p=0,001) and interaction between aim and time (p<0.001) 
(Figure 5.4). There was no significant difference between the time to peak 
hyperaemia and the shear rate area under the curve between the coated and 
uncoated sheath at different study time (Table 5.7).
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Figure 5-4 Changes in flow-mediated dilatation in the catheterized and non- 
catheterized arms pre and post-procedure
Top panels are coated sheath and lower panels are uncoated sheath. Data are presented as 
mean ± SD. * significantly different from pre (p<0.05)
Coated Sheath
Catheterised arm Control arm
Catheterised arm
Uncoated Sheath
Control arm
Table 5-7 Time to peak, baseline diameter and shear rate area under the 
curve (SRauc) pre-procedure (pre), the day following the procedure (post) 
and three months post-procedure (Recov) in the catheterized (cath) and 
non-catheterized (contr) arms
n=6for FMD and GTN in the coated group, n—13 for FMD and n~12for GTN 
in the uncoated group.
Endothelium-dependent flow-mediated dilatation (FMD) and endothelial- 
independent function (GTN-mediated dilatation) was assessed in the coated and 
uncoated catheter sheath groups. Cath; catheterized arm. Contr; non- 
catheterized control aim. ^significantly different from “pre” (p<0.05); 
$ significantly different from “post”.
Data are presented as mean ± SD.
Baseline diameter (mm) Time to peak (s) SRauc (s’1 10j)
Pre Post Recov Pre Post Recov Pre Post Recov
FMD PROTOCOL
Coated 26±5 29±4 27±6 94±49 100±54 113±27 25.2±19.2 28.5±17.3 27.2 ±13.8
CATH
Uncoated 29±4 32±4 27±4S 109±46 86±44 90±56 31.7±17.9 20.6±14.0 33.2±23.8
CONTR Coated 26±5 24±4 26±5 67±50 66±25 81 ±45 17.2±8.6 24.8±10.9 32.5±22.3
Uncoated 26±4 29±4* 28±4$ 87±24 103±68 89±48 23.0±7.1 27.3±15.7 26.8±16.9
GTN PROTOCOL
Coated 27±05 29±5 25±3 316±110 372±63 343±100
CATH
Uncoated 30±5 32±2 27±3S 353±84 250±128 278±104s
Coated 27±2 29±5 28±3 323±148 303±103 293±131
CONTR
Uncoated 29±3 29±3 3l±4s 245±105 297±109 266±114s
5.11 The impact of sheath coating on non-endothelium- 
dependent vasodilatation
In the coated group there was a reduction in the GTN response in the catheterized 
arm, with no change in the non-catheterized aim. ANOVA revealed no
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significant effect of time, but there was a significant effect of arm and interaction 
between arm and time.
In the uncoated group there was a reduction in GTN in the catheterized arm with 
no change in the non-catheterized arm. There was no significant effect of time, 
but there was a significant effect of arm and interaction between arm and time 
(Figure 5.5).
Figure 5-5 Changes in GTN-mediated dilatation.
Top panels are coated sheath and lower panels are uncoated sheath. Data are presented as 
mean ± SD. * significantly different from pre (p<0.05)
Coated Sheath
Cathetehsed arm Control arm
Uncoated Sheath
Cathetehsed arm Control arm
O 15
Although there was significant interaction among arm, time, and coating with the 
three-way ANOVA, there was no significant difference in the magnitude of 
change in FMD between the coated and uncoated conditions in the catheterized 
arm, with a two-way ANOVA demonstrating a significant effect of time, but no 
interaction of time and coating. Likewise, an ANOVA on the GTN data 
comparing the effect of time and coating in the catheterized arm showed a 
significant effect of time but no interaction between time and coating.
5.12 The impact of sheath coating on the recovery of 
endothelium-dependent vasodilation
In the subjects who participated in the three month follow up, matched data 
revealed that FMD decreased non-significantly and then returned towards 
baseline at three months in the coated sheath group. In the control limb, FMD 
was similar at all three time points. ANOVA on the post-procedure vs. recovery 
data comparing time and arm revealed no significant effect of time, a significant 
effect of ann, but no significant interaction. In the uncoated group, the FMD 
decreased significantly and returned to baseline at three months, hi the 
contralateral control limb, FMD was similar at all three time points (Table 5.8). 
ANOVA on the post-procedure vs. recovery data comparing time and arm 
revealed no significant effect of time, a nearly significant effect of arm and a 
significant interaction.
Table 5-8 FMD before, after and at follow-up in coated and uncoated 
sheaths
Sheath type Arm “pre” “post” “recov”
Coated sheath Catheterized arm 8.3±3.0% 3.7±2.5% 6.4±1.4%
Control arm 11.5±4.2% 10.5±3.8% 10.4±3.4%
Uncoated sheath Catheterized arm 8.2±2.4% 5.4±4.0% 9.4±4.1%
Control arm 8.8±2.6% 8.3±2.8% 8.2±3.5%
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Figure 5-6 Changes in flow-mediated dilatation from post-procedure to 
three month follow-up
Top panels are coated sheath and lower panels are uncoated sheath. Data is presented as 
mean ± SD. * significantly different from post (p<0.05)
Coated Sheath
Catheterised arm Control arm
18 18
Recov
□---------
Recov
Uncoated Sheath
Catheterised arm Control arm
— -----------
Recov Recoi
5.13 The impact of sheath coating on the recovery of 
non-endothelium-dependent vasodilation
The GTN data in the coated group decreased significantly and then returned to 
baseline at three months. In the contralateral limb, GTN-mediated function was 
similar at all three time points. ANOVA on the post-procedure vs. recovery data 
comparing time and arm revealed no significant effect of time or arm, but a
significant interaction between ami and time. In the uncoated group, GTN- 
mediated dilatation decreased significantly post-procedure and returned towards 
baseline levels at three months, hi the control limb, GTN-mediated function was 
similar at all three time points (Table 5.9). ANOVA on the post-procedure vs. 
recovery data comparing time and ann showed a significant effect of time, an 
almost significant effect of aim and a significant interaction between ann and 
time (Figure 5.6).
Table 5-9 GTN-mediated vasodilatation before, after and at follow-up in 
the coated and uncoated sheath groups.
Sheath type Arm “pre” “post” “recov”
Coated sheath Catheterized arm 17.9±5.7% 10.0±5.2% 16.6±5.6%
Control arm 15.7±5.6% 17.5±4.8% 14.6±3.9%
Uncoated sheath Catheterized arm 12.5±4.1% 7.4±3.9% 12.1±3.9%
Control arm 11.9±2.8% 12.3±2.4% 11.5±3.3%
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Figure 5-7 Changes in GTN-mediated dilatation from post-procedure to 
three-month follow-up.
Top panels are coated sheath and lower panels are uncoated sheath. Data is presented as 
mean ± SD. * significantly different from post (p<0.05)
Coated Sheath
Catheterised arm Control arm
RecovRecov
Uncoated Sheath
Catheterised arm
Recov
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A two-way analysis of variance was used to examine whether recovery of flow- 
mediated and GTN-mediated dilatation differed in the groups receiving coated 
and uncoated sheaths. There was no significant difference in the recovery of 
FMD from the post-procedure study to the follow-up study between the coated 
and uncoated conditions in the catheterized arm, with a two-way ANOVA
demonstrating a significant effect of time but no interaction of time and coating. 
There was also no significant difference in the recovery of the GTN-mediated 
dilatation from the post-procedure study to the follow-up study between the 
coated and uncoated sheaths in the catheterized arm, with two-way ANOVA 
demonstrating a significant effect of time but no interaction between time and 
coating. Baseline arterial diameters, time to peak, and shear rate area under the 
curve are presented in Table 5.7.
5.14 Hemodynamic measurements during the study
Mean arterial pressure during the study period is shown in Table 5.8. The mean 
arterial pressure was similar during various stages of flow-mediated dilatation 
measurement. In contrast the mean arterial pressure was significantly lower 
following administration of glyceryl trinitrate.
Table 5-10 Mean arterial pressure (MAP) during baseline measurements 
and post-cuff release or after glyceryl trinitrate (GTN) administration
pre-procedure (pre), the day following the procedure (post) and three months follow-up 
(Recov) in the catheterized (cath) and non-catheterized (No cath) arms.
Mean arterial pressure (MAP) was assessed in the contralateral arm. Measurements were taken 
during the baseline period and one minute after cuff release or three minutes after GTN 
administration. * significantly different from baseline (p<0.05). Data are presented as mmHg 
(mean ±SD).
COATED
Catheter Control
Baseline During Baseline During Baseline During Baseline During
FMD FMD GTN GTN FMD FMD GTN GTN
Pre 95±11 95±10 96±I0 89±11* 95±9 96*11 94*11 89*12*
Post 97±12 93±8 94±12 91*11 93*10 94*10 90*12 86*10*
Recov 89±11 83±10 83±14 75±9 85*16 81*18 83*12 77*11*
UNCOATED
Catheter Control
Baseline During Baseline During Baseline During Baseline During
FMD FMD GTN GTN FMD FMD GTN GTN
Pre 93*13 94*14 92*14 85*10* 93*14 93*11 93*14 90*11
Post 91*11 88*11 88*12 82*10* 91*16 88*13 88*12 82*12*
Recov 94*15 93*18 94*15 92*15 93*19 99*12 94*18 91*17
5.15 The impact of radial artery to introducer sheath 
diameter ratio on vascular function
There was significantly greater reduction in flow-mediated dilatation in patients 
with a radial artery to introducer sheath ratio of less than one compared to 
patients with a ratio more than one at the distal measurement site (Table 5-11). 
This was similar at the proximal measurement site (Table 5-12).
Similarly, there was a significantly greater impairment of GTN-mediated 
vasodilatation in patients with a radial artery to introducer sheath ratio of less 
than one (Table 5-13 and Table 5-12).
5.16 The impact of hydrophilic coating of the introducer 
sheath on the vascular function
There was no significant difference in the degree of impainnent of flow- 
mediated dilatation between coated and uncoated introducer sheaths at either the 
distal or proximal measurement sites. Impairment of GTN-mediated 
vasodilatation was also similar after coated and uncoated introducer sheaths.
Table 5-11 Flow-mediated dilatation at the distal radial site before and after 
the procedure
n FMD-D pre­
procedure
(%)
FMD-D post­
procedure
(%>
p value
Artery: sheath ratio
<1 10 10.57±3.59 4.49±3.50
>1 25 8.35±2.83 5.48±3.46 0.01
Coating of the sheath
Coated 15 10.23±3.68 5.18±3.14
Uncoated 20 8.05±2.45 5.20±3.74 0.06
Table 5-12 Flow-mediated dilatation (FMD-P) at the proximal radial site 
before and after the procedure
n FMD-P pre­
procedure (%)
FMD-P post­
procedure (%)
p value
Artery: sheath ratio
<1 8 10.28±4.00 4.30±1.97
>1 24 8.16±2.92 5.05±3.75 0.06
Coating of the sheath
Coated 12 9.46±2.78 6.67±3.29
Uncoated 20 8.22±3.55 3.78±3.01 0.24
5.17 The Impact of length of the introducer sheath on 
the vascular function
There was no significant difference in the degree of impairment of flow- 
mediated dilatation between long and short introducer sheaths at either the distal 
or proximal measurement sites. Impairment of GTN-mediated vasodilatation was 
also similar with long and short introducer sheaths.
Table 5-13 GTN-mediated vasodilatation before and after the procedure
n GTN-mediated
dilatation pre­
procedure (%)
GTN-mediated
dilatation post­
procedure (%)
p value
Artery: sheath ratio
<1 9 20.33±6.71 8.34±5.10
>1 25 11.16d=3.41 8.51±4.00 <0.001
Coating of the sheath
Coated 15 16.77±6.85 9.56±4.00
Uncoated 19 11.08±3.86 7.60±4.37 0.10
Chapter 6. Discussion
6.1. Introduction
The benefits of a transradial approach have clearly been documented in 
numerous studies in the past two decades (2, 101, 103-108, 111,112,). Access 
site bleeding complication rates are lower and early ambulation results in a 
significant reduction in patient morbidity and lower total procedure costs (101, 
112). Both patients undergoing the transradial procedure, and the staff caring for 
these patients, overwhelmingly prefer the transradial approach (120).
As a result of these benefits, there has been a worldwide increase in the use of 
radial artery for interventional procedures in the past several years. This 
experience has led to an understanding of the problems and complications that 
can result from the transradial approach. These complications often cause 
discomfort to the patient and can result in an inability to complete the intended 
procedure via the transradial approach. The ramifications of temporary or 
permanent radial artery injury are important not only in patients undergoing 
repeat interventional procedures, but also in patients in whom the radial artery 
may be used as a conduit for coronary artery bypass surgery.
As the transradial approach is evolving, there has been an influx of a variety of 
equipment including introducer sheaths, radial artery puncture needles, guide 
wires and guide catheters, manufactured by different commercial companies in 
the market. This equipment intends to facilitate the procedure by reducing
complications rates and improving procedural success rates. Despite the 
significant volume of research on the transradial approach in the setting of 
different clinical syndromes, there is a paucity of data making comparison 
between different designs of introducer sheath and compression device. 
Moreover, there is very limited data on vascular injury caused by the transradial 
approach.
In this study I have investigated the impact of length and coating of the 
introducer sheath on clinical outcomes and complications in patients undergoing 
coronary procedures via a transradial approach. I have also studied the effect of 
two commonly-used haemostatic compression devices. In order to understand the 
mechanism of the clinical impact of the different types of equipment used, we 
have studied in greater detail the effect of radial catheterisation on vascular 
function in a selected subset of patients.
6.2. Study design and sample size
The randomised controlled trial is often seen as the gold standard in study design 
and it provides the best quality evidence in medical research (144). This trial was 
an intervention study with different treatment arms. Hydrophilic-coated and 
uncoated, and long and short introducer sheaths are widely used by physicians 
during transradial coronary catheterisation with no definite evidence of one being 
superior to the other. I have used a randomised allocation of the various different 
introducer sheaths and randomisation was performed in the blocks of eight to 
keep nearly equal number of patients in each intervention group. An independent
researcher carried out the randomisation procedure and the treating physician 
was informed of the allocated treatment before the procedure. This helped to 
reduce any bias on the part of the treating physician. Randomisation is also 
important in avoiding the effects of known and unknown confounding factors 
that may affect the results e.g. age, sex, biophysical profile, or clinical condition 
of the patient. This trial was single-blinded and the patient was unaware of the 
type of introducer sheath allocated, but the treating physician was necessarily 
aware of the type of the introducer sheath at the time of the procedure. The 
physician could not be blinded to the sheath type as the long and short sheaths 
are obviously different to look and the coated sheaths differ in colour to the 
uncoated sheaths. Lack of blinding of the physician could potentially induce bias 
in the reported results; however, both physician-reported and patient-reported 
end-points were used in the study. I found good correlation between patient- 
reported discomfort and physician-reported measures of radial artery spasm 
(Patient-reported discomfort was seen in 63% of the patients with physician 
reported spasm as compared to only 4.2% in the no spasm group, odds ratio: 
19.84; C.I: 13.38-30.67, p< 0.0001).
I have used a factorial design to calculate the sample size and the analysis of 
results. Factorial designs provide an efficient method of evaluating more than 
one intervention (three interventions in our study) without loss of power. The 
important requirement of factorial design is that there is no interaction between 
the different interventions. I found no significant interaction between the length 
and coating of the introducer sheath.
6.3. Radial artery spasm
6.3.1. Definition of radial artery spasm
Radial artery vasospasm is induced by the introduction of a sheath or catheter 
into the radial artery and is usually manifest as difficulty in manipulating the 
catheter and/or the experience of discomfort in the forearm or ann by the patient. 
This is usually caused by the friction between the outer lining of the arterial 
sheath and the radial artery wall or pressure due to the oversfretching of the 
arterial wall. Several operator- and patient-specific questionnaires have been 
developed and used to qualitatively assess radial artery spasm. These 
questionnaires rate the difficulty perceived by the operator and the discomfort 
experienced by the patient during the procedure. Some investigators have tried to 
quantify radial artery spasm using an automated pull-back device (13). They 
have shown that all patients who experienced clinical radial artery spasm, as 
assessed subjectively by the difficulty perceived by the operator /or pain 
perceived by the patient during the procedure, had an mean pull back force of 
greater than 1 kg-force, while all other patients without a clinical spasm has 
mean pull back force of less than 1 kg-force. However, this study used a small 
number of patients. Similarly, Saito et al (21) tested in vitro friction resistance as 
a surrogate for radial artery spasm. They concluded that a hydrophilic coating on 
the introducer sheath results in significantly less friction resistance. Objective 
methods of assessing radial artery spasm are cumbersome and impractical in a 
clinical setting.
We have used a combination of definitions using operator- and patient- 
completed questionnaires used in previous studies (12, 13, 14) to quantify radial 
artery spasm both objectively and subjectively. Kiemeneij et al (14), using 6F 
23cm long radial sheaths has shown a direct correlation between the patient’s 
assessment of pain during withdrawal of the radial artery sheath and the 
maximum pull back force using an automated pull back device. We have used 
the same pain score and considered a pain score of IV and V (severe pain and 
unbearable pain respectively) as patient-defined radial artery spasm. In a 
previous study (14) these scores correlate with significant radial artery spasm 
measured objectively.
We have used a definition of operator-defined radial artery spasm similar to the 
one used in a previous validation study by Salmeron et al (13). They 
demonstrated radial artery spasm in 18% of cases using this definition and found 
a correlation with radial artery diameter response to different spasmolytic agents.
In these studies, we have used outcomes which are clinically relevant and take 
into account both operator-defined difficulty and patient-experienced discomfort 
to define the incidence of clinical radial artery spasm. These methods of 
assessing radial artery spasm are subjective and an important limitation of our 
study, but we used a standard questionnaire in all patients. We attempted to 
eliminate difficulty in manipulating catheters experienced during the procedure 
due to vascular tortuousity and other external or patient related factors to try to 
get a true assessment of radial artery spasm.
6.3.2. Mechanism of and factors predisposing to radial artery 
spasm
The radial artery has a prominent medial layer, composed of smooth muscle, 
which is largely dominated by alpha-1 adrenoreceptor function (61). Thus, 
increased levels of circulating catecholamines predispose to radial artery spasm.
It has also been well established that the vascular endothelium synthesizes and 
releases potent vaso-active factors that play active roles in vascular biology and 
pathophysiology. Among the various compounds formed in the endothelium are 
nitric oxide (NO) and endothelin-1 (ET-1), vasoactive factors that strongly 
influence the modulation of vascular tone (155). In the intact blood vessel wall, 
there is continuous basal release of both NO and ET-1, Mechanical forces such 
as shear stress and the activation of various receptors regulate the release of these 
vasoactive substances (156). However, the balance between the two antagonistic 
substances, together with other released factors and the reactivity of smooth 
muscle cells, play an important role in the determination of vascular tone and 
various other physiological processes. In the vascular wall, endothelial cells and 
smooth muscle cells also generate superoxide, which is involved in the 
pathogenesis of radial artery spasm through its effects on NO scavenging, on 
peroxynitrite generation, and on redox-sensitive cell-signaling pathways (157). 
An in vitro study by Aksungar et al (158) has shown that basal and thrombin- 
stimulated release of NO from the internal mammary artery is higher than from 
the radial artery, while the release of ET-1 from the internal mammary artery is 
less than from the radial artery. This observation shows the functional difference 
between the two arterial beds and the higher tendency to spasm in the radial 
artery in reaction to various stimuli. Similarly, a better understanding of the
contractile properties of radial artery smooth muscle will help address the critical 
question of radial artery spasm and its pathogenesis. Vascular smooth muscle 
tone is directly dependent on intracellular calcium concentration, which in turn is 
largely determined by the regulation of calcium-influx through voltage-gated 
calcium channels. Potassium and calcium currents also play important roles in 
regulating the vascular tone. Several factors including stretching and injury to the 
radial artery following radial artery manipulation could effect ion channel 
function and subsequently interfere with the vasomotor response. It is known that 
potassium channel function is intricately regulated by endothelium-released 
autocoids, including prostaglandin 12, nitric oxide and endothelium-derived 
hyperpolarising factors (159).
Local anaesthesia and adequate sedation to control anxiety during sheath 
insertion and catheter manipulation are potentially important preventative 
measures. Moreover, the friction or pressure caused by the mismatch between the 
outer diameter of the introducer sheath and the inner diameter of the radial artery 
could result in radial artery spasm by the various mechanisms discussed above. 
Therefore, increasing the mismatch between the size of radial artery and the 
radial sheath could potentially cause more irritation, damage and stimulation of 
the endothelium and smooth muscle cells. This would result in increased 
secretion of procoagulant and other vasoactive agents (ET-1 and superoxide 
radicals) causing radial artery spasm and injury. The length and coating of the 
introducer sheath could also impact on the occurrence of radial artery spasm. A 
long sheath, extending into the larger diameter brachial artery, allows insertion, 
manipulation and withdrawal of multiple catheters, without Motion between the 
moving catheter and the surface of the radial artery. This results in less
mechanical stimulation of the wall and also less irritation and damage to the 
endothelium and smooth muscle cells, and therefore could be associated with less 
spasm. However, if spasm develops it could be more difficult to retrieve a longer 
sheath. Sheaths coated with hydrophilic or lubricious coating may be easier to 
retrieve in the event of spasm.
There are other factors, such as the radial artery puncture needle and guide wire 
used to gain access to the radial artery, which can provoke radial artery spasm.
To reduce any confounding bias we used introducer sheaths from the same 
manufacturer (Cook Vascular Inc), thereby keeping all ancillary equipment 
constant.
Patient-related factors which might play a role in the genesis of radial artery 
spasm, such as fixed atherosclerotic lesions (160-162), vessel tortuousity, 
reduced radial artery diameter or erroneous entrance into small side branches.
6.3.3. The incidence of radial artery spasm
The routine use of vasodilator spasmolytic cocktails is widespread and several 
studies have shown radial artery spasm rates ranging from 10% to 20% (11-14, 
16) with the routine use of a vasodilator cocktail during introducer sheath 
insertion. In the placebo aim (where no vasodilator cocktail was used) of the 
SPASM study (16) 22.2% of the patients experienced moderate or severe 
discomfort during a transradial procedure compared to 4.5%-8.3% in the 
treatment arm. We deliberately avoided the use of vasodilator cocktail, to assess 
the effects of sheath design on the radial artery spasm without the confounding
influence of vasodilators. In our study radial artery spasm was observed in 29.4% 
of patients and 21.8% of patients experienced significant discomfort during the 
procedure, with 10.4% of patients deemed to require treatment with a vasodilator 
because of spasm. Our results are similar to the placebo arm of the SPASM study. 
However, three quarters of the patients in the SPASM study underwent a 
transradial procedure using a 5F introducer sheath and we used a 6F introducer 
sheath in all patients.
6.3.4. The impact of hydrophilic coating of the introducer 
sheath on radial artery spasm
There was significantly less clinical radial artery spasm observed in patients 
receiving a hydrophilic coated sheath. There was significantly less operator- 
defined radial artery spasm and patient-reported discomfort in patients receiving 
a hydrophilic coated sheath. This is the largest study to date evaluating the 
impact of a hydrophilic coating on radial artery spasm. Hydrophilic coating on 
the introducer sheath reduces the friction force between the radial artery wall and 
the introducer sheath resulting in less radial artery spasm and patient discomfort. 
The hydrophilic coating could potentially reduce irritation of the vascular wall 
and therefore also reduces occurrence of radial artery spasm as compared to 
uncoated introducer sheaths. This reduction in radial artery spasm is due to the 
reduced mechanical initation of the radial artery by the hydrophilic coated sheath. 
This in turn results in diminished release of vasoactive agents and procoagulants 
resulting in less radial artery spasm as discussed in the previous section.
Previous small studies have shown a similar beneficial effect of a hydrophilic 
coating on the incidence of radial artery spasm. A study of 90 patients by
Kiemeneij et al (23) showed that there was a significant reduction in the 
incidence of radial artery spasm with the use of a hydrophilic-coated long (23cm) 
introducer sheath. These rates of spasm in this study were lower than in our study, 
which could be due to the routine use of vasodilator cocktail. Saito et al (21) 
have shown a similar reduction in radial artery spasm with a hydrophilic coated 
16 cm long sheath compared to an uncoated sheath of similar length. The main 
limitation of this study was the small number of subjects (n=30). These two 
studies showed that a hydrophilic coating was associated with a significant 
reduction in the friction resistance measured quantitatively during pull-back of 
the introducer sheath. Recently, Caussin et al (163) have also shown that radial 
spasm was significantly reduced when using the long hydrophilic coated sheath 
compared to short sheath (4% vs. 18%) in a series of 351 patients. However, 
other factors, such as a different patient population, operator experience and 
material of the introducer sheath could have influenced the results. More recently, 
Hemetsberger et al (164) evaluated the effect of nitric oxide-coating of 
introducer sheath on local complications in juvenile porcine femoral arteries of 
similar size to human radial artery. They reported significantly less spasm, as 
measured by the femoral artery diameter at the access site, when using the nitric 
oxide-coated sheaths. They have showed significantly less luminal thrombosis 
and a reduced intima inflammation score on histopathology after their use. This 
study demonstrates the beneficial role of NO-coating in causing less 
complication during trans-arterial manipulation.
6.3.5. The impact of length of the introducer sheath on radial 
artery spasm
No difference was observed between long and short sheaths in the incidence of 
radial artery spasm and the patients discomfort level. Before concluding that 
sheath length has no effect it is necessary to consider the possibility of a type II 
error (acceptance of null hypothesis when it is false). As well as the absence of a 
statistically significant difference, a study should be sufficiently powerful to 
detect a physiologically meaningful difference between the mean control value 
and the intervention group, based on previous consideration of what constitutes a 
physiologically meaningful change. This also depends on the incidence of the 
outcome and, given a 10%-20% incidence of radial artery spasm, to make an 
intervention worthwhile we judged we would need to reduce the incidence by 
50% to be clinically relevant.
The measurements of clinical radial artery spasm and patient discomfort level 
were adequately powered to detect a difference of 50%. It is therefore unlikely 
that these results represent a type II error, and it may be concluded that there is 
no difference, at a level that may be important, in the occurrence of clinical radial 
artery spasm in the long and short introducer sheath groups.
6.3.6. Predictors of radial artery spasm
We identified younger age, female sex, diabetes mellitus, smaller wrist 
circumference, low body mass index, and the use of uncoated introducer sheaths 
as predictors of radial artery spasm in univariate analysis. Younger age, female
sex, diabetes mellitus, smaller wrist circumference, and low body mass index 
remained significant independent predictors of clinical radial artery spasm in 
multivariate analysis.
Previous studies, using fewer patients, have also identified younger age (16, 18), 
and female sex (16, 19), as independent predictors of radial artery spasm. 
Coppolla et al (18) also identified radial artery size, radial artery size to height 
ratio, radial artery size to sheath diameter ratio, and radial artery size to body 
mass index ratio as predictors of radial artery spasm. Our results are similar to 
these studies and we identified additional predictors of radial artery spasm such 
as wrist size, diabetes mellitus, and body mass index. However, as for 
simplicity’s sake we did not measure the size of radial artery, we cannot 
comment on morphometric indices involving measured artery size.
Morphometric indices might reflect mismatch between the radial artery size and 
the outer diameter of the introducer sheath, resulting in more friction resistance 
and over-stretching, thereby causing more radial artery spasm and patient 
discomfort. Younger patients could be more anxious with higher resting 
sympathetic tone and this could play a role in inducing radial artery spasm. 
Female patients generally have smaller wrist circumference, and a smaller radial 
artery diameter and this could predispose them to radial artery spasm. Whether 
differences in hormone status, pain tolerance or anxiety between men and women 
will lead to different levels of catecholamine release, resulting in different rates 
of radial artery spasm is unknown. Similarly, in diabetic patients, there could be 
a smaller internal diameter of the radial artery due to generalised atherosclerosis
or increased intima-media thickness, which could predispose to radial artery 
spasm.
6.4. Procedural success and the impact of radial artery 
spasm
The intended coronary procedure was successfully completed via the ipsilateral 
radial route in 96% of the patients. The majority of failed cases were successfully 
completed via the contralateral radial artery but in five cases (0.63%) the 
procedure was completed via the transfemoral route.
Radial artery spasm was the most common reason (2.1%) for failure to complete 
the procedure via the intended route (and is therefore important) but the overall 
failure rate, even in the absence of routine use of a vasodilator cocktail, was very 
low.
6.4.1. How the results from this study relate to other studies
Other studies have compared the procedural success rates using the transradial 
and transfemoral approaches in a randomised fashion, hi 1997 Kiemeneij et al 
(101) reported successful coronary cannulation in 93.0% of patients in the 
transradial group. They reported that the procedure failed because of inability to 
puncture the radial artery in 4.6% of cases, failure to advance a 6F sheath in the 
radial artery in 0.7% of cases, and an inability to advance the guide wire towards 
the ascending aorta in 1.7% of cases. They also mentioned that twenty patients 
(6.7%) crossed over to a femoral approach and one patient (0.3%) crossed over
to a left radial approach to complete the procedure. This study did not mention 
the incidence of radial artery spasm resulting in procedural failure, and failure to 
puncture the radial artery and crossover to a femoral approach was significantly 
higher than seen in our study. Our results suggest a significant improvement in 
procedural success compared to this earlier study, which could be related to 
improved equipment, techniques and accumulating operator experience over the 
years.
More recently, Agostoni et al (9) performed a meta-analysis to compare the 
clinical and procedural outcomes of transradial and transfemoral approaches. 
They reported a higher number of procedural failures with a transradial approach 
in comparison to a femoral approach (7.2% vs. 2.4%; OR 3.30, 95% Cl 1.63 to 
6.71; p <0.001). There was significant heterogeneity present in the rate of 
procedural failure over years. They divided the trials into those completed before 
and after the year 1999. In more recent trials (after 1999) procedural failure was 
seen in 3.9% of the patients in the transradial group. This review did not report 
the reasons for procedural failure and the equipment used and patient population 
was different, but the recent results are very similar to those seen in our study. 
Radial arterial anatomic variations could also be a potential cause for procedural 
complications and failure. Lo et al (165) have reported the influence of radial 
artery anomalies on transradial coronary procedure outcome. Their reported 
incidence of radial artery anomaly was 13.8%. Seven percent of patients had a 
high-bifurcating radial artery origin, 2.3% had a radial loop, 2.0% had extreme 
radial artery tortuousity and 2.5% had other miscellaneous anomalies such as 
radial atherosclerosis and accessory branches. Procedural failure was more
common in patients with anomalous anatomy (14.2% vs. 0.9%, p < 0.001). 
Similarly, Norgaz et al (166) have shown anatomic variations in 18.6% of 
patients and these patients were significantly older, more commonly female, and 
with significantly higher procedural failure rates (8.8% vs. 5.5%, p = 0.006). 
Anomalous radial artery anatomy could have been the cause of some of the 
procedural failures in our study, particularly in the eight cases where it was 
difficult to pass the wire after an apparently successful radial artery puncture. We 
did not systematically perform radial angiography to ascertain the impact of 
anatomic variations.
6.4.2. The impact of length and coating of the introducer 
sheath on procedural success rates
The study failed to demonstrate any statistically-significant difference between 
the rates of procedural failure in the long versus short sheath groups or the coated 
versus uncoated sheath groups. The higher incidence of radial artery spasm with 
the use of an uncoated sheath did not result in higher rates of procedural failure 
in our study. The procedure could still be completed successfully in the event of 
radial artery spasm, albeit causing some discomfort to the patients and with more 
frequent use of an intra-arterial vasodilator cocktail (verapamil and/or glyceryl 
trinitrate). However, considering the low overall incidence of this outcome, a 
study would need to have sample size of 2000 patients to detect a 50% reduction 
with a confidence level of 80%. This study therefore camiot exclude the 
possibility of a difference (type II error).
6.5. Radial artery occlusion
Radial artery occlusion after a transradial procedure is a major concern, although 
the immediate consequences of radial artery occlusion are usually benign. The 
collateral blood supply to the hand effectively prevents significant ischaemia. 
However, occlusion of the radial artery prevents its use as an arterial conduit for 
aorto-coronary bypass surgery, as the preferred artery for use in the creation of 
an arterio-venous fistula for haemodialysis access and as the access route for 
future percutaneous procedures.
6.5.1. The definition of radial artery occlusion
The radial pulse is frequently present even after occlusion of the artery at or more 
proximal to the access site. The occluded radial artery distal stump has been 
found to have up to 70% of mean arterial pressure because of macro-collateral 
circulation from the palmar arches (167), leading to a palpable pulse. Hence 
palpation of radial pulse does not prove radial artery patency. A reverse Allen’s 
test and plethysmographic evaluation of palmar circulation has provided a 
rapidly available and reliable means to detect radial artery occlusion (41, 118). It 
has shown equivalent diagnostic accuracy in the diagnosis of radial artery 
occlusion, with extremely high correlation with duplex Doppler ultrasonography 
(41). Doppler ultrasound is not easily available and is time-consuming in the 
clinical setting. Therefore, we have developed a clinical algorithm to detect 
radial artery patency which could be performed quickly and cheaply. We used 
the reverse Allen’s test to assess radial artery patency in all patients, confirmed in 
equivocal cases by plethysmography and oximetery or Doppler ultrasound. This
could have potentially led to an underestimate of the actual incidence of radial 
artery occlusion as the gold standard is Doppler ultrasound. However, there are 
no established criteria for radial artery occlusion and most of the historical data 
comes from coronary graft assessment studies. Kamienski and Barnes (168) have 
shown that arterial obstruction results in distal arterial velocity signals which are 
attenuated with a resultant decrease in the systolic component and loss of normal 
diastolic sounds. Using these abnormal criteria of Doppler ultrasonography, the 
reverse Allen’s showed complete concordance with the findings obtained by 
Doppler ultrasonography.
6.5.2. The mechanisms of radial artery occlusion
The Virchow’s triad (146) for tlirombogenesis postulate that three features 
predispose to thrombus formation: abnormalities in blood flow, abnormalities of 
the vessel wall and abnormal blood constituents. ‘Abnormal blood flow’ is 
evident in patients undergoing transradial procedures by various mechanisms. 
Firstly, mismatch between the introducer sheath size and the radial artery 
diameter can result in stagnation of blood flow through the radial artery during 
the procedure and this can predispose to thrombus formation. Secondly, non- 
thrombotic occlusion secondary to severe prolonged spasm or dissection of radial 
artery could predispose to thrombus formation. Similarly, abnormalities of the 
vessel wall secondary to damage to the endothelium could initiate the cascade of 
thrombus formation resulting in radial artery occlusion. This could also be 
contributed to by compression devices used to achieve haemostasis after the 
procedure. In a classical Virchow’s triad, vascular damage has been considered 
to be of prime importance in arterial thrombosis (169). Mechanical trauma
induced by a transradial sheath might lead to dysfunction of endothelium and 
consequently to the loss of its antithrombotic properties and represent a trigger to 
thrombus deposition. A pathogenic role of endothelial dysfunction has been 
shown for arterial thrombosis (170).
The endothelium, a thin monolayer of cells covering the inside of both arteries 
and veins, has emerged as one of the pivotal regulators of haemostasis through its 
ability to express anticoagulant and vasodilatory molecules in healthy conditions, 
and, in diseased conditions, to release vasoconstrictors and to express 
procoagulant and cell adhesion molecules and cytokines. Under normal 
conditions endothelial cells exert a vasodilatory, antiplatelet and local fibrinolytic 
tone that prevents platelet adhesion, leukocyte attachment, as well as blood 
coagulation. A non-thrombogenic endothelial surface is maintained through a 
number of mechanisms, including the production of thrombomodulin (TM), an 
activator of anticoagulant protein C, the expression of heparin and dermatan 
sulphate, which accelerate the thrombin-inhibitory activity of antithrombin III 
and of heparin cofactor II, the constitutive expression of tissue factor pathway 
inhibitor (TFPI), an inhibitor of tissue factor, and the local production of tissue 
plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), 
the main effectors of physiological fibrinolysis. Crucial to many of the 
antithrombotic activities of endothelium are the synthesis of prostacyclin (PGI2) 
and nitric oxide (NO).
Nitric oxide is a powerful vasodilatory agent, but also has strong anti­
aggregatory effects on platelets, is an inhibitor of leukocyte adhesion and
activation and a suppressor of smooth muscle cell proliferation (171). 
Prostacyclin is a vasodilator, an inhibitor of platelet activation and a suppressor 
of leukocyte adhesion and activation (171). Noxious stimuli, either physical 
(trauma by sheath) or functional (stasis of blood), provoking a disturbance of the 
endothelial monolayer, turn the endothelium into a prothrombotic and 
proinflammatory surface favouring platelet and leukocyte deposition, local blood 
clotting activation and smooth muscle cell proliferation. In particular, upon 
activation, endothelial cells respond with an increased surface expression of cell 
adhesion molecules (such as P- or E-selectin, ICAM-1 or VCAM-1) that promote 
the adhesion and activation of leukocytes, an event that initiates and amplifies 
inflammation and contribute to thrombosis. Activated leukocytes, in particular 
monocytes, express tissue factor (TF), a strong trigger of blood clotting. 
Endothelial dysfunction has been conclusively shown to be an early event in the 
progression of thrombosis and smooth muscle proliferation (170, 172). In the 
context of arterial thrombosis, endothelial dysfunction, and in particular a 
reduction of the biosynthesis or the biologic activity of NO, has been identified 
as fundamental component of the pathophysiology of atherothrombotic 
complications and shown to be associated with risk factors such as diabetes, 
hypercholesterolemia, smoking and hypertension ( 170, 172). Endothelial 
dysfunction is associated with increased oxidative stress and with inflammatory 
changes that play a role in the development of intimal thickening in the early 
stages, while later they increase the vulnerability of thrombosis (172).
Transradial procedures result in endothelial dysfunction as a result of mechanical 
injury to the intimal lining of radial artery, stasis of blood during the procedure
and during achieving haemostasis, resulting in triggering of the thrombotic 
cascade as described. In Virchow’s triad of the twenty-first century, endothelial 
dysfunction emerges as the most important component of thrombosis.
6.5.3. The incidence of radial artery occlusion
Clinical evidence of radial artery occlusion was seen in 9.2% of patients at the 
time of discharge from hospital in our study. However, none of these patients 
reported any symptoms of vascular compromise or functional impairment of the 
hand. Similar early radial artery occlusion rates are reported in other studies 
ranging from 5% to 9% (28, 35). We have found no difference in the incidence 
of radial artery occlusion between long and short introducer sheaths and between 
coated and uncoated sheaths. There is a paucity of data available relating to this 
effect in literature.
6.5.4. Predictors of radial artery occlusion
We have identified younger age, female sex, occurrence of radial artery spasm, 
failure to use heparin during the procedure, smaller wrist size, and shorter height 
as predictor of radial artery occlusion in univariate analysis. The type of 
introducer sheath, compression device, procedure time, and the time taken to 
achieve haemostasis had no impact on the incidence of radial artery occlusion.
Several variables have previously been shown to influence the incidence of radial 
artery occlusion. Catheter size has been shown to be an important predictor of
post-procedure radial artery occlusion. Saito et al (29) have shown that the 
incidence of occlusion was 4% in patients with a radial artery internal diameter 
to introducer sheath outer diameter ratio of greater than one, compared to 13% in 
those with the ratio of less than one. We did not measure the radial artery 
diameter in our study population but did find several morphometeric factors like 
wrist size, shorter height, and female sex as predictors of radial artery occlusion. 
These factors potentially reflect smaller radial artery size and the introducer 
sheath outer diameter (2.4 mm) were fixed in our study population.
When the radial artery is used for haemodynamic monitoring in critically ill 
patients, the incidence of radial artery occlusion is significantly higher in patients 
with cannulation duration of more than 24 hours, compared to those with one of 
less than 24 hours (31, 32, and 33). Catheters and the introducer sheaths are 
usually removed immediately after cardiac catheterisation and interventional 
coronary procedures. However, prolonged post-procedure compression force and 
duration may play an important role in the pathogenesis of radial artery occlusion. 
We will discuss this effect in future sections.
6.5.5. The impact of radial artery spasm on radial artery 
occlusion
This is the first study to demonstrate that there was a higher incidence of early 
radial artery occlusion in patients experiencing radial artery spasm during the 
procedure. The risk of radial artery occlusion in those experiencing spasm was 
14.3% (33/230), compared to 5.2% (40/560) in those not experiencing spasm. 
Nearly half of patients experiencing radial artery spasm demonstrated radial
artery occlusion at the time of discharge from the hospital. There are several 
potential mechanisms predisposing to this association; firstly, spasm could cause 
endothelial trauma leading to a thrombogenic surface; secondly, spasm of a 
section of the artery could lead to stasis in the rest of the artery and thereby 
predispose to thrombosis; thirdly, a reduced diameter due to spasm will cause an 
increase in blood flow velocity and shear strain, resulting in increased platelet 
activation; fourthly, traction on a introducer sheath in a spastic radial artery can 
lead to transection or avulsion of the artery resulting in radial artery discontinuity. 
This suggests that measures taken to avoid spasm should have beneficial effect 
on subsequent occlusion rates.
Endothelial dysfunction is a predisposing factor for both vasospasm and 
thrombus generation. In addition to regulating vascular tone and blood pressure, 
vascular endothelium has antithrombotic properties and modulates interaction 
between the blood vessel wall, circulating leukocytes, and platelets. Nitric oxide 
is a powerful antithrombotic molecule and vasodilator produced by endothelial 
nitric oxide synthase (e-NOS) through L- arginine (173, 174, 175). Endothelial 
dysfunction contributes significantly to vasospasm and thrombosis (176, 177, 
178). In addition to e-NOS, L-arginine is also a substrate of arginase, the final 
enzyme of the hepatic urea cycle hydrolyzing L-arginine to urea and L-ornithine 
(179, 180). This cycle could potentially be a therapeutic target for preventing 
vasospasm and thrombosis. Using acetylcholine-stimulated endothelium- 
dependent relaxation (EDR), initial studies in several animal models revealed 
that acute arterial thrombosis causes endothelial dysfunction. Lack of blood flow 
(ischaemia) alone without intraluminal thrombus did not affect EDR. Nitric
oxide levels are decreased accordingly, and L-arginine administration restored 
EDR, suggesting normal e-NOS function and that impaired L-arginine 
availability underlies arterial thrombosis-induced endothelial dysfunction (181, 
182, 175). It has been shown in these studies that thrombin plays a central role in 
thrombus-induced endothelial dysfunction. They have also investigated the 
molecular mechanisms of arginase changes after thrombin exposure. Thrombin is 
a coagulation system protease present at the sites of vascular injury (caused by 
radial sheath manipulation and compressive device application in our study). In 
addition to catalyzing the conversion of soluble fibrinogen into an insoluble 
fibrin clot, thrombin is a potent endothelial cell function agonist inducing several 
genes in endothelial cells (183, 184). Endothelial cells are the first cells in an 
artery to encounter circulating thrombin, one of the key stimuli leading to the 
activation of multiple signalling pathways. Zhu et al (185) have shown in the 
exposure to rat aortic endothelial cells and provided with the evidence supporting 
a key role for the transcription factor activating protein-1 in mediating 
endothelial arginase, an enzyme that can modulate L- arginine levels. Their 
findings highlight the arginase pathway as a potential therapeutic target in 
limiting endothelial dysfunction and thereby vasospasm and thrombosis,
6.5.6. Anti-thrombotic therapy and radial artery occlusion
Antithrombotic therapy has been found to influence radial artery occlusion (34, 
28). Patients undergoing interventional procedures are routinely given systemic 
antithrombotic therapy, but this is not universal in patients undergoing diagnostic 
angiography. The incidence of radial occlusion can be as high as 30% in patients 
receiving only 1000 units of heparin during diagnostic catheterisation (34). The
incidence of radial occlusion is reduced significantly by administering at least 
5000 units of heparin during the procedure (34, 28). The importance of treatment 
with heparin during the procedure is further confirmed in our study. In our study 
weight-adjusted heparin was used in all interventional cases, while the use of 
heparin was left to the operator’s discretion in diagnostic catheterisation cases. A 
total of 61(7.7%) patients in our study did not receive any heparin during the 
procedure and radial artery occlusion was seen in 20 patients (32%), a similar 
rate to that reported in the literature.
Heparin is a sulfated polysaccharide with a molecular weight range of 3000 to 
30000 Da (mean 15000 Da). It produces its major anticoagulant effect by 
inactivating thrombin and activated factor X (factor Xa) through an antithrombin 
(AT) -dependent mechanism (186). Heparin binds to AT through a high-affinity 
pentasaccharide, which is present on about a third of heparin molecules. For 
inhibition of thrombin, heparin must bind to both the coagulation enzyme and 
AT, whereas binding to the enzyme is not required for inhibition of factor Xa. By 
inactivating thrombin, heparin not only prevents fibrin formation but also inhibits 
thrombin-induced activation of platelets and of factors V and VIII. The 
anticoagulant response to heparin varies among patients. It is standard practice to 
adjust the dose of heparin and monitor its effect by measurement of the activated 
thromboplastin time (APTT) or, when very high doses are used, by the activated 
clotting time (ACT). Similarly, low molecular weight heparin (LMWH) is 
derived from heparin by chemical or enzymatic depolymerisation to yield 
fragments approximately one third the size of heparin. LMWH’s have a mean 
molecular weight of 4500 to 5000 Da with the distribution of 1000 to 10000 Da.
All the anticoagulant, pharmacokinetic, and other biological differences between 
unffactionated heparin and LMWH can be explained by the relatively lower 
binding properties of LMWH.
The use of a weight-adjusted dosage of heparin has shown a significant reduction 
in radial artery occlusion rates as discussed above. More recently, investigators 
have investigated low molecular weight heparin and bivalirudin (a direct 
thrombin inhibitor) to assess their impact on radial artery occlusion rates 
following transradial procedures. Bertrand et al (187) have compared bivalirudin 
(bolus 0.75mg/kg, infusion 1.75mg/kg/h) and standard heparin (70units/kg) 
during transradial procedures. In a study involving 400 patients they have 
reported radial artery occlusion rates of 5.3% at 4-8 weeks with no significant 
difference between the two groups (3.5% bivalirudin vs. 7.0% heparin, p= 0.18). 
The incidence of radial artery occlusion in our study is 7.2% early post­
procedure and 5.7% late (at 4-6 months post procedure) with the use of weight- 
adjusted unfractionated heparin and this is similar to Bertrand’s study. Pancholy 
(188) has compared the outcomes following intravenous or intra-arterial 
administration of unfractionated heparin in 500 patients. Early radial artery 
occlusion was seen in 5.5% of the intravenous group and 6% of the intra-arterial 
group. They have concluded that intra-arterial and intravenous heparin 
administration provide comparable efficacy in preventing radial artery occlusion, 
suggesting a systemically mediated mechanism of action, rather than a local 
effect. We used heparin directly into the aorta in our study to avoid the local 
irritant effect of administration directly into the radial artery.
There have been some attempts recently to treat radial artery occlusion seen 
following transradial procedures. Zanki et al (189), has assessed the effect of 
therapeutic low molecular weight heparin for four weeks in patients with 
documented radial artery occlusion following transradial procedures. They 
reported radial artery thrombosis in 10.5% of patients one day after procedure. 
After four weeks 86.7% of affected patients showed partial or complete 
recanalization of the radial artery after treatment with low molecular weight 
heparin. Bemat et al (190) have evaluated the efficacy and safety of transient 
ipsilateral ulnar artery compression to achieve acute radial artery recanalization. 
Radial artery patency was assessed by duplex ultrasonography three to four hours 
after haemostasis, and, in patients with occluded arteries, immediate ulnar artery 
compression was applied for one hour. After ulnar artery compression, the final 
incidence of radial artery occlusion was reduced to 4.1% from 5.9% in the 2,000- 
IU Heparin group and 0.8% from 2.9% in the 5,000-IU Heparin group (p=0.03). 
Therefore, all patients should receive weight-adjusted heparin to reduce the 
incidence of radial artery occlusion following transradial procedures and 
pharmacological and non pharmacological measures can be applied to the select 
group of patients with documented radial artery occlusion.
6.6. Ulno-palmar collateral circulation
The original recommendation by Kiemeneij (2) was that a transradial procedure 
should only be performed in patients with a documented patent ulnar artery and 
palmar arch. This has traditionally been evaluated using the Allen’s test, but
Doppler ultrasound and plethysmography prior to the procedure are more 
accurate methods (27).
6.6.1. Allen’s test
In the original description of his test used for examining patients with 
thromboangitis obliterans,(121) Allen did not define the test results as positive or 
negative, nor did he give a time limit for the appearance and maximal blushing. 
Obviously, time to maximal blushing becomes more difficult to judge when it 
occurs over a longer period. Also, pallor, inadequate patient cooperation, patient 
unconsciousness, overextension of the wrist, or contralateral ulnar compression 
by skin stretching adds to the difficulty and subjectivity of this test.
In the available literature, the upper limit of the time taken for blushing to occur 
during Allen’s test suggested as acceptable before radial artery camiulation, 
varied from five to 15 seconds. With various upper limits for Allen’s test, 
absence or inadequate hand collaterals during radial artery compression varied 
between 1% and 27% (1,31, 32, and 45). In our study 79.8 % of patients had 
blushing within 10 seconds, 89.9% with 20 seconds, and in 11% it took more 
than 20 seconds or did not occur at all. These values are consistent with what is 
reported in the literature.
6.6.2. Plethysmography and oximetry test
Plethysmography and oximetry tests were recorded with a pulse oximeter as 
previously described. Barbeau et al (27) have shown that that a finding of 
PL&OX type A, B, or C on either side was more frequent and would exclude
fewer patients from eligibility for a transradial procedure than an Allen’s test, 
while being a more objective test to assess ulno-palmar collateral circulation. In 
this study of 1000 patients a type A, B, or C pattern, which was considered 
indicative of adequate collateral circulation, was seen in 95% of the patients. 
Similar results are shown in our study, a type A or B pattern was seen in 90.7%, 
a type A, B, or C pattern was seen in 93%, and a type D or inadequate pattern 
was seen in 7% of patients.
6.6.3. Comparison of the Allen’s test and the plethysmography 
and oximetry test
hi our study, we have identified more patients with the use of PL&OX test than 
with the Allen’s test as fulfilling the criteria for adequate collateral supply. Two 
thirds (65%) of the patients with an unfavourable Allen’s test (more than 10s) 
showed a PL&OX type A, B, or C, suggesting adequate collateral supply. All 
patients showing a favourable Allen’s test (less than 10s) showed PL&OX type 
A, B, or C. Similar results were shown by Barbeau et al (27).
6.6.4. The relation between ulno-palmar circulation adequacy 
and ischaemic complications
No study to date has demonstrated a relationship between the time to maximal 
blushing using the Allen’s test and ischaemic symptoms or complications in the 
hand, although Greenwood et al (47) reported that among patients with an 
abnormal Allen’s test, occlusion of the radial artery results in an immediate 
reduction in blood flow to the principal artery of the thumb as measured by
lactate levels. The Allen’s test has nevertheless been advocated to avoid acute
and long-term ischaemia of the hand in cases of radial artery occlusion.
The radial artery approach has been widespread and is used at hundreds of 
cardiac centres. Many centres have abandoned the use of the Allen’s test, though 
there is no published data to support this relaxed approach. Therefore, it is 
important not to deny this access site to patients with an abnormal Allen’s test 
and a more objective test (PL&OX) should be performed. This is even more 
important in patients in whom a femoral procedure carries increased risk. We 
assessed ulno-palmar circulation in all patients before the procedure, but this was 
not used to deny the patients a radial approach. None of our patients with 
apparently-inadequate collaterals suffered ischaemic complications after radial 
artery cannulation.
6.7. Access site complications
The most important benefit of transradial procedures is the virtual elimination of 
significant access site bleeding complications (9, 110-113, ). The radial artery 
puncture site is located over bone and can easily be compressed with minimal 
pressure. Thus, significant bleeding from the radial access site can virtually 
always be prevented. Although manual pressure from an experienced operator is 
the ideal method to achieve haemostasis, several compression devices have been 
developed in an attempt to maximize operator and staff efficiency. Local 
haematomas may occur as a result of improper device application or device 
failure. It should be emphasized that compression of the radial artery both
proximal and distal to the puncture site must be perfonned because of retrograde 
flow from the palmar arch collaterals.
Bleeding after a transradial approach may occur’ from a site in the radial artery 
remote to the access site. The most common cause is perforation of a small side 
branch by the guide wire. Avulsion of a small radial recurrent artery arising from 
a radial loop is another important cause of remote bleeding (113,114). 
Hydrophilic guide wires preferentially select this small arterial remnant in 
patients with a radial loop and forceful advancement of the guide catheter can 
result in avulsion of the vessel. Radial artery perforation has been described in 
about 1% of patients. One should have a low threshold to perform a radial artery 
angiogram when any resistance to guide wire or catheter insertion is encountered 
to prevent this complication. Remote access site bleeding should be recognised 
early and pressure should be applied at remote site with the help of compressive 
bandage. A blood pressure sphygmomanometer may also be utilized.
Very rarely, compartment syndrome can develop due to radial artery 
haemorrhage (147). A large haematoma causes hand ischaemia due to pressure- 
induced occlusion of both the radial and ulnar arteries. Fasciotomy with 
haematoma evacuation must be performed as an emergency procedure to prevent 
chronic ischaemic injury.
6,7.1. Results from our study
A large local haematoma of more than 2cm diameter was seen in 17 patients 
(2.2%) and a small haematoma was seen in 5.4% of patients. Radial, brachial, or 
subclavian artery dissection was seen in one patient each (0.4%). All these 
complications were managed conservatively by compression bandage where 
necessary and observation, and none of these patients needed surgery or blood 
transfusion or suffered long term sequelae. However, superficial ecchymosis and 
oozing was frequently encountered and was seen in 17% patients, with no 
sequelae. Agostoni et al (9) has reported a 0.3% incidence of major bleeding 
complications needing blood transfusion or surgical intervention in a meta­
analysis involving 1472 patients. Similarly, Keimeneij et al (14) has reported no 
major entry-site complications in a series of 300 patients.
Large local haematomas have been reported in literature and are frequently due 
to injury or perforation of the radial artery or its branches. We have not observed 
any difference in vascular complications between long and short introducer 
sheaths. However, large local haematomas were more frequent in patients 
receiving an uncoated introducer sheath. This could be related to excess radial 
artery spasm or friction in this group, thereby increased movement of the artery 
during sheath manipulation, avulsing small branches.
6.8. Late access site vascular complications
Permanent radial artery injury presenting late after discharge from hospital, with 
or without occlusion, may occur following transradial coronary procedures in
some patients. Spontaneous recanalization is reported in 40% to 60% of patients 
with radial artery occlusion by clinical evaluation and colour Doppler 
measurement respectively (27, 34). Late radial artery occlusion was seen in three 
to five per cent of patients at follow-up of one to three months in these studies.
We have evaluated late vascular site-related complications in 625(79.1%) of our 
patients at the time of routine follow-up at four to six months. Persistent radial 
artery occlusion was observed in 43 (6.9%) patients with no evidence of vascular 
compromise or functional impairment of the hand. These results are similar to 
those reported in the literature. However, we have used a clinical evaluation of 
radial artery patency and Doppler ultrasound was not systematically used. This 
could potentially underestimate the true incidence in our study as Doppler 
ultrasound is the gold standard to identify radial artery occlusion.
6.8.1. Late access site inflammatory reactions
There have been reports of late sterile abscesses or allergic reactions at the site of 
introducer sheath insertion (62, 116). This complication has been reported in 
1.6% of patients who had catheterisation via the transradial approach (62). In this 
study radial access site reactions occurred in 2.8% of patients in whom a 
hydrophilic coated sheath was used (and no patients in whom uncoated sheaths 
were used). The hydrophilic coating is believed to facilitate passage of the sheath, 
perhaps with the shedding of the coating at the time of sheath retrieval or 
insertion resulting in this complication. The inflammatory lesion is usually noted 
two to three weeks after the procedure with a relapsing and remitting clinical 
course. Cultures are reported as sterile in most patients, and biopsy specimens
show the presence of an amorphous material compatible with the sheath coating. 
The exact pathogenesis is unknown but it is particularly seen with one brand of 
gel-coated hydrophilic sheaths, suggesting a coating-specific reaction.
We have used similar introducer sheaths from the same manufacturer with or 
without coating in our study. We have found patient-reported late swelling or 
abscess at the radial artery puncture site in 21 patients (3.4%) in the entire cohort. 
The majority of these are associated with the use of hydrophilic coated introducer 
sheaths. The results of our study are similar to other reported studies and further 
confirm the causal relationship between the hydrophilic coating of the introducer 
sheath and the incidence of this complication.
These sterile abscesses cause discomfort to the patient and in some patients 
unneeded surgical incision and drainage is carried out. From the evidence 
accumulated so far, management of individual patients with this type of reaction 
should be conservative with local wound care and drainage if abscess formation 
is present. The manufacturer has now changed the materials used to make the 
coating and the impact of this needs to be tested.
6.9. Assessment of haemostatic compression devices
There are a number of devices that have been developed in last two decades to 
obtain haemostasis after transradial catheterisation. Earlier, tourniquet-related 
devices were used because of their simplicity and easy availability. However, 
marked venous congestion and compression of the ulnar artery could occur with
this method and could be the cause of patient discomfort and additional 
complications. To avoid this problem several devices have been developed to 
provide selective compression of the radial artery. The TR band and the Radistop 
compression devices are the commonest devices used to achieve haemostasis 
after transradial procedures.
6.9.1. Potential advantages of TR Band and Radistop
The TR band selectively provides compression of the radial artery and the 
transparent band allows visualisation of the puncture site during the post­
procedure period. The pressure in the compression pad can be controlled by 
releasing air from or adding air to the pad. Moreover, this device does not limit 
the wrist movement, which could reduce discomfort and improve mobility of the 
patient.
The Radistop also provides selective compression of the radial artery puncture 
site with no effect on the ulnar artery flow and the venous circulation. The use of 
this device involves immobilisation of the wrist until haemostasis is achieved.
6.9.2. Comparison of the time taken to achieve haemostasis by 
TR Band and Radistop
Both the TR band and Radistop provide effective haemostasis following 
transradial procedures and the devices are removed over a period of time. The 
aim of these devices is to secure haemostasis and remove the device as soon as
possible to reduce local discomfort and vascular complications. This is the first
study comparing the time taken to achieve haemostasis with two different 
devices allocated in a randomised fashion. The time taken to achieve haemostasis 
could be dependent on several variables such as baseline patient-related factors, 
procedure-related factors, the use of anticoagulants, procedure duration, and 
device-related factors. Baseline characteristics, including risk factors, wrist size 
and other morphometeric factors, were similar in both device groups. Procedural 
characteristics such as procedure time, coronary procedures perfonned, number 
of catheters used, type of introducer sheath used, and heparin use was well 
balanced between both groups. To control for device-related factors we have 
used similar protocols (Appendix 3 and 4) for the application and removal of the 
devices after a transradial procedure.
In our study we have observed that the time taken to achieve haemostasis was 
significantly longer with the TR Band compared to the Radistop. However 
haemostasis was achieved successfully in all patients. There is limited literature 
regarding compression devices used and the time taken to achieve haemostasis in 
contemporary settings. Chatelain et al (38) have described the initial use of the 
Radistop device and reported a compression time ranging from two to four hours 
with this device. However, the majority of the procedures were performed using 
a 5F introducer sheath and were diagnostic coronary angiography. The time 
taken to achieve haemostasis is longer in our study and could be explained by the 
use of 6F introducer sheaths in all patients, with more than 90% patients 
undergoing coronary intervention procedure with a high rate of use of heparin.
6.9.3. Comparison of patient tolerance of the TR Band and 
Radistop devices
The other important factors in deciding on the type of compression device to use 
is patient tolerance. A compression device could cause patient discomfort as 
mechanical pressure is needed to achieve haemostasis. This pressure can vary 
from patient to patient. In our study population more patients complained of 
moderate or severe discomfort with the Radistop compared to the TR Band and 
three patients initially treated with a Radistop crossed over to a TR Band because 
of severe discomfort. In the initial clinical evaluation of the Radistop (38) the 
authors reported that 18% of patients reported the device as uncomfortable or 
painful, but in no patient was it necessary to interrupt compression for that reason.
This could potentially influence the decision of choosing one or the other 
haemostatic device in an individual patient. The high success rate with both 
devices is reassuring and the patient tolerance should be considered in making 
this decision.
6.9.4. Comparison of access site-related complications with 
the use of the TR Band and Radistop devices
The main advantage of the transradial approach is to reduce access site-related 
complications. Local access site-related bleeding complications, patency of the 
radial artery and other complications could be influenced by the type of 
compression device used following transradial procedure. Other factors such as 
the size of the introducer sheath, the dose of heparin used and adjuvant treatment 
could also influence this outcome. Chatelain et al (38) have reported that 15% of
patients developed a small or large local haematoma after the use of Radi stop, 
and no specific treatment was required. In our study 5.4% of patients developed a 
small haematoma and 2.2% patients developed a large haematoma with all being 
managed conservatively. These results are a significant improvement over the 
early description in the above mentioned study. There was no difference seen in 
the local complications between the TR Band and the Radistop groups. There 
were no serious bleeding complications needing blood transfusions or surgical 
intervention, and no deaths as a result of bleeding complications. More recently 
Bernat et al (190) has evaluated the incidence of haematomas larger than 15cm 
with very low dose (2000 IU) or low dose (5000 IU) heparin following a 
transradial procedure and using the TR band as a haemostatic compression 
device. The incidence of local haematoma was 2.3% and 3.7% in the 2000 and 
5000 IU groups respectively (p=0.42).
Radial artery occlusion is an important complication of transradial catheterisation 
and the haemostatic device could contribute to the risk of this. Radial artery 
occlusion after transradial approach appears to be a complex interplay of 
processes such as local trauma and compression post-procedure. Radial artery 
compression is required to achieve haemostasis and this could potentially initiate 
the process of thrombus formation by interrupting forward blood flow in the 
radial artery.
Some studies (41, 118) have shown that occlusive compression of the radial 
artery is a predictor of subsequent radial artery occlusion. Pancholy et al (118) 
showed that a guided haemostasis strategy, with careful prevention of
interruption of radial artery flow during haemostatic compression, is highly 
effective in decreasing radial artery occlusion after transradial catheterisation 
(5% vs. 12%). There has been an accumulation of data supporting the “patent 
haemostasis” approach. Only enough compression should be applied to achieve 
haemostasis and at the same time forward flow in the radial artery should be 
preserved. We have applied patent haemostasis concepts in our study population 
and early radial artery occlusion was seen in 9.2% of cases with no difference 
observed between the TR Band and Radistop group. Our radial artery occlusion 
rates are slightly higher than described in the above study by Pancholy et al (118). 
This could be related to the use of 4F introducer sheath in Pancholy’s study and a 
6F sheath in our study.
The overall access site bleeding complications in our study are similar to that 
reported in other studies with conventional pressure haemostasis as compared to 
patent haemostasis in our study. As no increase in bleeding complications was 
noted in our population, there appears to be no drawback of a lower pressure 
haemostasis and maintaining forward flow in the radial artery as opposed to the 
poorly tolerated higher pressure approach used conventionally. Another 
important factor is that the haemostatic device should be progressively loosened 
over time, increasing the likelihood of non-occlusive radial artery compression. 
Haemostatic devices allowing application of measured pressure adjusted to a 
value less than patient’s systolic blood pressure that provides local haemostasis 
may be ideal. Frequent access site evaluation (eveiy 30 minutes in our study) and 
application of the shortest duration of compression needed to achieve
haemostasis may also be of help in reducing the occurrence of radial artery 
occlusion.
6.10. The impact of the introducer sheath on
vascular function following transradial procedures
6.10.1. Introduction
Studies have demonstrated that permanent radial artery injury without occlusion 
may occur following transradial coronary procedures. The mean radial artery 
diameter, as measured by ultrasound, was smaller in patients undergoing repeat 
transradial interventional procedures compared to that measured before the initial 
procedure (30). This smaller diameter was not present on the day following the 
procedure, but developed during a mean follow up of 4.5 months. Wakeyama et 
al (36) have demonstrated with intravascular ultrasound that this progressive 
narrowing is due to intimal hyperplasia, presumably induced by trauma from the 
cannulation, sheath or catheter. The degree and incidence of significant intimal 
injury in patients undergoing transradial procedures is yet to be determined.
It is possible that insertion of the introducer catheter sheath has a direct physical 
impact on the endothelial lining of the vessel wall, a squamous monolayer which 
is easily damaged as a consequence of mechanical disruption. Removal of or 
damage to the endothelial lining has been shown in animals to impair 
endothelium-dependent arterial relaxation by decreasing nitric oxide 
bioavailability. They may also promote intimal hyperplasia, thrombus formation 
and the development of atherosclerotic plaques (122, 123). This could have 
implications for the use of the artery as a donor graft for coronary artery bypass
surgery, as graft longevity is, in part, related to the capacity to remodel and dilate 
in response to changes in metabolic demand and blood flow. Several studies have 
observed immediate and long term trauma in the radial artery following 
transradial coronary angiography; transradial catheterisation can lead to tissue 
necrosis and adventitial inflammation (124) and has been shown to cause intimal 
hyperplasia and reduce early graft patency (35,48, 124), with reductions in radial 
artery diameter noted as late as 12 months after catheterisation (35, 36,).
Several variables in the design of introducer sheaths, including the hydrophilic 
coating and the length of the sheath, could impact on arterial dysfunction, 
damage or occlusion.
6.10.2. Flow-mediated dilatation and its measurement 
techniques
The endothelium regulates vascular haemostasis through the release of a variety 
of autocrine and paracrine substances, such as nitric oxide, prostacyclin, and the 
endothelium-derived hyperpolarising factors (74). Beyond its vasodilator effects, 
nitric oxide has anti-atherogenic properties, inhibits platelet aggregation and 
adhesion, smooth muscle proliferation, leucocyte adhesion, vascular permeability, 
and inflammatory mechanisms (74). Flow-mediated dilatation is an in vivo 
bioassay of largely NO-mediated endothelial function (84, 125). It was 
demonstrated by Celermejer and colleagues (85) that using cuff occlusion, 
endothelial function could be tested by inducing arterial shear stress. Several 
studies since then have shown that human conduit arteries dilation response to 
increased blood flow (83, 85), that in animals this response is dependent on an
intact endothelium (88) and that shear-sensitive ion channels exist in endothelial 
cells (90). Joannides and colleagues (90) showed for the first time that an L-N 
Monomethyl-Arginine (L- NMMA) infusion blocks nitric oxide production after 
cuff inflation and abolishes flow-mediated dilatation, thus providing strong 
evidence that flow-mediated dilatation is an endothelium-dependent process, 
mediated by nitric oxide.
Doshi et al (91) and Mullen et al (92) have shown the importance of placement 
of the cuff distal to the measurement site and that this provides a true reflection 
of nitric oxide mediated dilatation. An important collaborative guideline was 
published in 2002 aimed at standardizing approaches for measurement of flow- 
mediated dilatation (97). In keeping with this literature and guidelines, we 
assessed FMD at various sites at the forearm by placing the cuff at the level of 
the wrist and measurements of the radial artery were perfonned proximal to the 
cuff following five minutes of ischaemia.
6.10.3. Analysis of radial artery ultrasound to detect FMD 
using novel edge-detection software
Brachial or radial artery flow mediated dilatation (FMD), as assessed by high 
resolution ultrasound, reflects endothelial-dependent vasodilator function (84). 
The technique for measurement and analysis of brachial FMD (126) has 
generally relied on a manual assessment of vessel diameter using visual 
inspection of single frames and placement of ultrasonic callipers (126). Manual 
assessment is subject to significant error (84, 126) and hence may be 
inappropriate for measurement of the arterial diameter response to increased flow,
which is generally of the order of 0.2- 0.4 mm and less in the presence of 
impaired endothelial function. Computer-assisted analysis utilizing edge 
detection permits multiple measurements along the vessel wall and would be 
expected to increase the sensitivity of the measurements.
We used a computerised edge-detection and wall-tracking software program to 
allow accurate and reproducible measurement of arterial diameter for assessing 
endothelial function (128). The reproducibility of measurements by this method 
was significantly better than traditional manual methods. These findings are 
important because previous reproducibility studies suggest that observer error for 
analysis of FMD may account for as much as 60% of the within-subject variation 
(84, 127), In addition, because the use of the software allows continuous 
monitoring of arterial diameter, true peak response is more reliably assessed.
This is limited only by image quality, the processing power of the computer (16- 
17 frames/s), and/ or the frame rate of the recording medium (25 frames/s),
6.10.4. FMD data corrected to shear-rate stimulus
The peak of the shear stress stimulus profile created with reactive hyperaemia 
occurs four to seven seconds after cuff release and then rapidly decreases, 
returning to baseline within two minutes. In contrast, the peak diameter 
adaptation is typically not observed until 45-75 seconds after cuff release (97). 
Thus the vessel is exposed to the peak stimulus and then an additional 35-65 
seconds of continued elevated shear stress prior to development of the peak 
response. Recently, Pyke et al (129) have shown that the independent
contribution of the peak shear stimulus is minimal, and it is the shear rate area 
under the curve (AUC), and not the peak itself, that is the critical detenninant of 
peak FMD response. Therefore, AUC is the best method of quantifying reactive 
hyperaemia shear stimulus for FMD normalisation. We have used the FMD 
corrected for shear rate stimulus in our observations.
6.10.5. Endothelium-independent vasodilatation
Endothelium-independent vasodilatation can be evaluated in the peripheral 
circulation after administration of agents that directly relax smooth muscle cells, 
such as glyeceryl trinitrate or sodium nitropmsside. This technique allows the 
investigator to assess the ability of the artery to maximally dilate. The role of 
vascular smooth muscle cells in vasodilatation has important implications for 
endothelial function testing. It is unclear whether factors that result in endothelial 
damage and dysfunction also lead to abnormalities in relaxation mediated by 
vascular smooth muscle cells. Because vascular smooth muscle cells are the final 
common pathway mediating vasodilatation, it is important realize that processes 
that cause decreased endothelium-independent vasodilatation responses, by 
definition, will also decrease endothelium-dependent vasodilatation. We have 
used glyceryl trinitrate administration sublingually to evaluate endothelium- 
independent vasodilatation with the methods described above.
6.11. Vascular function after transradial 
catheterisation and recovery in our study
Our findings indicate that endothelium-dependent and -independent functions 
were decreased acutely as a result of radial artery catheterisation, impairment that 
largely resolved during three months of recovery. There was around a 40% to 
50 % relative reduction in endothelium-dependent vasodilatation and a similar 
reduction in endothelium-independent vasodilatation measured the next day after 
the transradial procedure. There was no difference seen in vascular function 
recorded simultaneously in the contralateral (non-catheterised) arm. This 
impairment in vascular function returned towards normal at the time of a follow­
up evaluation after three to four month. There is limited previous data on the 
impact of radial artery catheterisation on vascular function in vivo. One previous 
study has examined the impact of transradial catheterisation on FMD and found 
it was impaired immediately post-procedure and up to nine weeks after 
catheterisation (49). They noticed a more than 70% reduction in vascular 
function after the procedure and at follow up to nine weeks. Our data largely 
reinforce this previous experiment, with the addition that our data show recovery 
of endothelium-dependent and-independent function three months post­
procedure, whereas Burstein et al (49) reported depressed function at nine weeks. 
These findings suggest that up to three months may be required for the arterial 
function to normalize after catheterisation and sheath insertion.
Our data, and that of Burstein et al (49), indicate that although FMD is reduced, 
it is not completely abolished. This might suggest that there is not complete 
denudation of the endothelium. Nonetheless, the substantial depression in FMD
we observed suggests that sheath insertion may have resulted in mechanical 
damage to the endothelial layer which, given the fragile nature of this monolayer, 
is a likely mechanism for impaired vasodilator function. It is also likely that the 
insertion of an introducer sheath into a relatively small radial artery may also 
result in structural damage to the wall, which in turn impairs GTN-mediated 
responses post-procedure. The acute increase in baseline radial artery diameter in 
the cannulated radial segment post-procedure further supports this hypothesis.
6.12. Radial artery diameter at baseline and at 
follow up
Radial artery luminal diameters ranged from 1.8 to 3.2mm in both catheterised 
and the control arm. We have found a negative correlation between the baseline 
radial artery diameter and the percentage vasodilatation in response to shear 
stress. Therefore, smaller the radial artery size greater the percentage change in 
the diameter of the radial artery in response to shear stress and GTN 
administration. Our results reinforce the published literature documenting an 
inverse relationship between radial artery diameter and the degree of 
vasodilatation (84, 85). Moreover, this negative correlation is abolished acutely 
after transradial catheterisation for both FMD and GTN-mediated vasodilatation. 
This is potentially due to significant vascular impairment acutely after the 
transradial procedure.
The mean radial artery diameter significantly increased from 2.79 to 3.02mm 
immediately after the procedure in the catheterised aim, with no difference in the 
control arm. The radial artery diameter returned back to its baseline size at long
term follow-up. This potentially explains the reversible effects on the vessel wall 
tone induced by transradial catheterisation. Similar changes in the radial artery 
diameter were observed by Burstein et al (49) following transradial 
catheterisation. Zhenxian et al (191) have evaluated the radial artery diameter 
and injury to the radial artery before, one day and one month after a transradial 
procedure, using ultrasound. They have reported the mean diameter of the right 
radial artery was 2.37±0.57, 1.95±0.50 and 2.23±0.41 mm, before the procedure, 
one day, and one month after the procedure respectively (p <0.01 at one day, p 
<0.05 at one month). The mean intima-media thickness of the radial artery was 
0.25±0.12, 0.69± 0.31 and 0.38±0.17mm before the procedure, one day, and one 
month after the procedure respectively.
Patel et al (192) have assessed the histological changes induced by 
catheterisation on the radial artery. They have compared the histopathological 
changes between previously catheterised radial arteries and non-catheterised 
arteries. The distal ends of the catheterised radial arteries showed significantly 
more intimal hyperplasia (73.3% vs. 21%, p=0.03), peri-arterial tissue or fat 
necrosis (26% vs. 0%, p=0.02), and more adventitial inflammation (33.3% vs. 
0%, p=0.01) than the distal ends of the non-catheterised radial arteries.
This study has therefore confirmed that transradial catheterisation induces 
changes in the radial artery size and the injury to the vessel wall which seems to 
recover towards baseline, as previously shown in limited studies. In addition we 
have shown substantial recovery in vasodilatory function three months after
catheterisation.
6.13. The impact of hydrophilic coating of the 
introducer sheath on vascular function
A novel and unique aspect of the present study was the examination of the 
impact of hydrophilic coating of the introducer sheath on vascular function. We 
assessed endothelial-dependent and -independent function in sections of arteries 
subjected to placement of coated and uncoated introducer catheter sheaths. 
Measures were collected before and after sheath placement and, in a subgroup, at 
approximately three months after catheterisation to determine whether arterial 
vascular function recovered. Within-subject control measures were also collected 
from the contralateral non-catheterised limb. Our findings indicate that there was 
no significant difference between the hydrophilic-coated and uncoated sheath 
groups in terms of the acute impact of catheterisation or recovery from this 
procedure. No changes in arterial function were observed in the non-catheterised 
arm at any point. These data indicate that a hydrophilic coating does not 
ameliorate the dysfunction associated with catheter sheath insertion in vivo.
The development of hydrophilic coating has purportedly led to a reduction in the 
force required to remove the sheath and a reduction in friction and likelihood of 
damage during removal (21). Indeed, there is evidence from our study and other 
studies that a coated introducer sheath has beneficial clinical effects including 
reduced spasm and discomfort to the patient (21, 22, and 23). We therefore 
hypothesised that coating of the introducer sheath would limit the impact of the 
friction on the vessel wall and that diminished impact on the endothelial lining 
may preserve its well established anti-atherogenic properties. However, our data 
show that there was no difference between hydrophilic-coated and uncoated 
introducer sheaths in terms of their impact upon endothelium-dependent and -
independent function after sheath placement. Furthermore, we observed no 
evidence of a beneficial effect of sheath coating on the recovery of the artery 
following sheath removal. These data indicate that, if clinical outcome benefits 
from coating sheath do indeed exist, then the mechanisms responsible are 
unlikely to be attributable to preserved endothelial or vascular smooth muscle 
function. In addition, several recent papers have suggested that subjects can 
develop a granulomatous inflammation, due to shedding of some of the 
hydrophilic coating into the artery (62, 116, 130, 131) These findings, in 
combination with our data, support the suggestion of Tharmaratam et al (131), 
that the increased cost of the hydrophilic coated sheaths, the cost of treatment of 
sterile inflammation and the apparent lack of difference in spasm and depressed 
function need to be carefully balanced against the benefits of reduced spasm and 
pain on removal.
6.13.1. Type II error
When concluding that there is no difference between two groups, it is necessary 
to consider the possibility of a type II error (acceptance of null hypothesis when 
it is false). As well as the absence of a statistically significant difference, a study 
or result should be sufficiently powerful to detect a physiologically meaningful 
change from the mean control value in the intervention group, based on previous 
consideration of what constitutes a physiologically meaningful change. Previous 
detailed analysis by Woodman et al (128) of power requirements using the edge- 
detection software indicates that, at an alpha level of 0.05, seven subjects are 
required in crossover design and 16 subjects are required in parallel design to
ensure 90% power to detect a 2% improvement in FMD. A measurement of 2% 
reduction in the clinical end point (FMD) is likely to have a significant clinical 
impact and would be considered clinically relevant. We assumed that the results 
in this study for a primary end-point of reduction in FMD would therefore be 
considered adequately powered if a difference can be detected that would result 
in a reduction of FMD by 2%.
The measurement of change in FMD was adequately powered to detect a 
difference of 2%. It is therefore unlikely these results represent a type II error, 
and it may be concluded that there is no difference, at a level that may be 
important, in the occurrences of impairment of vascular function as measured by 
percentage change in FMD between uncoated and coated introducer sheath 
groups.
6.14. The impact of length of the introducer sheath 
on vascular function
Different lengths of the introducer sheaths cover different lengths of the radial 
artery during introducer sheath placement. The long introducer sheath (23 cm) 
extends for a longer length in the radial artery and thereby reduces contact of the 
catheter on the wall of the radial artery during the catheter manipulation. There is 
a possibility of a different degree of endothelial and radial artery injury with the 
use of long and short introducer sheaths during transradial catheterisation. We 
therefore measured vascular function at both proximal and distal sections of the 
radial artery in order to determine whether function was affected within the 
region of the introducer sheath alone, or whether transradial catheterisation has
more generalised effects on vasodilator function. Our findings indicate that 
endothelium-dependent and -independent function is decreased acutely as a 
result of catheterisation, both within and above the site of the sheath. This 
impairment largely resolved during three months of recovery. No changes in 
arterial function were observed in the non-catheterised aim at any time point. 
These data indicate that the impact of catheterisation extends beyond the site of 
sheath placement, but is not generalised to the entire circulation and resolves 
after a period of recovery.
We have not observed any difference in the degree of vascular impairment at the 
proximal and distal measurement sites with the use of long or short introducer 
sheaths. While the long sheath might protect the more proximal part of the radial 
artery from damage from the catheter movements, it has a greater diameter than 
the catheter and may therefore cause more damage in this area due to vessel- 
sheath size mismatch.
6.15. The impact of radial artery to introducer 
sheath diameter ratio on vascular function
Impairment of vascular function of the radial artery following transradial 
catheterisation is due to the interaction between the internal lining of the radial 
artery and the outer lining of the introducer sheath. This results in endothelial and 
deeper damage to the radial artery following transradial catheterisation. It is 
plausible that in patients with a radial artery diameter to introducer sheath outer 
diameter ratio of less than one would experience a greater degree of friction and 
damage to the endothelial lining of the radial artery during introducer sheath
manipulation. Saito et al (29) have shown a greater degree of radial artery spasm 
and the patient discomfort when the artery to sheath ratio is less than one during 
transradial catheterisation.
We have observed a significantly higher degree of vascular impairment in 
patients with a radial artery diameter to introducer sheath ratio of less than one as 
compared to the patients with a ratio of greater than one. These findings were 
seen in both endothelium-dependent and -independent arterial function. These 
findings further reinforce the hypothesis that radial artery size and introducer 
sheath size mismatch results in greater degree of vascular impairment and more 
radial artery spasm and discomfort to the patient (29).
6.16. The clinical impact of vascular dysfunction 
following tansradial catheterisation
The recovery of endothelial-dependent and -independent function in the 
catheterised arm indicates that transradial catheterisation should not be 
considered an absolute contraindication to the subsequent use of the radial artery 
as a donor graft for coronary artery bypass surgery (CABG). We have shown for 
the first time that the vascular function improves and returns towards normal 
after three to four months.
Some caution is warranted, however, as cannulation of the radial artery, in 
particular repeat cannulation, has been shown to reduce arterial lumen size and 
result in intima-medial thickening (35, 36, 37, and 133). Damage to smooth 
muscle may also be associated with intimal hyperplasia, cell proliferation and
collagen synthesis (132) leading to inward vascular remodelling (133). 
Furthermore, transradial catheterisation has been shown to induce intimal 
hyperplasia, medial inflammation and tissue necrosis at the puncture site (124). 
Despite good clinical outcomes (136) caution in using the radial artery as a graft 
is advocated by several groups due to propensity to spasm, increased likelihood 
of development of atherosclerosis and damage induced by transradial 
catheterisation (36, 48, 58, 133-135).
The mechanism of injury is suggestive of injury to the endothelium and the 
vessel wall as reflected by impairment of both endothelium-dependent and - 
independent vascular function.
6.16.1. Limitations of the vascular function study
The present study has a number of limitations. There were a relatively small 
number of subjects in each group and not all patients attended for follow-up 
studies after the three month recovery period. This limitation is somewhat 
mitigated by our within-subject design and analysis. We did not control for age, 
pre-existing vascular disease, history of smoking or drug treatment. However, 
the use of the contralateral ami as an internal control helped to negate this 
limitation and our data set has the advantage of representing responses in typical 
unselected patients
6.16.2. Conclusions and future directions
In conclusion, transradial catheterization results in reversible depression in NO- 
mediated endothelial and smooth muscle function in the catheterized arm. This 
effect is not mitigated in subjects who received a hydrophilic-coated sheath. The 
purported benefits of hydrophilic-sheath coating need to be weighed up against 
the increase cost, possible increased risk of inflammation and lack of reduction in 
arterial dysfunction. Future research and technological development should seek 
to minimise the effects of the catheter as well as the sheath on the vasculature. It 
is also possible that optimising the function and size of the artery prior to its 
camiulation may improve the outcome and recovery of the artery and reduce the 
chance of graft failure if the artery is removed for CABG (138,). To this end, 
exercise training has been shown to improve arterial function and induce outward 
remodelling as shown by Homig et al (139) Hambrecht et al.(138), Gokce et al. 
(140), Green et al.(141), and Tinken et al. (142)). Therefore, exercise training 
before the radial catheterisation could improve the endothelial function of the 
radial artery and might also reduce the degree of endothelial damage and 
dysfunction following the procedure.
Conclusions
Radial artery spasm is commonly encountered in patients undergoing transradial 
cardiac catheterisation or coronary intervention. This can cause discomfort to the 
patient and may prevent completion of the procedure in some patients. We 
performed a study to see if the length and coating of the radial artery sheath 
affected the incidence of spasm and other complications of transradial 
catheterisations. We observed radial artery spasm in 30% of our patients and this 
resulted in procedural failure in 17 (2.2%) patients. We also investigated the 
tolerability and safety of two different compression devices used to achieve 
haemostasis after radial sheath removal.
Hydrophilic coated introducer sheaths significantly reduce clinical radial artery 
spasm and the discomfort experienced by the patients when compared to 
uncoated introducer sheaths. There were similar rates of radial artery occlusion 
rates (9%) and early access site complications in both sheath types. There was a 
significantly higher incidences of late local access site complication, 
predominantly an inflammatory reaction seen with the use of a hydrophilic 
coated introducer sheath (3%).
There was no impact of the length of the introducer sheath on clinical outcomes 
observed in our study.
We have identified younger age, female gender, diabetes, smaller wrist size, 
lower body mass index, and use of uncoated introducer sheath as independent 
predictors of clinical radial artery spasm.
Haemostasis after transradial procedures was successfully achieved by TR Band 
or Radistop compression devices in all patients. The time taken to achieve
haemostasis was longer with the use of the TR Band but the discomfort 
experienced while the device was applied, was greater with Radistop. However, 
access site complications were similar in both groups.
We have identified younger age, female gender, smaller wrist size, occurrence of 
radial artery spasm, and failure to use heparin during the procedure as 
independent predictors of radial artery occlusion at the time of discharge from 
the hospital.
We have evaluated the impact of transradial catheterisation on endothelium- 
dependent and -independent vascular function of the radial artery acutely and at 
follow up. We have shown that transradial catheterisation results in reversible 
impairment of endothelial-dependent and -independent function in the 
catheterised arm. Our findings indicate that vascular function is severely 
decreased acutely (24 hours after procedure) and that this dysfunction has largely 
resolved following 3 months of recovery. We have not found any correlation 
between hydrophilic coating and the length of the introducer sheath on vascular 
function impairment after trasradial catheterisation. However, we have observed 
higher degree of endothelium-dependent and -independent vascular function 
impairment in the patients with radial artery internal diameter to introducer 
sheath outer diameter ratio of less than one. This reflects a higher degree of 
injury to the radial artery in these patients.
The thesis will provide important insight into clinical information and problems 
encountered during transradial catheterisation in contemporary clinical practice. 
This work will also help clinicians in choosing between various different 
introducer sheaths and compression devices available to be used during 
transradial catheterisation. Operators should be aware of physiological impact of
these procedures on the vasculature and its clinical impact. The work of this 
thesis could be expanded with further studies investigating the impact of other 
patient and device related characteristics on vascular function. Further studies 
looking into optimisation and improving the endothelial function during this 
procedure may improve patient outcome.
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Appendix 1
PATIENT INFORMATION SHEET
Randomised Comparison Of Introducer Sheaths And 
Compression Devices In Patients Undergoing Transradial 
Coronary Procedures
Introduction
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it 
would involve for you. Your cardiologist and the study doctor would like to 
ensure that you completely understand the study and the study requirements. 
Please take your time to read the following information carefully and discuss it 
with others if you wish. Ask your study doctor if there is anything that is not 
clear or if you would like more information. Taking part in the study is entirely 
voluntary. Take time to decide whether or not you wish to take part.
What is the purpose of the study?
As you are aware you have been diagnosed with coronary artery disease. The 
procedure that is recommended by your cardiologist is coronary angiography or 
coronary balloon angioplasty. The procedure could be performed by gaining 
access through the artery in your wrist or through the artery in your groin. Both 
access sites have been widely used for many years. Arterial access from wrist has 
been incieasingly used and it has shown to cause less local complications and be 
better tolerated by patients. To gain vascular access different sheath types are 
licensed and commercially available and are widely used. After the procedure is 
completed the bleeding from the wrist is stopped by applying pressure by 
compression devices.
The TR Band and the Radistop are compression devices that are widely used.
The main objective of this study is to compare the performance of four different 
types of sheath with different length with and without slippery coating. We will 
also be comparing the performance of two different kinds of compression 
devices used to stop bleeding at the end of procedure. We will be studying the 
impact of these devices on radial artery spasm, radial artery blockage, patient 
tolerance and local vascular complications.
If you choose to participate in this study, the type of sheath and the type of 
compression device will be randomly chosen. The rest of the procedure will be 
performed as it would be normally.
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Why have I been chosen?
Your treating consultant cardiologist has advised the research team to approach 
you for this study. All patients like you who need treatment for coronary artery 
disease via radial route are being invited to take part. A total of 800 patients will 
be recruited and treated from this centre [The Cardiothoracic Centre, Liverpool].
What will happen to me if I take part?
If you agree to participate in this study you will undergo your procedure using 
either of the long coated, long uncoated, short coated or the short uncoated 
sheaths. At the end of procedure you will receive either the TR band or the 
Radistop to stop bleeding from wrist. The type of sheath and the type of 
compression device you receive will be randomly assigned [equal chance of 
being in any of the groups] so neither you nor your physician will be able to 
choose which sheath or compression device you will receive. You have an equal 
chance of receiving either sheath or either compression device.
The risks and benefits of this technique will be explained to you as per usual 
hospital practice. The procedure will be performed according to your study 
doctor’s usual practice.
Your progress will be monitored throughout your hospital stay. You will have 
your wrist assessed for any complication or blockage of radial artery.
A summary of the study tests and procedures is provided in the table below.
Before the procedure Information sheet and consent form 
provided in Pre-assessment clinic or on 
wards
After the procedure Assessment of radial artery spasm, wrist 
examination by hand held Doppler 
ultrasound and clinical examination.
At four months Assessment of wrist by ultrasound 
examination.
Day 1- Consent taken and procedure performed
Day 1- Assessment of radial artery spasm by questionnaire.
Day 1/2 [pre discharge] - Assessment of the wrist by Doppler ultrasound to 
detect radial artery patency and any local vascular complications.
4 month [follow up] - Assessment of wrist by Doppler ultrasound to detect 
patency of radial artery.
It is important for you to understand that participation in the study is entirely 
voluntary. In addition if you agree to participate initially and reconsider at a later 
date then you may decline to continue with the study follow up.
What are the possible disadvantages and risks of taking part?
There are some potential known risks involved with transradial coronary 
procedures. These include: the risk of radial artery blockage [3-7%], radial artery 
spasm [15-30%], bleeding from wrist [l-2%] and haematoma [2-3%] in the 
forearm or arm.
All these risks are the known complications from the transradial coronary 
procedure and are not specific to this study. The study is intended to explore the 
ways to minimise the above risks.
What are the risks associated with pregnancy?
Pregnant women are excluded from this study. If you are or think you could be 
pregnant please inform the doctor treating you.
What are the possible benefits of taking part?
It is important for you to understand that the information obtained during this 
study may be used to help others. You should also understand that there may be 
some benefits to you, as some sheaths or compression device used during study 
may cause less discomfort.
The study will help determine and compare the performance of four different 
sheaths and two different compression devices used in this trial.
Do I have to take part?
You have the right to choose whether you wish to participate in this trial. In 
addition you have the right to withdraw from this trial at any time, without 
having to provide a reason. This will not affect your relationship with your 
cardiologist or with any of the nursing staff at any time. This will also not affect 
your normal treatment and care.
Your cardiologist may also withdraw you from the study without your 
pennission, if she/he deems it is in your best interest or if the investigator decides 
to end the study.
What are the alternatives?
If you prefer not to participate in this study your study doctor can discuss the 
alternative treatments for you. These may include the sheath and compression 
device routinely used.
Who is organising and funding the research?
You will not be paid for participation in this study. The routine costs for this 
procedure will be billed to your insurance company or National Health Service as 
normal. Your study doctor is not paid for your participation in this study.
You can ask the study co-ordinator for any additional costs as result of your 
participation in this study.
What if something goes wrong?
In the event of an injury during your participation in this study as a result of the 
procedure, you will be treated by your cardiologist according to local hospital 
practice. It is important however that you inform your cardiologist via the study 
co-ordinator of any change in your health, or any other medical treatment that 
you may require during the course of this study.
If you have any problems, concerns, complaints or other questions about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal complaints mechanisms of the NHS are available to you. You 
should preferably contact the investigator first, Dr Sudhir Rathore on telephone 
0151 228 1616 Bleep-760. Alternatively you may contact the hospital complaints 
department on telephone number 0151 600 1257.
Will my taking part in this study be kept confidential?
The ethics committee, which reviews research projects for this hospital, has 
approved our participation in this study. With your permission your GP will be 
notified of your participation in this study. When signing the consent form you 
will be asked to give approval for this to happen. Please be assured that 
confidentiality of your records will be maintained at all times.
Any data that is collected in this trial will be managed in accordance with current 
codes of practice and data protection legislation such as the Data Protection Act 
1998. The trust will archive the data for 10 years. If you withdraw from the trial 
at any time the data collected from your participation will be included in the final 
trial results up until the time that you withdrew from this study.
What will happen to the results of the study?
The results of this study will be reported in medical journals and/or at medical 
meetings. When this occurs the identification of individuals taking part is not
disclosed. If you wish to receive a copy of these, you should let your study 
doctor know so that it may be sent to you when it is ready.
What if new information becomes available?
If any new information becomes available that could affect your participation in 
the study we will let you know as soon as possible.
Who has reviewed the study?
The study has been approved by the Local Research Ethics Committee 
responsible for this hospital. Their role is to check that the study is acceptable 
from an ethical and safety point of view in the interests of the patients 
participating.
Contact for further information?
If you wish to obtain more information regarding this study or its risks, 
advantages or medical alternatives, please contact your study doctor. You should 
also inform your study doctor via the study co-ordinator, if you have been unwell 
or hospitalised for any reason during the study. Should any problem or question 
arise with regard to this study, either concerning your rights as a participant in 
clinical research, or with any research related injury, you should contact the
Principal Investigator, Dr-John Morris on 0151 228 2264.
Principal Co-Investigator and Co-ordinator, Dr Sudhir Rathore on 0151 228 
1616 Bleep-760.
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PARTICIPANT CONSENT FORM
Patient Identification Number for this trial (CRF No.):
Study Number: 719. 06/Q1502/94
Title of Project: Randomised Comparison Of Introducer Sheaths and Compression 
Devices In Patients Undergoing Transradial Coronary Procedures
Name of Researcher : Dr Sudhir Rathore
Please initial t
1. I confirm that I have read and understand the information sheet dated 27 July, 2006 
(final version)for the above study and have had the opportunity to ask questions and 
have had these answered satisfactorily. c
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected. □
3. I understand that sections of any of my medical notes may be looked at by responsible 
individuals from the Clinical Trials Unit at cardiothoracic cenfre NHS Trust or from 
regulatory authorities where it is relevant to my taking part in research. I give 
permission for these individuals to have access to my records. c
4. I agree to take part in the above study and agree to my GP being informed of my 
participation in the study. c
Name of Patient Date
Signature
Name of Person taking consent Date
Signature
(if different from researcher)
Researcher Date
Signature
When completed, 1 for patient, 1 for researcher file; 1 [original] to kept in medical records.
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Protocol for the Application and Removal of the 
TERUMO TR BAND at the Cardiothoracic Centre,
Liverpool.
Application [IN CATH LABI
1. On completion of the procedure withdraw the introducer sheath by 
2-3 cm.
2. Align the green marker [which is located on the centre of the 
compression balloon] over the arterial puncture site, approximately 
0.5 to 1.0 cm above [proximal] the skin incision. Wrap the Velcro 
strap around the wrist leaving a space over the ulnar artery [not too 
tight].
3. Using the syringe provided, inject 15-18 cc of air through the side 
arm to inflate the compression pad. After inflation immediately 
remove the syringe.
4. Remove the arterial sheath and observe for any bleeding.
5. Re-attach syringe and remove air slowly, watching through the 
transparent band. When a show of blood is visible re- introduce 1-2 
ml of air. Note final residual air volume.
6. At this stage there will be palpable radial pulsation distal to device 
and early forward flow is achieved.
Removal TON THE WARDS!
7. After one hour of return to ward, using the dedicated syringe, slowly 
start to remove the air from the TR BAND. Observe the local 
bleeding at all times. If bleeding shows, simply re inflate the 
compression pad by 1- 2 ml of air and recheck in 30 minutes.
8. Thereafter check every 30 minutes and repeat the process that has 
just been described, as required.
9. Completely remove the TR BAND when bleeding stops and check the 
puncture site for any complications. Then apply dressing over wound.
10, Note the time when TR BAND is removed.
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Protocol for the Application and Removal of RADISTOP at the 
Cardiothoracic Centre, Liverpool 
Application UN CATH LABI
1. Place the hand in the support plate, with the distal Velcro strap at the base of 
the thumb. Adjust the distal strap to fit.
2. Wrap the proximal strap around the patients forearm and secure.
3. Thread the compression pad onto the separate Velcro strap. NOTE!
Fluffy side of the Velcro strap will be facing down, towards the patients skin.
4. Centre the compression pad directly over the puncture site. Apply pressure 
while removing the sheath. NOTE! Positioning directly over the puncture site 
will help prevent bleeding from collateral blood supply.
5. Continue to apply manual compression while tightening and securing the strap. 
NOTE! Hold the thumb firmly on the pad and the fingers securely around the 
support plate, in C-grip.
6. Pulse should be checked after application and if no pulse is palpable the Velcro 
should be loosened slightly until the pulse is palpable or bleeding starts.
Removal TON THE WARDS!
7. After one hour of return to ward consider reducing pressure maintaining 
haemostasis with no local oozing. Observe for local bleeding at all times. If 
bleeding shows, simply re tighten the strap and recheck in 30 minutes.
8. Thereafter check every 30 minutes, and repeat the process that has just been 
described, as required.
9. Completely remove the RADISTOP when bleeding stops and check the 
puncture site for any local complication. Then apply dressing over the wound.
10. Note the time when RADISTOP was removed.
Version02/rathor e 09/10 /2006
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Appendix 5
NHS Trust
PATIENT DETAILS
1 Patient’s name
2 Hospital / Unit number
3 Address: House no./Street
4 Address line 2
5 City
6 Post code
7 Country
8 Telephone number
9 NHS number
DETAILS OF RELATIVE OR FRIE ND NOT AT THE SAME ADDRESS
10 Relative’s or friend’s name
11 Address: House no./Street
12 Address line 2
13 City
14 Post code
15 Country
16 Telephone number
DETAILS OF G.P.
17 GP name
18 Surgery name
19 Street
20 Address line 2
21 City
22 Post code
23 Country
24 Telephone number
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SCREENING PHASE - ELIGIBILITY CRITERIA
Inclusion Criteria
25 Referral for coronary angiography or 
coronary angioplasty via Transradial route
Yes [ ] No [ ] stop
If ‘no’, stop, patient not eligible.
Exclusion Criteria
26 Previous ipsilateral transradial procedure Yes [ ] stop No [ ]
27 Haemodynamically unstable patient- 
Cardiogenic shock, Yes [ ] stop No [ ]
28 Chronic renal failure** Yes [ ] stop No [ ]
29 Patient on Haemodialysis with A-V Fistula Yes [ ] stop No [ ]
If ‘yes’ to any of above, patient should not be randomised.
CONSENT
30 Has patient been fully informed and
received patient information sheet Yes [ ] No [ ]
31 Has patient signed consent form Yes [ ] No [ ]
32 Date of consent (dd/mm/ww) / /
33 Name of person obtaining consent
34 Is copy of consent form in medical records
and site file Yes [ ] No [ ]
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SCREENING PHASE - CLINICAL HISTORY
35 Gender Male [ ] Female [ ]
36 D.O.B. (dd/mm/yyyy) / /
37 Documented hypertension Yes [ ] No [ ]
38 Documented hyperlipidaemia Yes [ ] No [ ]
39 Diabetes mellitus: No history of diabetes 
[ ]
Type I
[ ]
Type II
[ ]
40 Cigarette smoking
Current 
[ ]
(Within last month)
Ex-smoker 
[ ]
(Stopped > 3 months)
Never smoked 
[ ]
41 Height [cm]
42 Weight [Kg]
43 Wrist circumference [cm]
44 ALLENS Test** < 5 sec 
[ ]
5-10 sec 
[ ]
10-20sec 
[ 1
>20 sec 
[ ]
Not at all 
[ ]
45 Plethysmography and 
Oximetery Test**
Type A 
[ ]
Type B 
[ ]
Type C 
[ ]
Type D 
[ ]
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IN-HOSPITAL PHASE
46 Date of procedure dd/mm/yyyy ........ /......... /.................
47 Clinical Syndrome Stable angina 
[ ]
ACS
[ ]
Acute Ml
[ I
48 Priority of Procedure Elective 
[ ]
Urgent 
[ ]
Emergency 
[ ]
RANDOMISATION
Please contact Sudhir Rathore Bleep 2760
49 Date of randomisation (dd/mm/yyyy)____ /_____
50 Randomisation code
[1] Long Hydrophilic + TR Band I ]
[2] Long Hydrophilic + Radistop [ ]
[3] Long Uncoated + TR Band [ ]
Treatment allocation- [4] Long Uncoated + Radistop [ ]O 1 Introducer Sheeth +
Compression Device [5] Short Hydrophilic + T R Band I ]
[6] Short Hydrophilic + Radistop [ ]
[7] Short Uncoated + T R Band [ ]
[8] Short Uncoated + Radistop [ ]
52
Randomised by Name:
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** IN HOSPITAL PHASE - PROCEDURE [COMPLETED IN CATH LAB BY OPERATOR]
53 Name of operator Name :
54 Radial artery access successful Yes [ ] No [ ]
55 If No why? [Please give reason]
RA puncture unsuccessful [ ]
Unable to pass wire [ ]
Recurrent RA [ ]
Difficult anatomy [ ]
Other [Specify]
56 Time Transradial sheath Inserted [24 hr clock]:__/_____ hrs
57 Time Transradial sheath removed 
and compression device applied [24 hr clock]:__/____ hrs
58 Total number of catheters used 1 [ ] 2[ ] 3[ ] 4 [ ] >4 [ ]
59 Radial spasm questionnaire 
completed by Operator Yes [ ] No [ ]
60
Operator’s Questionnaire- [Please indicate one or more features ]
Patient reported presence of continuous pain Yes [ ] No [ ]
Patient reported forearm pain only during catheters manipulation Yes [ ] No [ ]
Patient reported forearm pain while sheath retrieval Yes [ ] No [ ]
Firm grip of the catheters during manipulation Yes [ ] No [ ]
Augmented resistance to sheath retrieval Yes [ ] No [ ]
61 Spasmolytic drugs needed Yes [ ] No [ ]
62 If Yes, spasmolytic drug used 
describe the dose and agent used Verapamil Nitroglycerine Other [specify]
260
Transradial Access Trial [RADIAL ACCESS] CRF No:
Clinical Trials Unit, Cardiothoracic Centre, Liverpool.
Final version 20/10/2006 Page 260
63. Coronary anatomy and outcomes
Coronary arteries attempted Successful Failure Number of catheters
LCA Diagnostic Imaging
LCA Intervention Imaging
LCA PCI Outcome
RCA Diagnostic imaging
RCA Intervention Imaging
RCA PCI Outcome
64 Procedure completed via radial
route Yes [ No
65 If No , Reason why Radial artery spasm 
[ 1
Difficult Anatomy 
[ 1
Other [Specify]
66 Heparin Dosage units
67 If Coronary Intervention, ACT 
at the end of the procedure _______ sec
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PRE DISHARGE ASSESSMENT
68 Time Compression device removed [24 hr clock]____ /_____hrs
69 Patient questionnaire for spasm completed Yes [ ] No [ ]
70 If No Reason why?
71 Is completed patient questionnaire in site
file Yes [ ] No [ ]
72 Patient assessment of radial artery spasm 1 [ ] 2[ ] 3 [ ] 4[ ] 5[ ]
73 Questionnaire regarding compression 
device completed Yes [ ] No [ ]
74 If No, Give reason
75 Questionnaire regarding compression 
device in site file Yes [ ] No [ ]
76 Local vascular complications Yes [ ] No [ ]
77 If Yes Describe
Oozing [Leakage of blood from puncture site requiring 
digital pressure] [ ]
Ecchymosis [ Bleeding into s/c plane causing bluish 
purple discoloration > 4cm] [ ]
Local small haematoma [< 2 cm] [ ]
Local large haematoma [> 2 cm] [ ]
Radial or Brachial artery dissection [ ]
Subclavian artery dissection [ ]
78 Radial artery pulsation felt distal to puncture 
site after compression device removal Yes [ ] No [ ]
79 Radial artery pulsation felt proximal to 
puncture site after device removal Yes [ ] No [ ]
80 If No, Confirm by hand held Doppler Doppler flow present 
[ ]
Doppler flow absent [ ]
81 Reverse Allen’s test* < 5 sec 
[ ]
5-10sec 
[ ]
10-20
sec
[ ]
> 20 sec 
[ ]
Not at all 
[ ]
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82 Reverse Plethysmography and Oximetery test **
Type A 
[ ]
Type B 
[ ]
Type C 
[ ]
Type D 
[ ]
83 Radial artery Occlusion ** Yes [ ] No [ ]
INVESTIGATOR’S DECLARATION
I declare that the information presented in the Case Record Form ( pages 1 to 12 ) accurately reflects 
the medical records, including the results of tests and evaluations performed on the dates specified.
84 Name of person completing form (capitals)
85 Signature of person completing form
86 Date form completed (dd/mm/yyyy) / /
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4-6 Month follow up
87 Any local access site complication after
-----------------------------------------discharge Yes [ ] No
88 If Yes , Please describe
Local Infection [ ] Medical Treatment Vascular surgery
Local allergic reaction [ ] Medical Treatment Vascular surgery
Pseudoaneurysm [ ] Medical Treatment Vascular surgery
A V Fistula [ ] Medical Treatment Vascular surgery
Local pain [ ] Medical Treatment Vascular surgery
Other [specify]
89 Radial artery pulsation felt distal to 
puncture site Yes No
90 Radial artery pulsation felt proximal to 
puncture site Yes No
91 If No, Confirm by hand held Doppler Doppler flow present 
[ ]
Doppler flow absent
92 Reverse Allen’s test* < 5sec 5-10sec 10-20sec >20 sec Not at all
[ ] [ ] [ ] [ ] [ )
93 Radial artery occlusion* Yes [ No
94 Any Functional impairment of hand Yes [ No
95 If YES, Please describe
INVESTIGATOR’S DECLARATION
/ declare that the information presented in the Case Record Form (follow up) accurately reflects the 
medical records, including the results of tests and evaluations performed on the dates specified.
96 Name of person completing form (capitals)
97 Signature of person completing form
98 Date form completed (dd/mm/yyyy) / /
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The Radial Approach: Is This the Route to Take?
SUDHIR RATHORE, M.D., M.R.C.P. (U.K.)1 and JOHN L. MORRIS, M.D., F.R.C.R (U.K.)2
'Specialist Registrar and 2Consultant Cardiologist, The Cardiothoracic Centre, Thomas Drive, Liverpool, United Kingdom
The benefits of the transradial approach have clearly been demonstrated over the years in various studies. The 
reduced incidence of access site complications and early mobilization are some of the benefits making this 
technique popular with inter\>entional cardiologists worldwide. With increasing experience and availability of 
dedicated equipment this technique is now been increasingly used for complex catheter interventions. However, 
there still remain some potential problems and complications with the transradial approach and it needs further 
research. The main purpose of this review is to highlight the benefits, complications, and poten tial problems with 
the transradial approach. (J Interven Cardiol 2008;21:375-379)
Introduction
The transradial approach for coronary angiography 
was first described by Campeau in 19891 and the tech­
nique was extended to percutaneous transluminal coro­
nary angioplasty and stenting by Kiemeneij and Laar- 
man.2 Since then a widespread proliferation of coro­
nary procedures via the radial artery has taken place.3-9
The safety of the transradial approach, compared to 
the conventional femoral approach for coronary proce­
dures, is mainly due to its favorable anatomic relations. 
No major veins or nerves are located near’ the radial 
artery at the wrist, minimizing the chance of neurolog­
ical or vascular injury. Hemostasis is easily achieved 
because of the superficial course of the radial artery. 
Thrombotic or traumatic radial arterial occlusion does 
not endanger the viability of the hand if an adequate 
collateral blood supply from the ulnar artery is present.
Comparison with the Transfemoral Approach
A recent meta-analysis published by Hamon et al.10 
considered 12 randomized trials published between
Address for reprints: Sudhir Rathore, M.D., M.R.C.P., The Cardio­
thoracic Centre, Thomas Drive, Liverpool, UK, L14 3PE. Fax: 0044 
151 600 1862; e-mail: sudhitTathore@hotmail.com
1989 and 2003, including a total of 3,224 patients, 
comparing transradial and transfemoral approaches for 
coronary procedures. The risk of major adverse cardiac 
events was similar for the radial versus the femoral ap­
proach (2.1% vs. 2.4%, OR 0.92, 95% Cl 0.57-1.48, 
P = 0.07), but radial access was associated with a sig­
nificantly lower rate of entry site complications (0.3% 
vs. 2.8%, OR 0.20, 95% Cl 0.09-0.42: P < 0.0001), 
although at the price of a higher rate of procedural 
failure in comparison to femoral access (107[7.2%] of 
1472 vs. 33[2.4%] of 1,373 subjects; OR 3.30, 95% Cl 
1.63-6.71: P < 0.001). The authors concluded that the 
transradial approach for coronary procedures is a safe 
and effective technique and virtually abolishes entry 
site complications.
There is also a clear’ trend toward equalization of the 
rate of procedural success over the years, mainly due 
to technological progress in equipment and increased 
operator experience. The transradial approach has been 
found to be safe and feasible in a large spectrum of 
clinical practice11-13 and in the setting of aggressive 
pharmacologic treatments such as glycoprotein Ilb/IIIa 
inhibitors8 and oral anticoagulants.14
Most of the trials included in the meta-analysis uti­
lized devices compatible with 6F or smaller catheters. 
The safety of transradial access with devices requir­
ing catheters with a larger internal diameter (7F or 
greater) need to be evaluated in large trials. Initial
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results are encouraging in selected patients by expe­
rienced operators.15-18
The procedural failure is rare with modern prac­
tice, experience, and availability of the new equip­
ment. There could be several reasons for procedural 
failure: Firstly, there may be failure to successfully 
puncture and cannulate the radial artery, because of 
the small vessel size, tortousity, or spasm. Secondly, it 
may be impossible to cannulate the coronary ostia due 
to difficulty in rotating and manipulating the catheters. 
Thirdly, the procedure may fail because of inadequate 
guide catheter support. These problems can be over­
come in the majority of cases with recent advances 
and availability of equipment dedicated to the transra­
dial approach.
Complications of the Transradial Approach
Radial Artery Occlusion. Although this was a 
major concern of the early transradial operators, the 
consequences of radial artery occlusion are usually be­
nign. The dual supply to the hand appears robust and 
the absence of ischemic complications is promoted by 
the original recommendation by Kiemeneij that trans­
radial procedures be performed only in patients with a 
documented patent ulnar artery and palmar arch. This 
has traditionally been evaluated using Allen’s test, but 
ultrasound, Doppler, and plethysmography prior to the 
procedure are more accurate.19
Several variables influence the incidence of ra­
dial artery occlusion. Adequate anticoagulation is ex­
tremely important. The incidence of radial artery oc­
clusion was as high as 30% in patients receiving 1,000 
units of heparin during diagnostic catheterization.20 
Stella et al.21 have shown radial artery occlusion rates 
of around 5% demonstrated by ultrasonography at 
1 month in patients undergoing coronary angioplasty 
with 6F guiding catheters. Many other operators have 
shown radial artery occlusion rates varying from 3% 
to 10% in anticoagulated patients.
Catheter size has also been shown to be a predictor 
of radial artery occlusion. Studies have shown that the 
ratio between the diameter of the radial artery and the 
radial sheath has an impact on the rate of radial artery 
occlusion.22 The incidence of occlusion was 4% in 
patients with a ratio of greater than 1, compared to 
13% in those with a ratio of less than 1.
In clinical practice, variable (short and long) length 
introducer sheaths with and without hydrophilic coat­
ings are available. There are also several different 
hemostatic compression devices available (Radistop, 
TR band, Tourniquet, etc). These are widely used clin­
ically but their impact on clinical outcomes and radial 
artery injury has not been tested in a randomized trial.
Nonocclusive Radial Artery Injury. Recent stud­
ies have demonstrated that permanent radial artery 
injury without occlusion may occur following trans­
radial intervention in some patients. Mean radial artery 
internal diameter as measured by ultrasound was 
smaller in patients undergoing repeat transradial in­
terventional procedures as compared to the first-time 
procedure.23 Nagai et al. evaluated the vascular com­
plications following transradial coronary procedures 
by two-dimensional echo and color Doppler ultrasonic 
studies before and late after catheterization.24 Early af­
ter the procedure, segmental stenosis was noted in 22% 
and no flow in 9% of patients. Late after the procedure, 
segmental stenosis was seen in 1%, diffuse stenosis in 
22%, and no flow in 5% of patients. Further studies 
have shown that this progressive narrowing is due to 
intimal hyperplasia.25 Recently Edmundson and Mann 
have shown that nonocclusive radial artery injury is 
common after transradial interventional procedures.26 
Intravascular ultrasound evaluation revealed a variable 
degree of intima-media hyperplasia in all patients who 
had had a previous transradial procedure. Although 
luminal cross-sectional diameter and area were signifi­
cantly smaller than a control group, vasoreactivity was 
maintained.
These studies have involved a small number of pa­
tients in cross-sectional fashion. The incidence and 
predictors of intimal hyperplasia in patients undergo­
ing transradial procedures are yet to be determined.
The ramifications of radial artery occlusion and in­
jury are important not only in patients undergoing re­
peat interventional procedures, but also in patients in 
whom the radial artery may be used as a conduit for 
coronary artery bypass surgery or for the creation of 
arteriovenous fistulae for hemodialysis.
Radial Artery Spasm. The radial artery is a mus­
cular artery with a prominent medial layer that is 
largely dominated by alpha-1 adrenoreceptor func­
tion 27 Much of the discomfort and difficulty of the 
transradial procedure is related to vasospasm induced 
by the introduction of a sheath or catheter into the radial 
artery. Circulating levels of catecholamine play a role 
in radial artery spasm; therefore local anesthesia and 
adequate sedation to control anxiety during catheter in­
sertion may be important preventative measures. The
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incidence of radial artery spasm has been reported to 
be around 10-20%, and in about 2—5% of patients 
prevents the successful completion of the procedure 
by the transradial route.28"30
It has been demonstrated in isolated radial artery 
ring segment that nitroglycerine and verapamil are ef­
fective agents in preventing arterial spasm.31 Attempts 
have been made to quantify radial artery spasm using an 
automatic pullback device.32 Studies using this device 
have shown that an intraarterial cocktail of verapamil 
and nitroglycerine reduces the incidence of pain from 
14% to 34%. The mean pullback force (MPF) was also 
significantly lower (0.53 =t 0.52 kg vs. 0.76 ± 0.45 
kg) compared to patients not receiving any vasodilat­
ing drug.29 Clinically important radial artery spasm 
was seen in 8% of patients receiving a spasmolytic 
cocktail compared to 22% in the control group (P = 
0.029). Salmeron et al. have shown in a randomized 
controlled trial that verapamil is more effective in pre­
venting radial artery spasm than phentolamine.30 Both 
vasodilator agents induced a significant increase in ra­
dial artery diameter (2.22 ± 0.53 to 2.48 ± 0.57 mm 
for verapamil and 2.20 ± 0.53 to 2.45 ± 0.53 mm 
for phentolamine). However, verapamil was more ef­
fective in preventing radial artery spasm (13.2% vs. 
23.2% in phentolamine-treated patients).
The size (both diameter and length) of the radial 
artery sheath may have an impact on radial artery spasm 
and also a hydrophilic coating might reduce the inci­
dence of radial artery spasm by reducing friction and 
irritation of the endothelium. The exact role of these 
factors in pathogenesis and prevention of radial artery 
spasm are yet to be established.
Local Access Site Bleeding. The most important 
benefit of transradial procedures is the elimination 
of access site bleeding complications.33"35 The radial 
artery puncture site is located over bone and can be 
easily compressed with minimal force. Several com­
pression devices have been developed to maximize 
operator and staff efficiency. Local hematomas may 
occur as a result of improper device selection, applica­
tion, or device failure. It is of paramount importance to 
understand that the radial artery should be compressed 
both proximally and distal to puncture site, to prevent 
retrograde flow from palmar arch collaterals.
Forearm Hematoma. Bleeding may occur from 
the radial artery remote from the access site. This 
may be due to perforation of a small side branch 
by the guide wire in patients receiving aggressive an­
tiplatelet agents, or due to avulsion of small branches 
during sheath or catheter manipulation.36’37 This can 
rarely lead to compartment syndrome38 and can lead to 
pressure-induced occlusion of radial and ulnar artery. 
Fasciotomy and hematoma evacuation should be per­
formed as an emergency procedure to prevent ischemic 
injury.
Access Failure. Failure to cannulate the radial 
artery now occurs in less than 5% of patients with 
improvements in equipment. It should be emphasized 
that the puncture site should be proximal to the sty­
loid process of the radius bone. Beyond this the radial 
artery usually bifurcates and becomes less superficial 
and attempting to puncture the vessel in this area is a 
common cause of access failure.
Aberrancies of the Radial Artery. A radial loop 
is the most common congenital anomaly and may be a 
cause of access failure.36,39 Some attempts have been 
made to delineate the radial artery anatomy in patients 
going for transradial procedures.40 At angiography, 
anatomic variations are noted in 22.8% patients and in­
clude tortuous configuration (3.8%), stenoses (1.7%), 
hypoplasias (7.7%), radioulnar loop (0.8%), abnormal 
origin of radial artery ( 8.3%), and lusoria subclavian 
artery (0.45%). However, the procedure was success­
fully performed by radial approach in 99.8% of patients 
with tortuous configurations, 91.9% of radial stenosis, 
93.9% of hypoplastic radial artery, 83.35 of radioulnar 
loop, 96.7% of radial axillary origin, and 60% of lu­
soria subclavian artery setting. Clinicians need to be 
aware of these anatomic variations and in most cases 
the procedure could be completed via radial route.
Rare Complications. There are some rare compli­
cations of transradial procedures which are worth dis­
cussing, Firstly, radial artery avulsion38 due to intense 
spasm has been described but this could be avoided by 
modern equipment and antispasm measures. Secondly, 
mediastinal hematoma41 has been reported and should 
be considered as differential diagnosis of chest pain fol­
lowing transradial cardiac catheterization. This needs 
prompt diagnosis and thoracotomy might be needed to 
evacuate hematoma and decompression.
Late Complications. Sterile abscess formation is 
reported in about 2-3% of patients in whom a sheath 
with hydrophilic coating is used.42"44 The time course 
for the development of such an abscess is typically 
2-3 weeks after the procedure. Biopsy specimens 
have shown granulomatous reaction and a few have 
also shown an amoiphous extravascular substance
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consistent with the catheter coating. No infectious 
agent could be implicated and all patients had good 
long-term outcomes with conservative treatment.
Physiological Changes in the Radial Artery 
Following Transradial Procedures
Besides causing anatomical changes, transradial 
catheterization may also cause physiological changes 
by injuring the radial artery endothelium. A small 
study has examined by ultrasound both endothelium- 
mediated and nonendothelium-mediated vasodilata­
tion of the radial artery before and after transradial 
catheterization.45 This study showed that hyperemia- 
induced vasodilatation did not change significantly; 
whereas nitroglycerine-induced vasodilatation was 
significantly attenuated at 24 hours, but had improved 
at 1 week and 1 month. This is probably related to 
the local trauma provoked by sheath and catheters. 
The exact extent of endothelial damage and its impact 
on radial artery physiology in the long term are not 
known.
Use of the Radial Artery as a Graft after 
Transradial Procedures
In view of anatomical and physiological changes 
caused by transradial catheterization, concerns have 
been raised regar ding the suitability of the use of the ra­
dial artery as a bypass conduit after transradial catheter­
ization. There are limited studies available looking into 
this issue. Kamiya et al. reported in a retrospective co­
hort study that there was significant intimal hyperplasia 
(68% vs. 39%) and reduced early graft patency (77% 
vs. 98%) in patients who had had previous transra­
dial procedures.46 However, this did not affect early 
clinical outcomes. The authors concluded that use of 
the radial artery as a bypass conduit after transra­
dial catheterization should be undertaken cautiously, 
particularly when multiple previous procedures have 
been performed. The impact of endothelial damage and 
long-term outcome following the use of radial artery 
as a bypass conduit are not yet known in prospective 
studies.
Conclusion
The transradial approach for coronary procedures is 
safe and yields clinical results similar to transfemoral
access. The transradial approach virtually abolishes 
vascular entry site complications and allows us to per­
form a wide range of diagnostic and therapeutic in­
terventions. However, further research into methods 
of reducing the incidence of radial artery spasm and 
minimizing anatomical and physiological changes in 
the radial artery following transradial procedure are 
needed.
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Impact of Length and Hydrophilic Coating 
of the Introducer Sheath on Radial Artery Spasm 
During Transradial Coronary Intervention
A Randomized Study
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Objectives The aim of this study was to assess the impact of length and hydrophilic coating of the 
introducer sheath on radial artery spasm, radial artery occlusion, and local vascular complications in 
patients undergoing transradial coronary procedures.
Background Radial artery spasm is common during transradial procedures and the most common 
cause for procedural failure.
Methods We randomly assigned, in a factorial design, 790 patients scheduled for a transradial coro­
nary procedure to long (23-cm) or short (13-cm) and hydrophiiic-coated or uncoated introducer 
sheaths. The primary outcome measure was clinical evidence of radial artery spasm, and secondary 
outcome measures were patient discomfort and local vascular complications.
Results Procedural success was achieved in 96% of the cases, and radial artery spasm accounted 
for 17 of 33 failed cases. There was significantly less radial artery spasm (19.0% vs. 39.9%, odds ratio 
[OR]: 2.87; 95% confidence interval [Cl]: 2.07 to 3,97, p < 0.001) and patient reported discomfort 
(15.1% vs. 28.5%, OR: 2.27; 95% Cl: 1.59 to 3.23, p < 0.001) in patients receiving a hydrophiiic- 
coated sheath. No difference was observed between long and short sheaths. Radial artery occlusion 
was observed in 9.5% of the patients and was not influenced by sheath length or coating. A local 
large hematoma or arterial dissection was seen in 2.6% of the patients with no difference in groups 
allocated at randomization. Younger age, female sex, diabetes, and lower body mass index were 
identified as independent predictors of radial artery spasm.
Conclusions Hydrophilic sheath coating, but not sheath length, reduces the incidence of radial ar­
tery spasm during transradial coronary procedures. (J Am Coll Cardiol Intv 2010;3:475-83) © 2010 
by the American College of Cardiology Foundation
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Transradial coronary artery access has been employed for 
diagnostic and interventional procedures since it was first 
described by Campeau in 1989 (1) and its improvement 
described by Kiemeneij and Laarman in 1993 (2). Improve­
ment in the technique and the equipment has led to the use 
of the radial approach for diagnostic and interventional 
procedures in varied coronary syndromes (3-8). The radial 
approach has become increasingly popular due to lower 
vascular complications rates, reduced procedural costs, high 
procedural success, early patient mobilization, and reduced 
hospitalization when compared with the femoral approach
See page 484
(9,10). Transradial intervention has been found to be safe 
and feasible in a large spectrum of clinical practice (11-14). 
Radial artery spasm (RAS) is one of the most common 
complications of the technique, causing significant discom­
fort to the patient and reducing the procedural success rate 
(15-21). A number of small studies have shown that sheaths 
and catheters with hydrophilic coating can reduce spasm 
and cause less discomfort to the patient (22-25). Long
introducer sheaths are used by 
some operators to reduce spasm 
j and difficulty in catheter manip- 
I ulation. However, there are no 
! studies assessing the impact of 
| introducer sheath length on the 
! incidence of RAS during transra­
dial angiography and intervention.
| The objectives of this study 
are to assess the impact of length 
and hydrophilic coating of the introducer sheath on the 
incidence of RAS, radial artery occlusion (RAO) rates, and 
local vascular complications in patients undergoing coronary 
angiography or intervention via the radial artery.
Methods
Patient population. Patients considered for coronary cathe­
terization and intervention by the transradial approach were 
screened for participation. Exclusion criteria were kept to a 
minimum but were as follows: hemodynamically unstable 
patients; patients with forearm arteriovenous fistulae or with 
chronic renal failure, previous ipsilateral transradial proce­
dure; and patients unwilling to participate. All patients had 
an Allen test performed, but were not excluded on the basis 
of an unfavorable result.
The study conformed to the standards set by the Decla­
ration of Helsinki, and ethical approval was obtained from 
the Liverpool Local Research Ethics Committee. Al pa­
tients gave written informed consent.
Study protocol and randomization. This is a prospective 
randomized study and patients were assigned in a factorial
design to 1 of 4 different introducer sheaths: long (23-cm) 
hydrophilic-coated, long uncoated, short (13-cm) hydrophilic- 
coated, and short uncoated (Cook Medical, Inc., Bloomington, 
Indiana). Randomization was performed by computer­
generated random numbers from a proprietary database. The 
randomization was performed in the blocks of 8 to keep an 
equal number of patients in different groups throughout the 
study period. The randomization list was generated and pa­
tients were assigned to the randomized intervention on an 
intention-to-treat basis. The person responsible for patient 
registration and randomization (S.R.) was not in any way 
concerned or involved in the treatment of the patient. The 
treating doctor was informed by the investigator of the ran­
domization code prior to the procedure.
RADIAL ARTERY CAN NUL AT ION. The radial artery was ap­
proached with the arm extended and supported, with the 
wrist in mild hyperextension. Local anesthetic (2% ligno- 
caine) was given after skin preparation at the puncture site. 
The radial artery was punctured with a 21-gauge arterial 
needle through which a 0.018-inch platinum-tipped nitinol 
guidewire was introduced. Following this, the needle was 
withdrawn and a small skin incision was made. A 6-F 
introducer sheath with a dilator taper length of 2.5 cm was 
inserted over the guidewire. The sheath length was deter­
mined by the randomization. All introducer sheath kits used 
were from the same manufacturer (Cook Medical Inc.). A 
weight-adjusted dose of heparin was administered into the 
central circulation following the introduction of the first 
catheter. Routine use of a vasodilator cocktail was avoided 
(to abolish the impact of vasodilator agent on primary end 
point, and this is also a standard practice at our institution), 
and intra-arterial vasodilators (nitroglycerin and verapamil) 
were only used in the event of RAS. The rest of the 
procedure was performed according to the operator s 
preference.
All introducer sheaths were removed immediately after 
the procedure and hemostasis was achieved in the catheter­
ization laboratory by either TR Band (Terumo Medical 
Corp., Somerset, New Jersey) or Radistop (RADI Medical 
Systems, St. Paul, Minnesota).
Patients were followed up clinically according to usual 
post-procedural care with most patients reviewed as outpa­
tients after 4 to 6 months. At the time of follow-up, 
complications related to radial artery patency and late access 
site were reassessed.
Outcome measures. The primary outcome measure was the 
incidence of operator-defined RAS. Secondary end points 
were the discomfort experienced by the patient during 
sheath manipulation, procedural success rates, rates of 
RAO, local vascular complications, and local inflammatory 
reactions.
Definitions. RAS. Clinical RAS was defined as pain per­
ceived by the patient and or difficulty perceived by the 
operator during insertion, manipulation, and/or withdrawal
Abbreviations 
and Acronyms
BIVtl = body mass index 
Cl = confidence interval 
OR = odds ratio
RAO = radial artery 
occlusion
RAS = radial artery spasm
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of the introducer sheath or catheter. This was assessed 
by questionnaires completed by operators and patients 
separately.
Operators reported the presence of spasm on the follow­
ing scores:
1. Patient reported presence of continuous forearm pain.
2. Patient reported forearm pain only during catheter 
manipulation.
3. Patient reported forearm pain during sheath insertion 
or retrieval.
4. Firm grip of the catheters during manipulation.
5. Augmented resistance to sheath retrieval.
This excludes cases of difficult catheter manipulation be­
cause of severely tortuous radial or subclavian artery. Radial 
artery spasm was defined as the occurrence of at least 2 
features or only 1 feature and a need for intra-arterial 
vasodilators.
Patients reported the pain perceived during removal of 
the introducer sheath on the following score:
1. Nothing felt.
2. Noticeable sensation but no pain.
3. Mild pain.
4. Significant (moderate) pain.
5. Unbearable (severe) pain.
Radial artery spasm was considered present when patient 
reported moderate or severe pain on sheath withdrawal. 
ASSESSMENT OF RADIAL ARTERY PATENCY. Radial artery 
patency was assessed before patient’s discharge and at 
follow-up. Patients were assessed at the time of routine 
follow-up scheduled for 4 to 6 months. RAO was defined as 
the absence of palpable radial artery pulsation confirmed by 
an abnormal reverse Allen test (26), plethysmography and 
oximetery test or absent flow signal on handheld Doppler. 
In brief, reverse Allen test is performed by compressing both 
radial and ulnar arteries and having the patient make a fist 
several times. In contrast to Allen test in which pressure on 
the ulnar artery is released, for the reverse Allen test, 
occlusion of the ulnar artery is maintained while pressure on 
the radial artery is released. If there is return of blush to the 
palm within 10 s, the test is considered positive and 
indicates patency of radial artery. Similarly, plethysmogra­
phy and oximetry test was performed as described, and the 
test was recorded with the occlusion of the ulnar artery to 
assess radial artery patency.
ACCESS SITE HEMOSTASIS AND LOCAL COMPLICATIONS. 
Vascular complications were assessed after the removal of 
compression device and were defined as oozing (leakage of 
blood from puncture site requiring digital pressure), ecchy- 
mosis (bleeding into subcutaneous tissue planes causing 
bluish-purple discoloration >4 cm in diameter); local he­
matomas were classified as small (<2 cm in all diameter) 
and large (>2 cm in diameter). Radial, brachial, and
subclavian artery dissections were reported if proven 
angiographically.
ASSESSMENT OF ULNO-PALMAR CIRCULATION. All patients 
were assessed for ulno-palmar arch circulation with the use 
of modified Allen test and the use of plethysmography and 
oximetry test as described by Barbeau et al. (27). The time 
taken for Allen test was recorded in seconds and plethys­
mography and oximetry test was graded in 4 categories. 
Plethysmography readings were divided into 4 types: A = 
no damping of pulse tracing immediately after radial artery 
compression; B = damping of pulse tracing; C = loss of 
pulse tracing followed by recovery of pulse tracing within 2 
min; D = loss of pulse tracing without recovery within 2 
min. Oximetry results were either positive or negative 
during radial artery compression.
Procedural success was defined as successful completion 
of the intended coronary procedure via the radial route. 
Statistical analysis. Clinical RAS is reported to occur in 
20% to 30% of cases in studies in the literature, using several 
qualitative and quantitative definitions. We assumed that a 
50% reduction in the incidence of RAS would be clinically 
significant. A factorial design was used to compare 
hydrophilic-coated and uncoated sheaths and short and long 
sheaths. We calculated that we needed 375 patients in each 
of the 2 arms of different introducer sheath types to detect 
this difference with significance level of 0.02 (alpha error) 
and power of 95% (beta error 0.05). We decided to recruit 
400 patients in each arm to compensate for missing cases.
Continuous variables are described as mean ± SD and 
compared using Student t test. Categorical variables are 
expressed as frequencies and compared using chi-square 
tests and, where appropriate, Fisher exact test. The com­
parison between long introducer sheaths and short intro­
ducer sheaths and between coated and uncoated introducer 
sheaths uses a factorial design. Analysis of variance was 
applied to detect any interaction between coating and length 
of the introducer sheaths. Multivariate analysis was per­
formed using logistic regression model to assess predictors 
of clinical RAS. Variables included in the model were age, 
sex, height, body weight, body mass index (BMI), diabetes, 
procedure time, and number of catheters used during the 
study. Variables were entered through forward stepwise 
analysis. All analyses were performed using SPSS version 15 
(SPSS Inc., Chicago, Illinois).
Results
Patient population. Between November 2006 and January 
2008, 794 patients were included in the study. During the 
initial 5 months, 570 patients were screened and 505 
patients were included in the study. The most common 
reason for exclusion was previous ipsilateral transradial 
procedure (n = 60) and 5 patients refused to consent. The 
recruitment occurred in 2 distant time periods with a gap
ded From: http://interventions.onlinejacc.org/on 11/14/2012
478 Rathore et al.
Impact of Sheath on Radial Artery Spasm
JACC: CARDIOVASCULAR INTERVENTIONS. VOL. 3, NO. S, 2010
MAY 2010:475-83
imposed by external factors. The remaining patients were 
recruited between July 2008 and January 2008; during this 
period, 344 patients were screened and 289 patients were 
included in the study: 40 patients were excluded because 
they had had previous ipsilateral transradial procedure, 10 
patients refused to participate in the study, and another 5 
patients were not included because of physician’s preference. 
Out of these 794 patients, 4 patients underwent primary 
femoral approach (physician preference, protocol violation), 
and the results from 790 patients are included in this 
analysis.
Baseline characteristics. Patients were compared in 2 differ­
ent analyses considering length and coating of the intro­
ducer sheath. Baseline characteristics as stratified by length 
and coating of the sheath are shown in Table 1.
The mean age was 62.88 years, and 74.2% of the patients 
were men. Patient age, height, weight, wrist circumference, 
BMI, male sex, hypertension, diabetes, hypercholesterol­
emia, and smoking incidence were similar in both groups. 
About two-thirds of patients presented with stable angina, 
and the proportion of patients with unstable presentations 
was similar in all groups. The procedure time and compres­
sion device usage were also similar in all groups.
Ulno-palmar circulation was assessed in all patients but 
was not an exclusion criterion. Ninety-four percent of the 
patients had a favorable Allen test and plethysmography and 
oximetry test, and 6% to 7% of patients had apparendy 
unfavorable ulno-palmar circulation, which was similar in 
both groups.
Procedural success. Procedural success was high in both 
groups at 758 of 790 (96%) patients. RAS prevented the 
completion of the procedure in 17 (2.2%) cases. In 15 
patients, we were unable to enter the radial artery or advance 
the catheter into the aorta because of unfavorable vascular 
anatomy, and 1 case was abandoned because of poor backup 
from the guide catheter.
Radial artery spasm. Operator-defined RAS was observed 
in 230 (29.4%) of the patients and 172 (21.8%) patients 
reported discomfort of moderate or severe intensity. There 
was significantly less clinical RAS (relative reduction 50%) 
observed in patients randomized to a hydrophilic sheath 
(Table 2). There was significandy less RAS (19.0% vs. 
39.9%, odds ratio [OR]: 2.87; 95% confidence interval [Cl]: 
2.07 to 3.97, p < 0.001) and patient-reported discomfort 
(15.1% vs. 28.5%, OR: 2.27; 95% Cl: 1.59 to 3.23, p < 
0.001) observed in patients receiving a hydrophilic sheath.
Table 1. Baseline and Procedural Characteristics of the Study Population
Variables
All
(N = 790)
Long
(n = 396)
Short 
(n = 394) p Value
Coated 
(n = 397)
Uncoated 
(n = 393) p Value
Age, yrs 62.88 ±11.14 62.74 ± 11.45 63.02 ± 10.83 0.732 62.66 ±1134 63.11 ±11.05 0373
Men 586 (74.2) 293 (74.0) 293 (74.4) 0.933 292 (73.6) 294 (74.8) 0.215
Hypertension 547 (69.2) 275 (69.4) 272 (69.0) 0.939 283 (713) 264 (67.2) 0.218
HL 719(91.0) 360 (90.9) 359 (91.1) 1.00 366 (92.2) 353 (89.8) 0.264
DM 155(19.6) 68 (17.2) 87(22.1) 0.089 79(19.9) 76(193) 0.858
Current smoker 188(23.8) 95 (24.0) 93 (23.7) 1.00 93 (23.4) 95 (23.9) 1.00
Allen test
Not at all 46 (5.8) 16(4.0) 30(7.6) 0.031 23 (5.8) 23 (5.9) 1.00
PL+OX test
Type D 56(7.1) 25 (6.3) 31 (7.9) 0.409 28(7.1) 28(7.1) 1.00
Clinical presentation
Stable angina 549 (69.5) 280 (70.7) 269 (68.3) 279 (70.3) 270 (68.7)
ACS 241 (30.5) 116(293) 125 (31.7) 0.487 118(29.7) 123 (313) 0.643
Wrist circumference, cm 17.24 ± 1.20 17.23 ± 1.23 1735 ± 1.16 0.817 17.24 ± 137 17.24 ± 1.12 0.984
Height, cm 168.84 ± 9.76 168.69 ± 10.07 168.98 ± 9.44 0.681 169.05 ± 1036 168.61 ± 9.10 0.445
Weight, kg 83.65 ± 16.39 83.18 ± 16.63 84.13 ± 16.15 0.426 83.56 ± 16.60 83.75 ± 1630 0.876
BMI, kg/m2 29.27 ± 4.87 29.16 ±4.79 29.38 ± 4.96 0.539 29.16 ±4.83 29.38 ± 4.92 0.524
Number of catheters used 1.68 ± 0.85 1.68 ± 0.86 1.68 ±0.85 0.961 1.67 ±0.88 1.69 ±0.82 0.740
Time sheath in situ, min 50.40 ± 28.28 50.24 ± 27.72 50.55 ± 28.89 0.880 47.36 ± 25.98 53.57 ± 30.21 0.003
Compression device
Radistop 395 (50.0) 196(493) 199(50.5) 198 (49.9) 197 (50.1)
TR Band 395 (50.0) 200(503) 195 (493) 0.831 199 (50.1) 196(49.9) 1.00
Procedure
Diagnostic 61 (7.7) 32(8.1) 29 (7.4) 37 (9.3) 24(6.1)
PCI 729 (92.3) 364 (91.9) 365 (92.6) 0.790 360 (90.7) 369 (93.9) 0.109
Values are mean ± SD or n (%).
ACS = acute coronary syndromes; EMI = body mass index; DM = diabetes mellitus; HI = hyperlipidemia, PCI = percutaneous coronary intervention, PL+OX = plethysmography and oximetery test.
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Table 2. Outcomes of the Study Patients
Variables
All
(N = 790)
Long
(n = 396)
Short 
(n = 394) p Value
Coated 
(n = 397)
Uncoated 
(n = 393) p Value
Operator RAS 230 (29.4) 110(27.9) 120(30.8) 0.389 75(19.0) 155 (39.9) <0.001
Patient discomfort 172 (21.8) 85 (21.5) 87 (22.2) 0.414 60(15.1) 112(28.5) <0.001
Local complication
Large hematoma 17(2.2) 8(2.1) 9 (2.3) 0.812 3 (0.8) 14(3.7) 0.006
Noncoronary dissection 3 (0.4) 0(0) 3 (0.8) 1.00 1 (0.3) 2 (0.5) 1.00
RAO at discharge 73 (9.5) 31 (8.0) 42(10.9) 0.178 35 (8.9) 28(10.0) 0.624
Late complication (n = 625) 625 324 301 315 310
Abscess 9 0.4) 5 0.5) 4(1.3) 9(2.8) 0(0)
Infection 12(1.9) 6(1.8) 6(2.0) 1.00 11 (3.5) 1 (03) 0.0001
Pseudoaneurysm 1 (0.1) 0(0) 1 (0.3) 0.510 1 (0.3) 0(0) 0.570
RAO at follow-up (n = 625) 43 (6.9) 27(8.3) 16(5.3) 0.116 24 (7.6) 19(6.1) 0.436
Values are n (%) or n.
RAO = radial artery occlusion; RAS = radial artery spasm.
No significant difference was observed between the groups 
receiving long and short sheaths.
An interaction test was applied to investigate the inter­
action between length and coating of the introducer sheath. 
There was no significant interaction observed between 
length and coating for operator-defined RAS (p = 0.108) 
and patient-assessed RAS (p = 0.631).
Local vascular complications. RAO at the time of discharge 
was observed in 9% of the patients, which was similar in 
both groups as shown in Table 2 (9.6% vs. 8.9%, p = 0.892, 
in Radistop and TR Band groups). None of these patients 
exhibited any clinical evidence of compromised perfusion of 
the hand.
A large local hematoma or arterial dissection was seen in 
17 patients (2.2%) as shown in Table 2. The rates were 
similar in all groups and all access-related complications 
were managed conservatively. There was a slightly higher 
incidence of a large local hematoma in patients randomized 
to an uncoated sheath. Minor complications such as small 
hematoma, ecchymosis, and oozing were observed in about 
20% of the patients in each group.
Predictors of clinical RAS. As shown in Table 3, several 
factors were associated with occurrence of operator-defined 
RAS during transradial procedures. Patients with spasm 
were younger and were more frequently female. There was 
a significantly higher incidence of spasm when an uncoated 
sheath was used. Patients with spasm were more frequendy 
diabetic, had smaller wrist circumferences, and had lower 
body weight. Other baseline characteristics, ulno-palmar 
circulation, clinical presentation, introducer sheath length, 
procedure time, and number of catheters used were not 
found to be associated with RAS.
In logistic regression analysis, the use of uncoated sheath, 
young age, female sex, diabetes, and lower BMI were shown 
to be independent predictors of RAS in patients undergoing 
transradial coronary procedures (Table 4).
Long-term follow-up for late complications. Follow-up was 
completed in 625 patients (79.1%) and persistent RAO was 
observed in 43 patients (6.9%) (8.0% vs. 5.6%, p = 0.273, in 
Radistop and TR Band groups). There was no difference 
seen in RAO rates between the groups receiving hydrophilic 
and uncoated sheaths; however, there was a higher inci­
dence of RAO at follow-up in patients receiving longer 
sheaths (8.3% vs. 5.3%, p = 0.042). In all affected patients, 
the RAO was asymptomatic.
Local infection or abscess at the radial artery puncture site 
was reported by 21 patients (3.4%) with no difference 
between the long and short sheath groups. There was a 
significantly higher incidence of late local access site swell­
ing and discomfort in patients randomized to hydrophilic 
sheaths (5.1% vs. 0.3%, p = 0.001). These symptoms were 
usually noticed after 2 to 4 weeks, often with a remitting and 
relapsing course, and a majority were treated conservatively 
with antibiotics. One patient underwent local surgical 
drainage with no long-term adverse effects.
Discussion
To our knowledge, this is the first prospective, large, 
randomized study comparing the clinical efficacy of several 
introducer sheaths in the prevention of RAS during un­
selected coronary procedures. The primary aim of our study 
is to assess the impact of length and coating of introducer 
sheath on the incidence of clinically relevant spasm during 
transradial coronary procedures. In the current study, there 
was a 50% reduction in RAS with a hydrophilic sheath, with 
40.5% of patients assigned to an uncoated sheath experi­
encing RAS compared with only 19.1% in the hydrophilic 
sheath group. There were higher occurrences of forearm 
pain and the augmented resistance during sheath retrieval 
with the use of uncoated sheath as compared to hydrophilic 
sheath (42.4% vs. 20.9%, p < 0.001; and 37.4% vs. 11.5%,
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Table 3. Baseline Correlates of Patients With RAS
All No RAS RAS
Variables (N = 783) (n = 553) (n = 230) p Value OR 95% Cl
Age, yrs 62.88 ±11.14 63.74 ± 10.87 60.86 ± 11.52 0.001 1.041 1.01-1.07
Sex
Male 581 (74.2) 438 (79.2) 143 (62.2)
Female 202 (25.8) 115(20.8) 87 (37.8) <0.001 1.750 1.41-2.16
Hypertension 542 (69.2) 383 (70.7) 159 (69.1) 1.000 1.004 0.79-127
Hyperlipidemia 714(91.2) 507(91.7) 207 (90.0) 0.489 1.150 0.80-1.63
Diabetes 155(19.8) 97(17.5) 58 (25.2) 0.018 1.585 1.09-229
Current smoking 188(24.0) 127 (23.0) 61 (26.5) 0.808
Allen test
Not at all 46 (5.9) 37 (6.7) 9(3.9) 0.180
PL+OX
Type D 56 (7.2) 46 (8.3) 10(43) 0.049
Clinical syndrome
Stable angina 548 (70.0) 392 (70.9) 156 (67.8)
ACS 235 (30.0) 161 (29.1) 74(32.1) 0.898
Length of the sheath
Long 394 (50.3) 284(51.4) 110(47.8)
Short 389 (49.7) 269 (48.6) 120 (52.2) 0389 1.152 0.84-136
Coating of the sheath
Hydrophilic 395 (50.4) 320 (57.9) 75 (32.6)
Uncoated 388 (49.6) 233 (42.1) 155(67.4) <0.001 2.838 2.05-3.92
Height, cm 168.84 ±9.76 169.6 ±9.7 166.8 ±9.5 <0.001 1.022 1.01-1.03
Weight kg 83.65 ± 16.39 85 ± 16.24 803 ± 16.32 <0.001 1.056 1.02-1.09
BMI, kg/m2 29.27 ± 4.87 29.48 ± 4.95 28.76 ± 4.64 0.067 1.021 1.00-1.05
Wrist circumference, cm 17.24 ± 1.20 17.37 ± 1.17 16.92 ± 1.19 <0.001 1.021 1.01-1.03
Time sheath in situ, min 50.40 ± 28.28 51.13 ± 27.95 48.69 ± 29.04 0.001 1.05 0.96-1.15
Number of catheters used 1.68 ± 0.85 1.69 ±0.87 1.67 ± 0.82 0.829 1.01 0.93-1.09
Values are mean ± SD or n (%).
Cl = confidence interval; OR = odds ratio; other abbreviations as in Tables 1 and 2.
p < 0.001, respectively). These results are similar to those in 
previous small studies (23,24,28). These reductions in 
spasm were also reflected in the level of discomfort experi­
enced by the patient during withdrawal of the introducer 
sheath. In the uncoated group, 29.1% of patients experi­
enced moderate to severe discomfort compared with only 
15.3% experiencing this discomfort in the hydrophilic 
sheath group. Dery et al. (23) demonstrated significant 
reduction in peak traction force (265 ± 167^ vs. 865 ± 318g) 
and mean maximal pain score (0.6 ± 1.2 vs. 4.8 ± 2.9) 
during withdrawal of hydrophilic-coated sheath. However,
Table 4. Independent Predictors of RAS
Variables OR 95% Cl p Value
Female sex 2.01 1.31-3.09 0.001
Age, yrs 0.96 0.95-0.98 <0.001
Diabetes mellitus 1.84 122-2.76 0.003
Wrist circumference, cm 0.86 0.72-1.02 0.096
BMI, kg/m2 0.96 0.92-1.00 0.059
Abbreviations as inTables 1,2, and 3.
there is a potential for bias in this study as they used 
introducer sheaths of different lengths. Similarly, Kiemeneij 
et al. (22) demonstrated a significant reduction in maximal 
pull-back force (0.24 ± 0.31 kg vs. 0.44 ± 0.33 kg, p = 0.003) 
and patient discomfort (7% vs. 27%, p = 0.02) with the use 
of a hydrophilic-coated sheath in a randomized study of 90 
patients. Saito et al. (24) have also shown that a hydrophilic 
coating on the introducer sheath reduced friction resistance 
by 70% with reduced trends in the incidence of spasm.
We have not demonstrated any significant difference in 
the overall incidence of spasm between long and short 
sheaths. In this study, 30.9% of patients assigned to short 
sheath group experienced spasm compared with 28.9% of 
the patients in the long sheath group. These results were 
similar when compared to the level of discomfort noticed by 
the patient during pull-back of the sheath. We have not 
come across any study comparing the performance of 
different length sheaths in the literature.
Overall in our study, we have observed that one-quarter 
of the patients experienced some degree of RAS, similar to 
that noticed in other studies (15-21). Although, the proce-
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dure was successfully completed via the radial route in 96% 
of the cases, RAS was the most common cause of procedural 
failure, accounting for about one-half of failed cases, with 
tortuous vascular anatomy accounting for another one- 
third of failures. The radial artery could not be punctured 
in only 3 cases, and in 1 patient, the procedure could not 
be completed because of poor guide catheter backup. In 
the majority of these patients, the procedure was success­
fully completed via the other radial artery and femoral 
access was needed in a few patients. These results are 
consistent with other large studies reported in the liter­
ature. The ACCESS study (9) has shown procedural 
success rates of 93% with radial approach with the major 
causes of procedural failure being an inability to puncture 
the radial artery or RAS.
We have also identified factors associated with occurrence 
of spasm in patients undergoing transradial coronary pro­
cedures. Young age and female sex were identified as 
independent predictors for spasm, which is consistent with 
previous studies (29,30). Small wrist circumference, lower 
height, and lower weight were also found to be associated with 
high incidence of spasm. It could be postulated that all these 
factors may reflect a small radial artery size in these patients 
that can predispose to clinically evident spasm. We did not 
measure the size of radial artery, but 1 previous study (28) has 
shown that a ratio of radial diameter to sheath size of <1:1 
predisposes to spasm. High levels of anxiety and increased 
circulating levels of catecholamines in the young patients could 
also predispose to spasm, and females have been reported to 
have smaller radial artery diameter (28).
Previous studies have reported RAO rates ranging from 
3% to 10% (9,31,32). RAO following a transradial coronary 
procedure was observed before discharge in 9% of our 
patients. Leferve et al. (33) has reported high (30%) RAO 
rates with 1,000 U of heparin. In our study, all patients 
undergoing coronary intervention received weight-adjusted 
heparin (70 U/kg). The administration of heparin in diag­
nostic cases was left at the operator’s discretion, and 11.8% 
of patients did not receive any heparin. RAO rate was 
7.2% in patients undergoing coronary angioplasty and re­
ceiving weight-adjusted heparin, similar to that reported in 
literature.
Persistent RAO was observed in only 43 (6.9%) patients 
at follow-up, and no patient reported any symptoms of 
compromised perfusion. We observed a high incidence of 
RAO in patients with documented spasm during their 
procedure (14.5% vs. 7.4%, p = 0.003). We have not 
excluded any patient on the basis of Allen test, and there is 
an ongoing debate about denying radial access to patients 
with abnormal Allen test (34,35). There is no evidence so 
far that a normal Allen test is required for the safe 
undertaking of transradial procedure (36). However, pro­
spective studies involving a large number of patients looking
at the incidence and consequences of RAO based on Allen 
test are needed to answer this question.
In this study, the incidence of large local hematoma or 
arterial dissection was low. A large hematoma occurred in 
17 (2.2%) patients and radial/brachial or subclavian dissec­
tion was observed in 3 (0.3%) cases. However, none of these 
patients needed blood transfusion or surgical intervention. 
However, about 20% patients had oozing needing manual 
pressure after compression device removal, ecchymosis, or 
small hematoma.
There have been reports of allergic or inflammatory 
reaction at the radial artery puncture site following the use 
of hydrophilic-coated sheaths (37,38). In this study, we have 
found a high incidence of local inflammatory reaction in 
the patients randomized to a hydrophilic-coated sheath. 
These reactions usually occurred 2 to 4 weeks after the 
procedure with relapsing and remitting course and usually 
presented as a small purple colored painful nodule. A 
majority of patients with this reaction were treated conser­
vatively with antibiotics and analgesics. This phenomenon is 
seen with hydrophilic-coated sheaths and can cause consid­
erable discomfort to the patient, though has no known 
long-term sequelae. It has been postulated that the hydro­
philic polymer is left behind at the puncture site following 
the removal of the sheath, causing a local allergic reaction 
and inflammatory abscess.
The transradial approach for coronary procedures has 
become more popular over the years and has been used in all 
clinical situations. The British Cardiovascular Intervention 
Society audit returns (39) reported that 28.1% of the 
coronary interventions performed in the United Kingdom in 
2007 were done via the transradial route. RAS is the most 
commonly encountered complication and can result in 
significant discomfort to the patient and can result in 
procedural failure in some cases. A hydrophilic coating on 
the sheath theoretically induces less friction and trauma to 
the endothelial lining of the radial artery and therefore 
causes less spasm and consequent discomfort to the patient. 
RAS results in difficulty in removing the introducer sheath 
and causes more damage to the endothelium of the radial 
artery. Theoretically the physical trauma caused by the 
spasm and the introducer sheath can result in damage to the 
endothelium and thereby predispose to thrombus forma­
tion. This could be one of the reasons for observing a higher 
incidence of RAO in patients with documented RAS. This 
is the first study observing this association and can be 
hypothesis-generating for future large studies.
The ramifications of RAO and injury are important 
not only in patients undergoing repeat coronaiy proce­
dures, but also in the patients in whom the radial artery 
may be used as a conduit for coronary artery bypass 
surgery or in patients needing an arteriovenous fistula for 
hemodialysis.
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Study limitations. First, our study was single-blinded, and 
this could result in some bias, but we have included both 
operator- and patient-defined RAS as end points. We 
have found a statistically significant association between 
operator-defined RAS and discomfort experienced by the 
patient (p < 0.0001). Second, a qualitative definition of 
RAS was used in the study, increasing the potential effect 
of bias. However, a close association has been shown 
between quantitative measurement of spasm and a qual­
itative definition (18). Third, avoidance of vasodilator use 
at the time of introducer sheath insertion might influence 
the incidence of RAS. However, our study was assessing 
the impact of different introducer sheaths on the inci­
dence of clinical RAS and the role of vasodilator is 
previously known.
Conclusions
We have shown in this randomized study that there is a 
significant reduction in the incidence of RAS and patient 
discomfort with the use of a hydrophilic coating on the 
introducer sheath during transradial coronary procedures. 
We have not found any significant effect of sheath length on 
the incidence of spasm. We have also identified young age, 
female sex, diabetes, and low BMI to be independent 
predictors of RAS.
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A Randomized Comparison of TR Band and Radistop 
Hemostatic Compression Devices After Transradial
Coronary Intervention
Sudhir Rathore,* md, mrcp, Rodney H. Stables, md, frcp, Maheshwar Pauriah, mrcp, 
Abdul Hakeem, frcs, Joseph D. Mills, md, mrcp, Nick D. Palmer, md, mrcp,
Raphael A. Perry, md, frcp, and John L. Morris, md, frcp
Background: The transradial route for coronary intervention has proven to be safe, effec­
tive, and widely applicable in different clinical situations. Several compressive hemostatic 
devices have been introduced that have shown to be safe and are effective in achieving 
hemostasis. Methods: Seven hundred ninety patients were randomly assigned to receive 
either TR band or Radistop hemostatic compression devices after transradial coronary 
procedure. The outcome measures were patient tolerance of the device, local vascular 
complications, and the time taken to achieve hemostasis. Results: The mean age was 
62.88 years, and 74.2% of the patients were men. Patient age, height, weight, wrist cir­
cumference, body mass index, mate sex, hypertension, diabetes, hypercholesterolemia, 
and smoking incidences were similar in both groups. There were significantly more 
patients reporting no discomfort in the TR band group compared to the Radistop group 
(77% vs. 61%; P = 0.0001). Patients in the Radistop group reported significantly more 
pain across all categories of severity and three patients in the Radistop group were 
crossed over to TR band because of severe discomfort. Oozing and ecchymosis were 
seen in about 16% of the patients. Local small hematoma and large hematoma were 
seen in 5.4% and 2.2% patients respectively, and similar in both groups. Radial artery 
occlusion at the time of discharge was seen in 9.2% of the patients though only 6.8% 
showed persistent occlusion at the time of follow-up. The time taken to achieve hemo­
stasis was significantly longer in the TR Band group (5.32 ± 2.29 vs. 4.83 ± 2.23 hr; P =
0.004). There was significantly higher incidence of radial artery occlusion in patients with 
smaller wrist circumference, the patients who experienced radial artery spasm during the 
procedure, and patients with no heparin administration during the procedure. Conclu­
sions: We have shown in a randomized comparison of Radistop and TR band that both 
devices are safe and effective as hemostatic compression devices following transradial 
procedures. However, more patients felt discomfort with the Radistop device and the 
time taken to achieve hemostasis was longer with TR band. © 2010 wney-uss, inc.
Key words: TRAD, transradial cath; CLOS, closure-vascular access; PCI, percutaneous 
coronary intervention; COMP, complications adult cath/intervention
INTRODUCTION
The transradial route for coronary intervention has 
proven to be safe, effective, and widely applicable in 
different clinical situations [1-10]. The radial approach 
has been shown to reduce access site vascular compli­
cations when compared to the femoral approach 
[11,12]. Another advantage is early mobilization and 
thereby early discharge from the hospital, reducing 
staff workload and overall cost [11,12]. As the arterial 
sheath can be removed immediately after the proce­
dure, with mechanical compression applied over the 
puncture site, early hemostasis can be achieved. This 
allows early mobilization and discharge from hospital. 
Several compressive hemostatic devices have been
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introduced that have shown to be safe and are effective 
in achieving hemostasis [13-15]. However, no studies 
have compared different hemostatic devices and their 
impact on the patient comfort, time taken to achieve 
hemostasis, and on local vascular complications.
Two commonly used compressive devices used to 
achieve hemostasis after transradial access are the 
Radistop (RADI, Uppsala, Sweden), and the TR Band 
(Terumo, Japan). Both have been shown to safely 
achieve hemostasis in large populations of patients. 
These devices allow selective application of controlled 
pressure over the radial artery, thereby allowing sus­
tained arterial flow and venous return. At our center 
we routinely use TR band compression device follow­
ing transradial procedures.
The objectives of our study are to compare the 
effects of Radistop and TR band on patient comfort, 
time taken to achieve hemostasis, and local vascular 
complications.
MATERIALS AND METHODS 
Patient Population
Patients considered for coronary catheterization and 
intervention via the radial approach were screened for 
participation. Hemodynamically unstable patients, 
patients with forearm arterio-venous fistulae or with 
chronic renal failure, previous ipsilateral transradial 
procedure and patients unwilling to participate were 
excluded from the study. All patients had an Allen’s 
test performed, but were not excluded on the basis of 
an unfavorable result.
The study conformed to the standards set by the 
Declaration of Helsinki and ethical approval was obtained 
from the Liverpool Local Research Ethics Committee.
Study Design
This is a prospective randomized study and patients 
were assigned to one of the two different hemostatic 
compression devices: TR Band and Radistop. Random­
ization was performed by computer-generated random 
numbers from a proprietary database. The person re­
sponsible for patient registration and randomization 
(SR) was not in any way concerned or involved in the 
treatment of the patient. The treating doctor was 
informed by the investigator of the treatment assigned 
prior to the procedure.
Outcome Measures
The outcome measures were patient tolerance of 
the device assessed by the questionnaire, local 
vascular complications, and the time taken to achieve 
hemostasis.
Assessment of Radial Artery Patency
Radial artery patency was assessed prior to the 
patient’s discharge and at follow-up. Radial artery 
occlusion was defined as the absence of palpable radial 
artery pulsation and one of the following three con­
firmatory tests; abnormal reverse Allen’s test, negative 
plethysmography (PL), and oximetry test during ulnar 
artery occlusion or absent Doppler flow signal on hand 
held Doppler.
Access Site Hemostasis and Local Complications
Vascular complications were assessed after the re­
moval of compression device and were defined as ooz­
ing (leakage of blood from puncture site requiring digi­
tal pressure), ecchymosis (bleeding into subcutaneous 
tissue planes causing bluish-purple discoloration >4 
cm in diameter), local hematomas were classified as 
small (<2 cm in all diameter) and large (>2 cm in 
diameter).
Assessment of Patient Comfort Following 
Application of Compressive Device
The patient’s comfort level at the site of application 
of device was assessed during the later wearing of the 
device using a short form of the McGill Pain Question­
naire (SF-MPQ) [16]. This includes the patient’s 
assessment of the compression device on 15 descrip­
tors, rated on an intensity scale of none, mild, moder­
ate, and severe. Therefore, the patient’s discomfort fol­
lowing application of the compression device was cate­
gorized as no discomfort, mild discomfort, moderate 
discomfort, and severe discomfort. The patients were 
particularly asked to describe the discomfort due to the 
compression device at the site of application and not 
mix up with other discomfort in the arm during the 
procedure.
Assessment of Uino-Palmar Circulation
All patients were assessed for ulno-palmar arch cir­
culation prior to the procedure with the use of modified 
Allen’s test and the use of PL and oxymetry (OX) test­
ing as described by Barbeau et al. [17]. The time taken 
for return of color to the hand during an Allen’s test 
was recorded in seconds and PL + OX test was graded 
in four categories. PL readings were divided into four 
types: A, no damping of pulse tracing immediately af­
ter radial artery compression; B, damping of pulse trac­
ing; C, loss of pulse tracing followed by recovery of 
pulse tracing within 2 min; D, loss of pulse tracing 
without recovery within 2 min. Oxymetry results were 
either positive or negative during radial artery com­
pression.
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Fig. 1. TR Band compression device: showing the band, and 
syringe used to inflate and deflate compression pad, top 
panel. Bottom panel shows its application on the wrist at the 
radial artery puncture site. [Color figure can be viewed in the 
online issue, which is available at wileyonlinelibrary.com.]
Radial Artery Cannulation
The radial artery was punctured with anterior wall 
puncture with a 21-gauge arterial needle through which 
a 0.018-inch platinum-tipped nitinol guidewire was 
introduced. Following this, the needle was withdrawn 
and a small skin incision was made. A 6F introducer 
sheath with a dilator taper length of 2.5 cm was 
inserted over the guidewire. All introducer sheath kits 
used were from the same manufacturer (COOK MEDI­
CAL, Bloomington, IN). Routine use of a vasodilator 
cocktail was avoided and intra-arterial vasodilators 
(nitro-glycerine and verapamil) were only used in the 
event of radial artery spasm. The rest of the procedure 
was performed according to the operator's preference.
Fig. 2. Radistop application over the radial artery puncture 
site after a transradial procedure. [Color figure can be viewed 
in the online issue, which is available at wileyonlinelibrary.com.]
Introducer Sheath Removal and Hemostasis
All introducer sheaths were removed immediately af­
ter the procedure and hemostasis achieved in the cathe­
terization laboratory by the physician using either TR 
band (Fig. 1) or Radistop (Fig. 2) as per randomiza­
tion. The aim with each device is to apply just enough 
pressure to stop the bleeding whilst maintaining for­
ward flow in the radial artery. Radistops were applied 
according to the manufacturer's instructions. The radial 
pulse distal to the compression site was checked after 
application and if the pulse was not palpable the Vel­
cro was loosened slightly until the pulse became palpa­
ble or bleeding started. Similarly, the TR Band was 
applied according to the manufacturer’s instructions 
with air from the occlusive balloon being slowly 
removed until a show of blood was visible, and then 
reintroducing 1-2 ml of air.
Reduction in the compressive pressure was started 
after 1 hr of the procedure observing for any bleeding 
and thereafter checking every 30 min until hemostasis 
was achieved and the device was removed. The com­
pression devices were managed by the nursing staff on 
the wards as per above mentioned protocol.
Baseline characteristics, including age, sex, body 
mass index, and wrist circumference were recorded, as
Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.
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were data on the procedure, including the number of 
catheters used, procedure time, and the time taken to 
achieve hemostasis. All patients were assessed prior to 
discharge to determine the outcomes as defined. All 
data were recorded on a clinical record form and 
entered into a customized database (Access 2003).
Procedure time was considered as the period ranging 
from sheath insertion to sheath withdrawal. Time taken 
to achieve hemostasis was defined as the time period 
ranging from application of the compression device to 
its complete removal.
Patients were followed up clinically as usual post­
procedural care, with most patients reviewed in outpa­
tients after 4-6 months. At the time of follow-up, radial 
artery patency and late complications were reassessed.
Statistical Analysis
Continuous variables are described as mean ± SD 
and compared using Student’s Mest. Categorical varia­
bles are expressed as frequencies and compared using 
chi-squared tests and, where appropriate, Fisher’s exact 
test. Multivariate analysis was performed to assess pre­
dictors of radial artery occlusion. Variables included in 
the model were age, gender, height, weight, wrist cir­
cumference, diabetes, procedure time, use of heparin, 
occurrence of radial artery spasm, and time taken to 
achieve hemostasis. All analysis was performed using 
SPSS Version 15.
RESULTS 
Patient Population
Between November 2006 and January 2008, a total 
of 794 patients were included in the study. During the 
initial 5 months, 570 patients were screened and 505 
patients were included in the study. The most common 
reason for exclusion was previous ipsilateral transradial 
procedure (60 patients) and five patients refused to 
consent. The recruitment occuned in two distant time 
period with a gap imposed by external factors (interim 
analysis was performed and the recruitment was 
stopped temporarily). The remaining patients were 
recruited between July 2008 and January 2009, during 
this period 344 patients were screened and 289 patients 
were included in the study. Forty patients were 
excluded because they had previous ipsilateral transra­
dial procedure, 10 patients refused to participate in the 
study and another five patients were not included 
because of physician’s preference. Out of these 794 
patients, four underwent femoral approach without an 
attempt at radial puncture (physician preference, proto­
col violation) and the results from 790 patients are 
included in this analysis. We perform 2,500 angio­
plasty procedures per year and 70% of these proce­
dures are performed via radial route (Five radial opera­
tors and two femoral operators).
Baseline Characteristics
The mean age was 62.9 years, and 74.2% of the 
patients were male. Patient age, height, weight, wrist 
circumference, body mass index, sex, hypertension, di­
abetes, hypercholesterolemia, and smoking prevalence 
were similar in both groups as shown in Table I. About 
two-thirds of patients presented with stable angina and 
the proportion of patients with unstable presentations 
was similar in both groups. The use of long and hydro­
philic sheaths was similar in both groups. The majority 
of the patients in this study received a weight-adjusted 
dose of heparin (70 U/kg) at the start of their proce­
dure and further heparin as judged necessary by the op­
erator during longer procedures. Coronary intervention 
was performed in 729 (92.3%) patients and the remain­
ing patients (7.7%) underwent diagnostic procedures. 
The procedure time was similar in both groups.
Ulno-Palmar Circulation
Ulno-palmar circulation was assessed in all patients 
but an unfavorable result was not an exclusion crite­
rion. Ninety-four percent of the patients had a favor­
able Allen’s test and PL and oximetry test, and 6-7% 
patients had apparently unfavorable ulno-palmar circu­
lation, similar in both groups.
Patient Discomfort During Application of 
Compression Device
There were significantly more patients reporting no 
discomfort in the TR band group compared to the 
Radistop group (77% vs. 61%; P = 0.0001) (Fig. 3). 
Patients in the Radistop group reported significantly 
more pain across all categories of severity and three 
patients in the Radistop group were crossed over to TR 
band because of severe discomfort.
Local Vascular Complications
As shown in Table II, local vascular complications 
were similar in both groups. Oozing and ecchymosis 
were seen in about 16% of the patients. Local small 
hematoma and large hematoma were seen in 5.4% and 
2.2% patients, respectively. One patient (0.1%) devel­
oped pseudo-aneurysm that was treated surgically. 
Radial artery occlusion at the time of discharge was 
seen in 9.2% of the patients though only 6.8% showed 
persistent occlusion at the time of follow-up. No 
patient had symptoms or signs of ischemia distal to the 
occlusion.
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TABLE I. Baseline and Procedural Characteristics of the Study Patients
Variables
All patients
V = 790
Radistop
N = 395
TR band
N = 395 P value
Age. yrs. mean ± SD 62.9 ± 11.1 63.1 ± 10.7 62.70 ± 11.57 0.660
Male sex, n (%) 588 (74.4) 290 (73.4) 298 (75.4) 0.304
Hypertension 547 (69.2) 268 (67.8) 279 (70.6) 0.441
Hyperlipedemia 719 (91.0) 364 (92.2) 355 (89.9) 0.320
Diabetes Mellitus 155 (19.6) 77 (19.5) 78 (19.7) 1.000
Smoker
Current 187 (23.7) 90 (22.8) 97 (24.5) 0.615
Ex Smoker 405 (51.3) 209 (52.9) 196 (49.6) 0.393
PL + OX Test
Type D 56 (7.1) 26 (6.6) 30 (7.6) 0.818
Clinical syndrome
Stable angina 555 (70.3) 279 (70.6) 276 (69.9) 0.912
ACS 235 (29.7) 116 (29.4) 119 (30.1) 0.823
Length of sheath
Long 396 (50.1) 196 (49.6) 200 (50.6) 0.831
Short 394 (49.9) 199 (50.4) 195 (49.4)
Coating of sheath
Hydrophilic 397 (50.3) 198 (50.1) 199 (50.4) 1.000
Uncoated 393 (49.7) 197 (49.9) 196 (49.6)
Wrist circumference, cm 17.24 ± 1.20 17.20 ± 1.16 17.27 ± 1.23 0.414
Height, cm 168.8 ± 9.8 168.7 ± 9.6 169.0 ± 9.9 0.632
Weight, kg 83.6 ± 16.4 83.1 ± 15.5 84.2 ± 17.2 0.367
BMI, kg/m2 29.3 ± 4.9 29.2 ±5.1 29.3 ± 4.7 0.810
Procedure time, min 50.4 ± 28.3 51.2 ± 28.4 49.6 ± 28.2 0.428
Number of caths used 1.7 ± 0.9 1.6 ± 0.8 1.7 ± 0.9 0.275
Heparin used during procedure 729 (92.3) 374 (94.7) 355 (89.9) 0.016
SD. standard deviation; PL + OX, plethysmography and oximctery: ACS, acute coronary syndrome: 
BMI. body mass index.
No mild moderate eewere
diecomfort diecomfort diaesmfort discomfort
Fig. 3. Comparison of discomfort level during radial artery 
compression by Radistop and TR Band devices. [Color figure 
can be viewed in the online issue, which is available at 
wileyonlinelibrary.com.]
Time to Hemostasis
The time taken to achieve hemostasis was signifi­
cantly longer in the TR Band group (Table II) and Fig. 4.
Predictors of Radial Artery Occlusion
As shown in Table III, several factors were associ­
ated with radial artery occlusion at the time of dis­
charge following transradial procedures. Patients with
radial artery occlusion tended to be younger and were 
more frequently female. There was a significantly 
higher incidence of radial artery occlusion in patients 
with a smaller wrist circumference, patients who expe­
rienced radial artery spasm during the procedure and 
patients with no heparin administration during the pro­
cedure. Other baseline characteristics, ulno-palmar cir­
culation, clinical indication, time taken to achieve 
hemostasis, length or coating of the introducer sheath 
and type of hemostatic compression device used were 
not found to be associated with radial artery occlusion 
in our study.
In logistic regression analysis (Table IV) young age, 
smaller wrist circumference, occurrence of radial artery 
spasm during the procedure, and failure to administer 
heparin during the procedure were shown to be inde­
pendent predictors of radial artery occlusion.
DISCUSSION
Both hemostatic compressive devices were effective 
and well tolerated, but patients complained of discom­
fort more frequently with the use of the Radistop de­
vice. Time taken to achieve hemostasis was signifi­
cantly longer with the TR Band. Local access site
Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.
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TABLE II. Outcomes of the Study Patients
Variable
All patients
N ~ 790
Radistop
N = 395
TR band
N = 395 P value
Time taken to achieve hemostasis, hrs 5.1 ± 2.1 4.8 ± 2.2 5.3 ± 2.3 0.004
Patient discomfort
Crossover to other device 3 (0.4) 3 (0.8) 0(0) 0.249
Local complication
Ecchymosis 87 (11.0) 42 (10.6) 45 (11.4) 0.918
Oozing 52 (6.6) 28 (7.1) 24 (6.1) 0.567
Large hematoma 17 (2.2) 6 (1.5) 11 (2.8) 0.327
Small hematoma 43 (5.4) 19 (4.8) 24 (6.1) 0.321
RAO (at discharge) 73 (9.2) 38 (9.6) 35 (8.9) 0.892
RAO (at F/U) 43 (6.8) 25 (8.0) 18 (5.6) 0.273
RAO, radial artery occlusion; F/U, at follow-up visit.
complications and radial artery occlusion rates were 
similar in both groups
To our knowledge, this is the first large randomized 
trial evaluating the efficacy and tolerance of commonly 
used hemostatic compression devices. Previous studies 
have evaluated the efficacy of individual hemostatic 
devices; Chatelain et al. [13] assessed the efficacy of 
Radistop in 159 patients and reported that 18% of 
patients found the device uncomfortable or painful. The 
mean compression time was 151 min and 19.4% had 
local vascular complications including radial artery 
occlusion in 4.4%. The compression time is shorter in 
this study as compared to our study because about two- 
third of patients in this study had diagnostic angiography 
with the use of 4F and 5F sheaths, compared to our study 
where 6F sheaths were used and 92% of the patients had 
coronary intervention. Ochiai et al. [15] reported the effi­
cacy of another compressive hemostatic device, Adapty 
(Medikit, Tokyo, Japan) in 199 patients and reported 
success rates in 99.5% with no vascular complications.
Choi et al. [14] compared the efficacy of a hydro­
philic wound dressing (Closur PAD) with a compres­
sive device (Radistop) in 80 patients. They reported 
significantly less compression time with the use of the 
dressing (58.7 ± 32.6 min vs. 131.3 ± 59.1 min; P < 
0.001) and similar vascular complication rates (5% for 
hydrophilic dressing vs. 2.5% for compressive devices). 
The majority of procedures in this study were per­
formed using a 5F sheath.
Recently, Pancholy et al. [18] evaluated conven­
tional pressure hemostasis using touniquet with the TR 
band in a randomized study of 436 patients. They 
reported a significantly lower incidence of early (at 
24 hr) radial artery occlusion for the TR band, com­
pared to conventional pressure compression (4.4% vs. 
11.2%, P < 0.005) and also late (at 30 days) radial 
artery occlusions (3.2% vs. 7.2%, P < 0.05). They 
speculated that hemostasis achieved by TR band and 
guided compression was responsible for better out­
Compr*«slon device
Tim* taken to aehelve haemottasit
Fig. 4. Comparison of time taken to achieve hemostasis in 
hours by Radistop and TR Band devices. “R,” Radistop com­
pression device; “T,” TR band compression device. [Color fig­
ure can be viewed in the online issue, which is available at 
wileyonlinelibrary.com.]
comes. All patients underwent diagnostic coronary 
angiography using 5F sheath. This could explain the dif­
ference in the radial artery occlusion rates as sheath size 
in relation to radial artery diameter plays a significant 
role [19]. In addition, the procedure time was signifi­
cantly less than our study group (19 min vs. 54 min).
The interruption of blood flow by compression devi­
ces can also influence the incidence of radial artery 
occlusion and other vascular complications. Sanmartin 
et al. [20] has analyzed the possible relationship 
between compression after transradial procedures and 
radial artery occlusion in 275 patients by the use of 
pulse oximeter. In this study, radial artery flow was 
absent in 174 cases (62%) immediately after entry site 
compression. After 2 hr of pressure hemostasis, radial ar­
tery flow was absent in 162 cases (58%) before bandage 
removal. At 7-day follow-up, 12 patients (4.4%) had 
absent pulsation and radial artery flow was absent in 29
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TABLE 111. Baseline and Procedural Variable Correlates of Radial Artery Occlusion at 
Discharge
Variables N (%) All pts N = 780 RAO V = 73 No RAO N = 707 P value
Age, mean ± SD
Sex
62.88 ±11.14 60.43 ± 11.18 63.12 ± 11.15 0.052
Male 586 (74.2) 42 (7.2) 537 (92.8) 0.051
Female 202 (25.6) 31 (15.3) 170 (84.7)
Hypertension 547 (69.2) 48 (65.8) 492 (69.6) 0.795
Hyperlipidemia 719 (91.0) 63 (86.3) 648 (91.7) 0.148
Diabetes Mellitus
Sheath length
155 (19.6) 14 (19.2) 141 (19.9) 0.287
Long 396 (50.1) 31 (42.5) 361 (51.1) 0.306
Short
Sheath coating
394 (49.9) 42 (57.5) 346 (48.9)
Coated 397 (50.3) 35 (47.9) 360 (50.9) 0.139
Uncoated
Compression device
393 (49.7) 38 (52.1) 347 (49.1)
Radistop 395 (50.0) 38 (9.6) 351 (90.4) 0.756
TR Band 395 (50.0) 35 (8.9) 356 (91.1)
Operator RAS 230 (29.4) 33 (45.2) 196 (27.7) 0.008
Heparin usage 729 (92.3) 53 (72.6) 666 (94.2) <0.0001
Height, cm 168.8 ± 9.8 166.9 ± 8.5 169.0 ± 9.9 0.056
Weight, kg 83.6 ± 16.4 82.4 ± 17.2 83.8 ± 16.4 0.524
Wrist circumference, cm 17.2 ± 1.2 16.8 ± 1.2 17.3 ± 1.2 0.001
BMI 29.3 ± 4.9 29.4 ± 5.0 29.3 ± 4.9 0.794
Time sheath in situ, min 50.4 ± 28.3 46.6 ± 28.2 50.6 ± 28.4 0.259
Time taken to achieve 
hemostasis, hrs
5.1 ± 2.1 4.9 ± 2.1 5.1 ± 2.3 0.590
SD, standard deviation; RAO, radial artery occlusion; RAS, radial artery spasm; BMI, body mass index.
cases (10.5%), Logistic regression analysis showed that 
absent flow before compressive bandage removal was the 
only independent predictor of radial artery occlusion at 
follow-up (OR = 6.7, IC 95%: 1.95-22.9; P = 0.002). 
Flow-limiting compression was frequently seen in this 
study and the absent radial artery flow during compression 
was found to be a predictor of the radial artery occlusion.
Therefore, adequate compression should be applied 
to reduce local bleeding complications and also to 
achieve adequate hemostasis. Pressure applied should 
be limited to the minimum required to achieve hemo­
stasis. This use of lower pressure will allow forward 
flow during the compressive period and this reduces 
the risk of vascular complications. The compressive 
pressure should be reduced as early as possible with 
careful monitoring for local vascular complications.
Previous studies have reported radial artery occlu­
sion rates ranging from 3 to 10% [11,21,22]. Radial ar­
tery occlusion following a transradial coronary proce­
dure was observed before discharge in 9% of our 
patients. Several factors have been found to be associ­
ated with radial artery occlusion including radial artery 
size at baseline, radial sheath to artery diameter ratio, 
duration of the sheath placement, prior procedure, and 
the presence of diabetes mellitus [19,21,23]. We have 
identified small wrist diameter, female sex, and young 
age as predictors of radial artery occlusion. However,
TABLE IV. Independent Predictors of Radial Artery Occlusion 
at Discharge
Variables O.R 95% C.I P value
Male sex 0.61 0.29-1.28 0.194
Younger age (per yr) 1.02 1.00-104 0.036
Smaller wrist size (per cm) 1.39 1.06-1.80 0.014
No operator RAS 0.53 0.31-0.90 0.021
No heparin usage 7.12 3.75-13.52 <0.0001
we did not measure the diameter of the radial artery. 
We have for the first time found association between 
radial artery spasm and radial artery occlusion and this 
needs to be tested in further large scale studies.
Lefvre et al. [24] have reported high (30%) radial ar­
tery occlusion rates with the use of 1,000 U of heparin. In 
our study, all patients undergoing coronary intervention 
received weight-adjusted heparin (70 units/kg) and the 
administration of heparin in diagnostic cases was left at 
operator’s discretion, 61 (7.7%) patients did not receive 
any heparin. Radial artery occlusion in these patients was 
observed in 15 (24.1%) patients, similar to that reported 
in literature. We have found failure to administer heparin 
as an independent predictor of radial artery occlusion.
In our study, the protocol for application of either he­
mostatic compression device was to achieve controlled 
compression and thereby maintain antegrade flow during 
the period of compression. The ramifications of the
Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.
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radial artery occlusion and injury are important not only 
in patients undergoing repeat interventional procedures, 
but also in patients in whom the radial artery may be used 
as a conduit for coronary artery bypass surgeiy or for the 
creation of arteriovenous fistulae for hemodialysis.
LIMITATIONS
We have used qualitative assessment of the patient 
comfort level for the compressive devices, this can 
induce some bias. Second, lack of allocation concealment 
and neither the patient nor the nurse removing the device 
could be blinded to the compressive device and this could 
induce bias due to a perceived superiority of the device 
over the other. Third, the release of pressure in the TR 
band can be semiquantitatively controlled by increasing 
the amount of air released, whereas there is no measure 
of the amount of pressure reduction as the Radistop is 
released and potentially can effect the outcomes.
CONCLUSIONS
We have shown in a randomized comparison of 
Radistop and TR band that both devices are safe and 
effective as hemostatic compression devices following 
transradial procedures. However, more patients felt dis­
comfort with the Radistop device and the time taken to 
achieve hemostasis was longer with TR band.
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ABSTRACT
The aim of this study was to determine the impact of catheter sheath insertion, a model of 
endothelium disruption in humans, on the conventional FMD (flow-mediated dilatation) response 
in vivo. Seventeen subjects undergoing transradial catheterization were recruited and assessed prior 
to, the day after, and 3—4 months postcatheterization. The catheter sheath’s external diameter was 
2.7 mm, and the average preprocedure internal radial artery diameter was 2.8 mm, indicating a high 
likelihood of endothelial denudation as a consequence of sheath placement. Radial artery flow- 
mediated and endothelium-derived NO (nitric oxide)-dependent function (FMD) was assessed 
within the region of sheath placement (sheath site) and also above the sheath (catheter site). GTN 
(glyceryl trinitrate) endothelium-independent NO-mediated function was also assessed distally. 
Measurements were made in both arms at all time points; the non-catheterized arm provided 
an internal control. Neither sheath (4.5 ±0.9%) nor catheter (4.4 ±0.9%) insertion abolished 
FMD, although both significantly decreased FMD from preintervention levels (9.0 ±0.8% sheath 
segment; 8.4 ±0.8% catheter segment; P < 0.05). The impact of sheath and catheter placement 
on FMD was no longer evident after ~ 3 months recovery (8.0 ± 1.5 and 8.1 ± 1.7%, sheath and 
catheter, respectively). GTN responses also decreased from 14.8 ± 1.7 to 7.9 ± 1.0 % (P < 0.05) as 
a result of sheath placement, but values returned to baseline at ~ 3 months (13.0 ± 1.8 %). These 
results suggest that the presence of an intact, functional endothelial layer and consequent NO 
release may not be obligatory for some component of the FMD response. This raises the possibility 
of an endothelium-independent contribution to the flow-induced vasodilatation in humans.
INTRODUCTION
In recent years, FMD (flow-mediated dilatation) has 
become a popular technique in cardiovascular medicine 
and clinical physiology, as evidence has accrued that 
depressed FMD is an independent prognostic index of 
incident and recurrent cardiovascular events, which adds 
predictive value to established risk factor approaches 
[1-5]. The physiological rationale for the use of FMD,
and a proposed reason for its prognostic relevance, is 
that it reflects endothelium- and (nitric oxide)-dependent 
vascular function.
When Celermajer, Deanfield and colleagues intro­
duced the now conventional and widely adopted FMD 
approach in the Lancet in 1992 [6], no direct evidence 
was available that brachial and femoral dilatation, 
subsequent to the release of cuff-induced ischaemia, 
were endothelium- or NO-dependent in humans. The
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approach was therefore based on evidence available 
at the time that the endothelium released a labile 
vasodilator substance [7,8], that increased luminal flow- 
induced vasodilatation in human conduit arteries [9- 
12] and, crucially, that FMD in animals was dependent 
upon the presence of an intact endothelial lining. In 
these latter studies, insertion of a catheter and balloon 
inflation was used to denude the endothelial layer, which 
abolished FMD. Very few studies of this nature have been 
undertaken in humans to examine FMD after endothelial 
damage [13-15]. While previous studies have reported 
a depression in the vasodilator function of the radial 
artery after it has been catheterized [13,14], the methods 
used to assess arterial vasodilator function were limited. 
In particular, discreet time measurements were used to 
assess the peak diameter, and as such, the ‘true’ peak is 
likely to have been missed. Furthermore, these studies 
did not assess the stimulus the artery received during the 
FMD test [SRauc (shear rate area under the curve)]. This 
has previously been demonstrated to be an important 
determinant of the FMD response and should be reported 
in order to elucidate whether any changes in FMD are due 
to alterations in the artery’s ability to dilate, as opposed 
to a reduction in the stimulus [16]. In addition, the 
time-course of recovery from endothelial damage remains 
largely unknown.
The relevance of determining the degree to which FMD 
responses are endothelium-dependent is heightened by a 
recent debate over the extent to which FMD represents 
an endothelium-dependent and NO-mediated response 
[18,19]. NO blockers have been infused during FMD 
in humans, with differing effects. Joannides et al. 
[20] demonstrated that l-NMMA (iVG-monomethyI-L- 
arginine) infusion converted flow-mediated vasodilata­
tion into constriction in the radial artery in healthy 
young humans, while Doshi et al. reported abolition of 
FMD with l-NMMA [21], Somewhat in contrast, Mullen 
et al. [22] Lieberman et al. [23] and Koojiman et al. 
[24] all observed decreased FMD in the presence of l- 
NMMA, but not FMD abolition by NO blockade in these 
studies. In addition, eNOS (endothelial NO synthase) 
knockout mice exhibit preserved FMD responses [25]. 
These studies suggest that compensatory mechanisms 
may play a role in the FMD response if the endothelial 
release of NO is dysfunctional or absent and/or that NO 
is not obligatory for a dilator response to ischaemia. 
They also raise the question of to what extent FMD 
responses are dependent upon the presence of an intact 
and functional endothelium.
The principal aim of the present study was to use a 
model of endothelial disruption in humans to determine 
the impact on FMD acutely. We also examined the im­
pact of sheath compared with catheter placement, the 
impact of sheath placement on endothelium-independent 
GTN (glyceryl trinitrate) responses and the time- 
course of recovery of FMD and GTN responses. We
hypothesized that sheath insertion would diminish or 
abolish the endothelium-dependent and -independent 
function within, but not above, the sheath site.
MATERIAL AND METHODS 
Patients
Seventeen subjects (16 men, one woman) were recruited 
from the list of patients requiring radial artery 
catheterization for coronary angiography or coronary 
angioplasty. The following were excluded: patients 
who had previously undergone coronary arteiy bypass 
surgery or coronary intervention via the radial route or 
had myocardial infarction during the previous 3 months, 
valvular heart disease, a left ventricular ejection fraction 
<40%, chronic obstructive lung disease, or renal or 
hepatic dysfunction.
The study conformed to the standards set by the 
Declaration of Helsinki and ethical approval was obtained 
from the Liverpool Local Regional Ethics Committee. All 
patients provided informed written consent.
Study design
Patients were tested on three occasions: the day of the 
transradial procedure (immediately before the catheter­
ization ‘Pre’), the day after catheterization (‘Post’) and 
~ 3 months after catheterization (‘Recov’). Volunteers 
were requested to abstain from alcohol or caffeinated 
beverages and cigarettes (if they were smokers) for 12 h 
prior to each testing session. Assessments were taken 
in a quiet, temperature-controlled room. Patients rested 
in the supine position for approximately 20 min to 
ensure that all haemodynamic variables had stabilized. 
The radial artery was assessed with the arm extended 
and supported at an angle of approximately 80° from 
the torso. A rapid inflation/deflation pneumatic cuff 
was positioned on the imaged arm around the wrist. 
A standard catheter sheath was then used to mark the 
length of the catheter on the surface of the arm, from 
the scaphoid process. Care was taken to image the same 
section of the artery during repeat measurements. We 
assessed both arms to determine whether changes as a 
consequence of catheterization were specific, or more 
generalized, throughout the vascular system. On each 
occasion, endothelial-dependent function (FMD) was 
assessed over a distal section of the radial artery (FMD 
sheath), within the zone containing the sheath and over 
a proximal section (FMD catheter), which lay above the 
sheathed region. A minimum of 20 min was observed 
between repeated FMD assessments in the same arm. The 
order in which the arms were tested was randomized for 
FMD and GTN. Endothelium-independent function was 
assessed as the vascular response to a sublingual dose of 
GTN with the scans taken in the distal section of the
© The Authors Journal compilation © 2010 Biochemical Society
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radial artery after the FMD assessments. A minimum of 
30 min was given between repeat doses of GTN.
Radial artery access and procedural 
details
In this study, we recruited patients undergoing treatment 
for coronary artery disease. These patients have their 
coronary arteries either imaged (angiography) or have the 
narrow arteries widened (angioplasty). In order to gain 
access to the coronary circulation, a catheter is placed 
into a peripheral artery, in this case the radial artery, and 
the catheter is guided up to the heart. Introducer sheaths 
are used to gain access to the radial artery and to keep 
the artery open in order to facilitate the exchange of the 
guiding coronary catheter to the heart.
The radial artery was approached with the arm 
extended and supported with the wrist in mild 
hyperextension. Local anaesthesia was achieved with 2 % 
lignocaine after disinfection at the puncture site. The 
radial artery was punctured with a 21-gauge arterial 
needle through which a 0.118-in platinum-tipped nitinol 
guidewire was introduced. Following this, the needle was 
withdrawn, and a small skin incision was made. A 6 
F introducer sheath (13 cm in length, external diameter 
2.7 mm; Cook Medical) with a dilator tip length of 
2.5 cm was inserted. A weight-adjusted dose of heparin 
was introduced into the central circulation following 
the introduction of the first catheter. All introducer 
sheaths were removed at the end of the procedure 
and haemostasis was achieved in the catheterization 
laboratory by a compression device. The patients were 
mobilized immediately, and the compression device was 
removed after 2-4 h.
Experimental procedures
Ultrasound assessment of conduit artery function
HR (heart rate) and MAP (mean arterial pressure) were 
determined from an automated sphygmomanometer 
(Dinamap; GE Pro 300V2) on the contralateral arm. A 
12-MHz multifrequency linear array probe attached to 
a high-resolution ultrasound machine (T30QQ; Terason) 
was used to assess radial artery function.
FMD (endothelium-dependent NO-mediated function)
Baseline scans assessing resting vessel diameter and flow 
were recorded in the final minute of the initial rest period. 
The occluding cuff was then inflated to >200 mmHg for 
5 min. Diameter and flow recordings resumed 30 s prior 
to cuff deflation and continued for 5 min thereafter. Blood 
pressure and HR were recorded during the resting period 
and once the cuff had been released.
GTN dilatation (endothelial-independent NO-mediated 
function)
Vessel diameter was recorded 1-min before and, 
continuously for 10 min after, sublingual administration 
of GTN (400 /zg). Blood pressure and HR were recorded 
during the rest period and 5 min after the GTN had been 
administered.
Data analysis
Posttest analysis was carried out using custom-designed 
edge detection and wall tracking software [26,27]. Our 
previous detailed analysis of power requirements using 
this software indicates that, at an alpha level of 0.05, 
seven subjects are required to ensure 90 power to 
detect a 2% change in FMD [27]. FMD or GTN were 
calculated as the percentage rise from preceding baseline 
diameters. The TTP (time to peak) diameter (in seconds) 
was calculated from the point of cuff deflation to the 
time of peak postdeflation diameter. Postdeflation shear 
rate data, derived from simultaneously acquired velocity 
and diameter measures at 30 Hz, were exported to a 
spreadsheet SRauc was calculated for data up to the 
point of maximal postdeflation diameter (FMD) using 
the Riemann sum technique for each individual. SRauc 
represents the stimulus for FMD [17],
Statistics
The responses were assessed using a two-way repeated 
measures ANOVA. Where significant interaction was 
observed, a one-way ANOVA was carried out on 
each arm separately to identify differences. Results 
are expressed as means ±S.E.M. A P value <0.05 was 
considered significant.
RESULTS
The clinical characteristics of the patients are described 
in Table 1, The majority of the patients were on aspirin, 
clopidogrel, a statin, an ACEI (angiotensin-converting 
enzyme inhibitor) and a /I-blocker. Efforts were made to 
avoid changes to the patients’ drug regimes throughout 
the study. In any event, the withm-subjects design, with 
contemporaneous contralateral limb measures at each 
time point effectively controlled for any drug effects.
Seventeen subjects completed the pre- and post-scans 
for the FMD sheath site, and 11 subjects completed all 
three testing points. For the FMD catheter site (proximal) 
data, 13 subjects completed the pre- and post-scans, 
and nine subjects completed all three testing sessions. 
For the GTN protocol, 15 subjects were tested pre- 
and post-catheterization, and 11 completed all three 
testing protocols. The average age of the subjects was 
64 + 10 years, mean blood pressure was 95 + 15 mmHg 
and HR was 59 ±7 beats/min, and the baseline clinical 
characteristics are shown in Table 1.
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Table 1 Clinical characteristics of the study patients (n =
17)
Values are number of patients (percentages). PCI, percutaneous coronary 
intervention.
Characteristic
Male 16(94%)
PCI 17(100%)
Current smoker 3 (18%)
Ex-smoker 11(65%)
Diabetes mellitus 3 (18%)
Hyperlipidaemia on medication 17 (100%)
Hypertension on medication 13 (77%)
There was no significant difference in resting radial 
artery diameter between arms at the sheath site (distal) 
prior to catheterization, but diameter was significantly 
larger (P < 0.05) in the catheter (proximal) section of 
the catheterized arm compared to the control (non- 
catheterized) arm (Table 2). This may relate to the fact 
that the catheterized arm was typically the dominant right 
arm. There was no significant difference in SRauc or TTP 
between arms or across time.
There was a significant increase in baseline diameter 
(Table 2) postprocedure in the catheterized arm 
(16 + 5%) in the sheath section only (P<0.05). There 
was no significant change in baseline diameter in the 
control arm at either the catheter or sheath sites. The re­
covery (15 ± 1 week) resting baseline diameters were not 
significantly different from preprocedure in either the 
catheterized or non-catheterized control arm.
There was no significant difference in FMD or GTN 
between arms precatheterization (Figure 1). There was a 
significant reduction in FMD at both the sheath (P < 0.01) 
and catheter sites (PcO.Ol) in the catheterized arm 
(Figure 1), but FMD was not completely abolished at 
either site. Similarly, there was a significant decrease 
(P < 0.05), but not abolition, of the artery response
Sheath Control Catheter Control Sheath Control
FMD Sheath Site FMD Catheter Site GTN Sheath Site
Figure I Changes in FMD (%) within the area of the sheath 
(sheath site, n = 17) and above the area of the sheath (cathe­
ter site, n = 13) and changes in GTN (%) within the area 
of the sheath (n= 15) in the catheterized and non-cathet­
erized (control) arms pre- (Pre) and post- (Post) procedure 
Results are presented as means+ S.E.M. ‘Significantly different from Pre 
(P < 0.0S).
to the GTN postprocedure in the sheath segment of 
the catheterized arm. These decreases had returned 
towards preprocedure values by 3^4 months after the 
catheterization (Figure 2). In contrast, there was no 
change in FMD or GTN across any of the time-points in 
the control arm (Figure 1). One patient had an occluded 
artery postprocedure that remained occluded at the 
3-month recovery period.
There was no change in MAP across time (Table 3). 
There was a decrease in MAP with administration of 
GTN, which was significant for both arms at the pre- 
and posttesting sessions (P < 0.01).
DISCUSSION
The aim of the present study was to determine the 
impact of radial artery sheath and catheter placement 
on vascular function in vivo. There are several novel
Table 2 Baseline diameter and time to peak vasodilation preprocedure (Pre), the day following the procedure (Post) and 
~ 3 months postprocedure (Recov) in the catheterized (sheath or catheter site) and non-catheterized (control) arms
Results are presented as means + S.E.M. Endothelium-dependent FMD was assessed in the distal section of the artery exposed to the catheter sheath (sheath site, 
n= 17 for Pre and Post and II for Recov) and the proximal section of the artery, above the sheath (catheter site, n= 13 for Pre and Post and 9 for Recov). 
Endothelial-independent function (GTN) was assessed in the distal section (n= 15 for Pre and Post and II for Recov) of the artery within the site of the atheter 
sheath. ‘Significantly different from Pre (P < 0.05); #significantly different from catherterized.
Measurement
Baseline diameter (mm) Time to peak (s) SRauc (s 1 I03)
Pre Post Recov Pre Post Recov Pre Post Recov
FMD sheath site Sheath 2.8 ±0.1 3.2 ±0.1* 2.7 ± 0.2 95± 10 87 ± 11 77 ±1 30.0 ± 2.9 20.7 ± 3.8 25.3 ± 3.6
Control 2.6 ±0.1 2.8 ±0.1 2.9 ±0.2 78 ±9 79 ±8 83± 14 23.5 ± 3.3 26.6 ± 1.9 32.6 ± 6.6
FMD catheter site Sheath 3.1 ±0.1 3.4 ±0.1 2.8 ± 0.2 73 ±9 105 ±11 63± IS 20.7 ± 3.5 23.7 ± 3.8 27.5 ± 6.5
Control 2.8 ±0.2# 2.8 ±0.1 2.8 ± 0.2 110 ± 14 90 ± 8 71 ± 13 31.7 ±6.2 28J ± 3.8 24.0 ± 3.9
GTN sheath site Sheath 2.8 ±0.1 3.2 ±0.1 2.6 ± 0.2 308 ± 23 263 ±31 333 ±30 — — —
Control 3.0 ± 0.2 2.9 ±0.1 3.2 ± 0.2 351 ±30 297 ± 28 276 ±28 - - -
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Table 3 MAP during baseline measurements and postcuff release or post-GTN 
administration preprocedure (Pre), the day following the procedure (Post) and 
~ 3 months postprocedure (Recov) in the catheterized (cath) and non-catheterized 
(control) arms
Results are presented as means+ S.E.M. Mean arterial pressure (FMD) was assessed in the contralateral arm. 
Measurements were taken during the baseline period and ~ I min after cuff release or ~ 3 min post-GTN 
administration. "Significantly different from baseline (P < 0.05); #Significantly different from Pre.
MAP (mmHg)
FMD sheath site FMD atheter site GTN sheath site
Baseline FMD During FMD Baseline FMD During FMD Baseline GTN During GTN
Cath
Pre 95 ±4 94 ±4 91 ±4 94 + 3 95 ±3 87 ±3*
Post 94 ±3 92 ±4 91 ± 3 90 ±4 89 ±3 85 ±3*
Recov 96 ±4 93 ±5 88 ±3 86 ±2 88 ±5 84 + 5
Control
Pre 95 ±4 95± 12 88 ±3 91 ± 3 93 ±3 86 ±3*
Post 89 ± 4 88 ±4 88 ± 5 87 ±3 88 ±3 83 ±4*
Recov 95 ±5 96 ±5 93 ±5 92 ±6 89 ±4 85 ±4
• Pt* □ Po*t BRecovery both within and above the site of ;
FMD Sheath Site FMD Catheter Site GTN Sheath Site
Figure 2 Changes in FMD (%) within the area of the sheath 
(sheath site, n = 11) and above the area of the sheath 
(catheter site, n = 9) and changes in GTN (%) within the 
area of the sheath (n = II) in the catheterized arm Pre, 
Post and ~ 3 months (Recovery) postprocedure 
Results are presented as means + S.E.M. "Significantly different from Pre 
(P < 0.0S).
findings. This is the only study, to our knowledge, which 
has assessed both distal and proximal sections of the 
radial artery in order to determine whether function 
was affected within the region of the catheter sheath 
alone or whether catheterization has more generalized 
effects on vasodilator function. Importantly, continuous 
measurement of artery diameter and flow allowed us to 
record the ‘true’ peak in vasodilatation in addition to the 
SRauc, which represents the stimulus the artery receives 
during the FMD test. We also repeated measures ~ 3 
months postcatheterization to determine whether arterial 
function recovered, and we included within-subjects 
control measures on the contralateral non-catheterized 
limb. Our findings indicate that endothelium-dependent 
function is decreased acutely as a result of catheterization,
changes in arterial function were observed in the non- 
catheterized control arm at any time-point. This is similar 
to the work of Heiss et al. [15] who also reported a 
reduction in brachial as well as radial artery function 
postcatheterization. The lack of a significant change in the 
SRauc> an estimate of the vasodilatory stimulus, supports 
the notion that the reduction in the FMD was due to an 
impaired ability of the artery to dilate. Impairment in 
FMD function was not complete, however, as substantial 
dilatation occurred despite sheath and catheter placement. 
Responses largely resolved, i.e. returned to near-baseline 
levels, following ~ 3 months recovery.
The external diameter of the catheter sheaths used 
in this study was 2.7 mm and the mean preprocedure 
internal radial artery diameter above the insertion site 
was 2.8 mm (range 2.2-3.5 mm). While we cannot 
say for certain that the artery was denuded, given 
the fragile nature of the endothelial monolayer, it is 
highly likely that placement of the sheath disrupted 
and/or denuded the endothelial layer, in a similar 
manner to the induction of endothelial denudation 
by balloon inflation in animal models [28,29], The 
suggestion that we induced endothelial disruption or 
denudation is supported by the finding that baseline 
arterial diameter in the sheathed radial segment was larger 
following the procedure (mean 3.2 mm). Studies of the 
impact of catheterization and subsequent denudation 
on radial arterial function are scant. Burstein et al. 
[13] reported that transradial catheterization impaired 
FMD immediately postprocedure. Recently, Heiss et al. 
[15] also observed a reduction in FMD in the radial 
artery 6 h postcatheterization. In contrast to our findings, 
values recovered after 12 h in non-smokers. Heiss and
© The Authon Journal compilation © 2010 Biochemical Society
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colleagues did not assess GTN function, so they were 
unable to determine whether smooth muscle function was 
affected. In contrast, Sanmartin et al. reported no change 
in postischaemic radial artery dilatation immediately 
after the procedure, although this was probably due 
to an initial impairment in function [14], Interestingly, 
despite a significant reduction in FMD in this study, 
there was still some vasodilatation in response to the 
hyperaemic challenge. This suggests that placement of 
a large sheath and consequent disruption or denudation 
of the endothelial layer decreases, but does not abolish, 
FMD. This is in agreement with some previous studies 
which have blocked NO function and found only 
partial reductions in FMD [22-24]. Likewise, eNOS 
knockout mice have been shown to have preserved FMD 
responses [25]. In these studies, it was assumed that 
some compensatory mechanisms, including the release 
of other endothelium-dependent vasodilators such as 
protoglandins [25], may come into play if the endothelial 
release of NO is impaired or absent. However, our data 
raise the possibility that there may be a non-endothelium- 
dependent vasodilatation in response to increased blood 
flow and shear stress in humans. Future studies will 
be required to elucidate the contribution of both the 
endothelium-dependent and independent vasodilators to 
the conventionally used FMD technique.
In addition to the assessment of endothelial-dependent 
function, we measured endothelial-independent NO- 
mediated responses to GTN. As a NO donor, GTN 
provides a measure of the smooth muscle component 
of the vascular NO-dilator system. It is possible that 
insertion of the relatively large sheath into the radial 
arteiy results in disruption of the smooth muscle layer 
of the vessel wall. Decreased GTN responses in the 
catheterized, but not the non-catheterized, arm supports 
the contention that sheath-related impacts may not be 
limited to the intima and is in agreement with the previous 
literature [13,14]. As with the FMD data, it is notable 
that sheath placement did not completely abolish GTN- 
mediated vasodilatation, suggesting that some smooth 
muscle cell function remains intact despite the placement 
of the sheath, and that sheath placement impairs but 
does not eradicate smooth muscle responsiveness to an 
NO donor. These observations have implications for the 
use of nitrovaso dilators in the clinical setting soon after 
percutaneous interventions are carried out.
It is possible that the mechanical stretch induced by the 
sheath insertion played a role in the depressed vascular 
function, as diameter is an important determinant of 
the dilator-response magnitude, at least when large 
differences exist in the resting diameter. In the present 
study, arteiy diameter increased modestly as a result 
of artery catheterization (0.4 mm). Our previous data 
suggests that this magnitude of change in resting diameter 
is unlikely to fully explain the change in FMD observed 
in the present study, with an expected FMD of 10% in
healthy subjects for a radial artery of 2.8 mm and 8 % for 
a radial artery of 3.2 mm [30].
In addition to measuring endothelial function within 
the region of the catheter sheath, we also examined 
endothelium-dependent function in the proximal section 
of the artery, which was exposed to the catheter but 
not the catheter sheath. As with the distal section of the 
artery, we observed a reduction in FMD in the section 
of the artery only exposed to the catheter. From these 
data, we can suggest that the impact of catheterization 
extends beyond the site of sheath placement. This is 
in agreement with Heiss et al. [15] who reported a 
reduction in brachial artery function 6 h postradial arteiy 
cannulation, although this depression recovered after 
12 h in non-smokers and remained depressed in smokers. 
It is feasible that the catheter itself may damage the 
endothelium as it is advanced. However, we cannot rule 
out the possibility that the catheter is associated with 
localized inflammation or irritation as a mechanism for 
reduced function in the catheterized arm [31]. Reduced 
function above the sheath site raises questions about 
injury to the rest of the arterial tree through which 
the catheter passes, including perhaps the coronary 
arteries. Since FMD in the contralateral arm was not 
depressed, a global impact of catheterization, mediated 
via inflammation or oxidative stress, seems unlikely.
It is interesting to note that both endothelial and 
smooth muscle responses return to near-baseline levels 
following a 3-month recovery period. This is in contrast 
to the study of Burstein et al. who previously reported 
that the impairment in FMD following transradial 
catheterization was still evident 6 weeks after surgery 
[13]. Our findings that vascular function had recovered 
~ 3 months postprocedure suggests that this period 
may be the minimum required for arterial function to 
normalize after catheterization and sheath insertion.
Limitations
This is the first study of its type to use automated-edge 
detection and wall-tracking software to derive operator- 
independent measures of arterial diameter and FMD. 
The study of two sites within and above the catheter 
sheath site along the radial artery also provides novel 
information, as does the repeated measurement following 
a recovery period. However, the present study also has 
some limitations. There were a relatively small number of 
subjects in each group, and we could not get all patients 
back for the 3-month recovery period. This limitation is 
somewhat mitigated by our wkhin-subjects design and 
analysis. "We did not control for age, pre-existing vascular 
disease, history of smoking or drug treatment. However, 
the use of contralateral arm as an internal control helped 
to negate this limitation.
Conclusions
In conclusion, transradial catheterization results in 
reversible depression in NO-mediated endothelial and
© The Authors Journal compilation © 2010 Biochemical Society
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smooth muscle function in the catheterized arm. This 
effect is evident in the region of the sheath and also 
above the site of the catheter sheath, suggesting that both 
sheath and catheter insertion impact upon the vasculature, 
possibly via a localized inflammatory or irritant response. 
Although FMD responses were impaired by sheath 
placement, they were not abolished, suggesting that some 
endothelium-independent vasodilator mechanisms may 
contribute to the vasodilatation response to an FMD 
test in humans. This hypothesis will require further 
investigation. From a clinical perspective, it is possible 
that optimizing the function and size of the artery prior 
to its cannulation may improve the outcome and recovery 
of the artery. To this end, exercise training has been 
shown to improve arterial function and induce outward 
remodelling [32-36], both of which might limit the impact 
of transradial catheterization and improve the health and 
recovery of the artery postprocedure.
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Impact of Introducer Sheath Coating on Endothelial 
Function in Humans After Transradial 
Coronary Procedures
Ellen A. Dawson, PhD* ; Sudhir Rathore, MD*; N. Timothy Cable, PhD; D, Jay Wright, MD;
John L. Morris, MD; Daniel J. Green, PhD
Background—The aim of this study was to compare the impact of transradial catheterization with hydrophilic-coated 
catheter sheaths versus uncoated sheaths on NO-mediated endothelial-dependent and -independent vasodilator function.
Methods and Results—Thirty-five subjects undergoing transradial catheterization were recruited and assessed before and 
the day after catheterization. A subgroup was also assessed 3 to 4 months after catheterization. Subjects received 
hydrophilic-coated sheaths (n—15) or uncoated sheaths (n=20). Radial artery flow-mediated dilatation and endothelium- and 
NO-dependent arterial dilatation were assessed within the region of sheath placement. Glyceryl trinitrate endothelium- 
independent NO-mediated function was also assessed. The noncatheterized ami provided an internal control. 
Flow-mediated dilatation in the catheterized arm decreased from 10.3±3.8% to 5.3±3.3% and 8.1 ±2.4% to 5.2±3.7% 
in the coated and uncoated groups, respectively (P<0.01). These values returned toward baseline levels ~3 months later 
(coated, 6.4±1.4%; uncoated, 9.4±4.1%; P<0.05) versus postprocedure. Glyceryl trinitrate decreased from 14.8±7.2% 
to 9.5 ±4.1% CP<0.05) in the coated group and from 12.2±4.6% to 7.5±4.2% (P<0.01) in the uncoated group. Values 
returned to baseline at ~3 months (coated, 16,6±5.6%; uncoated, 12.1 ±3.9%; P<0.05). There was no difference in the 
magnitude of decrease in flow-mediated dilatation or glyceryl trinitrate between coated and uncoated groups. No 
changes in function occurred in the noncatheterized aim.
Conclusions—Placement of a catheter sheath inside the radial artery disrupts vasodilator function, which recovers after 3 months. No 
differences were evident between hydrophilic-coated and uncoated sheaths. (Ore Cardiovasc Interv. 2010;3:148-156.)
Key Words: flow-mediated dilatation ■ radial artery catheter ■ endothelium
Since its introduction in 1989, transradial catheterization has gained popularity as an approach for diagnostic and 
coronary interventional procedures.1 This approach has been 
associated with lower vascular complication rates, reduced 
procedural costs, comparable procedural success rates, earlier 
patient mobilization, improved quality of life, and reduced 
hospitalization costs.2"10 However, it is probable that inser­
tion of the catheter sheath into the relatively small radial 
artery has a direct physical impact on the endothelial lining of 
the vessel wall, a squamous monolayer that is easily damaged 
as a consequence of mechanical disruption. Removal or 
damage of the endothelial lining impairs arterial relaxation by 
decreasing NO bioavailability. It may also promote intimal 
hyperplasia, thrombus formation, and the development of 
atherosclerotic plaques,11-12 which could have implications 
for the use of the artery as a donor graft for coronary artery 
bypass surgery because graft longevity is partly related to the 
capacity to remodel and dilate in response to changes in 
metabolic demand and blood flow.
Clinical Perspective on p 156
Recent advances in the development of catheter sheaths 
include the development of hydrophilic coatings that aim to 
reduce frictional resistances during sheath placement and 
removal.13 Although hydrophilic-coated sheaths have been re­
ported to result in a reduction in the occurrences of discomfort 
and clinical spasm,4-14 no previous study has addressed the 
questions of whether sheath coating results in less endothelial 
dysfunction. The aim of this study, therefore, was to measure 
endothelium-dependent and -independent vasodilator function in 
patients undergoing transradial catheterization with either a 
hydrophilic-coated or an uncoated sheath.
Methods
Informed written consent was obtained from 35 subjects (32 men) 
recruited from the list of patients requiring radial artery catheteriza­
tion for coronary angiography or angioplasty. The exclusion criteria 
were as follows: previous coronary artery bypass graft or coronary
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intervention through the radial route or myocardial infarction during 
the previous 3 months, valvular heart disease, left ventricular 
ejection fraction <40%, chronic obstructive lung disease, and renal 
or hepatic dysfunction. The study conformed to the Declaration of 
Helsinki, and ethical approval was obtained from the Liverpool 
Local Regional Ethics Committee.
Study Design
In this prospective randomized study, patients were assigned to 1 of 
the 2 different introducer sheath groups: hydrophilic-coated sheath 
(coated group), sheath without coating (uncoated group). Patients 
were tested on 3 occasions: the day of the transradial procedure 
(before catheterization [pre]), the day after catheterization (post), and 
“3 months after catheterization (recov).
Radial Artery Access and Procedural Details
The radial artery was approached with the arm extended and 
supported with the wrist in mild hyperextension. Local anesthesia 
was achieved with 2% lignocaine after disinfection at the puncture 
site. The radial artery was punctured with a 21-gauge arterial needle 
through which a 0.118-inch platinum-tipped nitinol guide wire was 
introduced. Next, the needle was withdrawn, and a small skin 
incision was made. A 6F introducer sheath (length, 13 or 23 cm; 
external diameter, 2.6 mm) with a dilator tip length of 2.5 cm was 
inserted. Routine use of vasodilator cocktail (nitroglycerine, verap­
amil, or diltiazem) was avoided if possible, and a weight-adjusted 
dose of heparin was introduced into the central circulation after the 
introduction of the first catheter. All introducer sheaths were re­
moved at the end of the procedure and hemostasis achieved in the 
catheterization laboratory through a compression device. The pa­
tients were mobilized immediately, and the compression device 
removed after 2 to 4 hours.
Experimental Procedures
Patients were requested to abstain from alcohol, caffeine, and 
cigarettes for 12 hours before each session. Assessments were taken 
in a quiet, temperature-controlled room. Patients rested in the supine 
position for ^20 min to ensure that all hemodynamic variables 
stabilized. The radial artery was imaged with the arm extended and 
supported at 80° from the torso. A rapid inflation/deflation pneu­
matic cuff was positioned on the imaged arm around the wrist. A 
standard catheter sheath was used to mark the length of the catheter 
on the surface of the arm from the scaphoid process. Care was taken 
to image the same section of the artery during repeat measurements. 
We assessed both arms to determine whether changes as a conse­
quence of catheterization were specific or more generalized through­
out the vascular system. On each occasion, endothelial-dependent 
function (flow-mediated dilatation [FMD]) was assessed over a distal 
section of the radial artery, within the zone containing the sheath, and 
above the cuff. Endothelium-independent function was assessed as 
the vascular response to a sublingual dose of glyceryl trinitrate 
(GTN). A minimum of 30 min was given between repeat doses of 
GTN. The sonographer was blinded to the catheter sheath type 
during scanning and analysis.
Ultrasound Assessment of Conduit Artery Function 
Heart rate and mean arterial pressure (MAP) were determined from 
an automated sphygmomanometer on the contralateral arm. A 
12-MHz multifrequency linear array probe attached to a high- 
resolution ultrasound machine was used to image the radial artery.
Flow-Mediated Dilatation (Endothelium-Dependent, 
NO-Mediated Function)
Baseline scans assessing resting vessel diameter and flow were 
recorded in the final minute of the initial rest period. The occluding 
cuff then was inflated to >200 mm Hg for 5 min. Diameter and flow 
recordings resumed 30 sec before cuff deflation and continued for 5
Table 1. Clinical Characteristics and Outcomes of the Study 
Patients (n=35)
Variables
Coated
(n=15)
Uncoated
(n=20) P
Age, y 62.7±9.7 62.0±10.5 0.82
Male 13(86) 19(95.0) 1.00
MAP, mm Hg 95±11 93±13 0.89
Heart rate, bpm 62±13 62±13 0.95
Hypertension 11 (73) 16(80) 0.71
Hyperlipidemia 13(87) 19(95) 0.57
Diabetes mellitus 3(20) 5(25) 1.00
Height, cm 153.5±9.2 165.3±8.1 0.38
Weight, kg 76.8±9.7 86.5 ±19.3 0.23
Wrist circumference, cm 16.3±3.9 17.1 ±1.0 0.37
Smoking
Current 2(13) 3(15)
Former 10(67) 14(70) 0.26
Stable angina 15 (100) 20 (100) 1.00
Time sheath in situ, min 70.4±30.3 64.2±24.0 0.54
Vascular complications
Ecchymosis 2(13) 3(15)
Oozing 4(27) 1(5) 0.18
Radial artery occlusion 1(7) 0(0) 0.43
Late local infection 1(7) 0(0) 0.43
Radial artery occlusion at follow-up 1(7) 0(0) 0.43
Data are presented as n (%) or mean±SD. Hypertension is defined as 
systolic blood pressure >140 or diastolic blood pressure >90 mm Hg. 
Hyperlipidemia was considered apparent on treatment for total serum choles­
terol >5.0 mnvmol/L. Diabetes mellitus was determined on treatment. Radial 
artery spasm is defined as discomfort felt by patient or resistance felt during 
removal of introducer sheath.
min thereafter.15 MAP and heart rate were recorded during the 
resting period and after cuff release.
Glyceryl Trinitrate Dilatation (Endothelial-Independent, 
NO-Mediated Function)
Vessel diameter was recorded 1 min before and continuously for 10 
min after sublingual administration of GTN (400 pg). Heart rate and 
MAP were recorded at rest and 5 min after GTN administration.
Posttest analysis was carried out using custom-designed edge 
detection and wall-tracking software.15-16 Our previous detailed 
analysis of power requirements using this software indicated that at 
an alpha level of 0.05, 7 subjects were required to ensure 90% power 
to detect a 2% improvement in FMD. FMD and GTN were 
calculated as the percentage rise from preceding baseline diameters. 
Time to peak diameter was calculated from the point of cuff deflation to 
die time of peak postdeflation diameter.15 Postdeflation shear rate area 
under the curve was calculated for data up to the point of maximal 
postdeflation diameter (FMD) using die Riemann sum technique for 
each patient. Shear rate area under the curve represents the stimulus for 
FMD.17 Further detailed mediods are available elsewhere.15
Data Analysis
The responses initially were assessed using 3-way ANOVAs with 
linear mixed models. We followed-up with 2-way repeated-measures 
ANOVAs on the coated or uncoated groups compared over time and 
between arms. Further post hoc analysis was carried out using paired 
t tests. The effects of the FMD test or GTN administration on MAP 
were assessed using a 1-way ANOVA. Baseline characteristic
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Figure 1. Changes in FMD (%) in the catheterized and noncatheterized control arms before and after procedure. Top panel shows 
coated sheath, and bottom shows uncoated sheath. Data are presented as mean±SD. ’Significantly different from pre P<0.05.
differences were determined using t tests or x2 tests. Results are 
expressed as mean±SD. and P<0.05 was considered significant.
Results
Study Patients
The clinical characteristics of the patients are described in Table 
l. The majority of the patients were taking aspirin, clopidogrel, 
a statin, an angiotensin-converting enzyme inhibitor, and a 
/3-blocker, and there were no systematic differences between the 
groups in terms of medication use. Efforts were made to avoid 
changes to the patients’ drug regimens throughout the study. In 
any event, the within-subject design, with contemporaneous 
contralateral limb measures at each time point, provided an 
important experimental control. All patients had successful 
transradial coronary procedures. Coronary artery angioplasty 
and stenting was performed in 33 patients, and 2 patients had 
only coronary angiography. The mean procedure time was 
61 ±21 minutes. Three patients needed intraarterial isosorbide 
dinitrate to treat radial artery spasm during the procedure (2 in 
uncoated group and 1 in coated group). One patient in the coated 
sheath group had an occluded artery postprocedure that re­
mained occluded at 3 months. Occlusion was confirmed by a 
reverse Allen's test, and the existence of impaired shear rate after 
ischemia. The data for this patient were removed from subse­
quent analysis. The other 14 subjects in the coated sheath group
had FMD data collected before and after catheterization, and 12 
of these had GTN before and after catheterization. A subgroup 
of 6 patients from the coated sheath group was retested =3 
months after procedure. Twenty patients were recruited to the 
uncoated group of whom all had pre- and post-FMDs, whereas 
19 completed pre- and post-GTN testing. From this group, 13 
patients were retested for FMD and 12 for GTN «=3 months 
later. The difference in group size was due to patient drop-out or 
poor ultrasound images.
Baseline Characteristics and Clinical End Points
The baseline clinical characteristics are shown in Table 1 and 
were similar in both groups. The incidence of minor access 
site complications was low in both groups. There was no 
significant difference in MAP between arms or between 
catheter sheath coatings.
The 3-way ANOVA produced a significant effect of arm 
(/>=0.003); time (P=0.000); interaction of arm and time; and 
coating, arm, and time for the FMD percent. For the GTN 
percent, there was a significant effect of coating, time, and 
arm and time. These data were followed up by a simple main 
effects model using 2-way ANOVAs.
Impact of Sheath Placement on 
Endothelium-Dependent and -Independent Vasodilation
In the coated group, there was a significant effect of time 
(P=0.046), arm (P=0.002), and interaction between arm and
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Figure 2. Changes in GIN (%) in the catheterized and noncatheterized control arms before and after procedure. Top panel shows 
coated sheath, and bottom shows uncoated sheath. Data are presented as mean±SD. ‘Significantly different from pre P<0.05.
time (P=0.003) on FMD. There was a reduction in FMD in 
the catheterized arm pre to post (PCO.OI), with no change in 
the noncatheterized arm (/>=0.18) (Figure 1).
In the uncoated group, there was a significant effect of time 
(P=0.005), arm (/>=0.001), and interaction between arm and 
time (P<0.001) on FMD. There was also a significant 
reduction in FMD in the catheterized arm (P<0.05), with no 
change in the noncatheterized arm (Figure 1).
In the coated group, ANOVA revealed no significant effect 
of time (/>=0.089), but there was a significant effect of arm 
(P=0.029) and interaction between arm and time for GTN 
data (/>=0.012). There was a reduction in the GTN response 
in the catheterized arm pre to post (P<0.05), with no change 
in the noncatheterized arm (f>=0.32) (Figure 2).
In the uncoated group, there was no significant effect of 
time (/>=0.11), but there was a significant effect of arm 
(P=0.017) and interaction between arm and time for GTN 
data (P<0.001) (Figure 2). There was a reduction in GTN in 
the catheterized arm pre to post (P<0.01), with no change in 
the noncatheterized arm (P=0.65).
Although there was a significant interaction among arm, time, 
and coating with the 3-way ANOVA, there was no significant 
difference in the magnitude of change in FMD between the 
coated and uncoated conditions in the catheterized arm. with a 
2-way ANOVA demonstrating a significant effect of time
(PcO.OOl) but no interaction of time and coating (P=0.085). 
Likewise, an ANOVA on GTN data comparing the effect of 
time and coating in the catheterized arm showed a significant 
effect of time (P<0.001) but no interaction between time and 
coating (P=0.63). Baseline arterial diameters, time to peak, and 
shear rate area under the curve are presented in Table 2.
Impact of Sheath Placement on the Recovery of 
Endothelium-Dependent and -Independent Vasodilation
In the subjects who participated in the 3-month follow-up, 
matched data revealed that FMD decreased nonsignificantly 
(P=0.063) as a result of catheterization and then returned toward 
baseline at 3 months (P<0.05 post to recov) in the coated group 
(n=6) (Figure 3). In the contralateral control limb, FMD was 
unchanged. ANOVA on the post versus recov data comparing 
time and arm revealed no significant effect of time (P=0.21), a 
significant effect of arm (P=0.004), but no significant interac­
tion (P=0.14). In the uncoated group (n=13), the FMD de­
creased from pre to post (P<0.01) and returned toward baseline 
post to recov (P<0.05). In the contralateral control limb, FMD 
was unchanged. ANOVA on the post versus recov data com­
paring time and arm revealed no significant effect of time 
(P=0.38), a near significant effect of arm (P=0.05). and a 
significant interaction (P=0.020) (Figure 3).
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Table 2. Baseline Diameter, Time to Peak, and Shear Rate Area Under the Curve 
Preprocedure and the Day After the Procedure in the Catheterized and Noncatheterized Arms
Baseline
Diameter, mm Time to Peak SRauC’s ’XIO3
Pre Post Pre Post Pre Post
FMD protocol
Cath
Coated 2.7±0.5 3.0±0.4* 97 ±42 107 ±47 28.9±21.6 27.2±13.4
Uncoated 2.9±0.4 3.1 ±0.4* 106±48 93 ±45 31.0±15.5 21.5±12.5
Contr
Coated 2.6±0.5 2.5±0.4 91 ±50 61 ±30 26.7±27.8 25.3±9.6
Uncoated 2.6±0.4 2.9±0.4* 86 ±28 103±58 15.4±8.6 27.7±13.1
GTN protocol
Cath
Coated 2.6±0.5 2.9±0.5 316±87 284 ±93
Uncoated 2.9±0.4 3.3±0.3* 345 ±83 254 ±117*
Contr
Coated 2.7 ±0.5 2.7±0.3 354±125 323 ±101
Uncoated 3.0±0.3 2.9±0.3 276 ±108 297 ±115
Data are presented as mean±SD. Coated group, n=14 for FMD and n=12 for GTN. Uncoated group, n=20 for 
FMD and n=19 for GTN. Endothelium-dependent (FMD) and endothelial-independent function (GTN) in groups. Cath 
indicates catheterized arm; Contr, noncatheterized control arm, SRAUC, shear rate area under the curve.
‘Significantly different from pre P<0.05.
The GTN data in the coated group (n=6) decreased from 
pre to post (/><0.05) and then returned toward baseline post 
to recov (P<0.05). In the contralateral control limb, GTN 
was unchanged. ANOVA on the post versus recov data 
comparing time and arm revealed no significant effect of time 
(P=039) or arm (f>=0.18) but a significant interaction 
between arm and time (T^O.OM). In the uncoated group 
(n= 12), GTN decreased from pre to post and returned toward 
baseline levels at 3 months post to recov (/><0.05). In the 
contralateral control limb, GTN was unchanged. ANOVA on 
the post versus recov data comparing time and arm showed a 
significant effect of time (P=0.036), an almost significant 
effect of arm (P=Q.Q52), and a significant interaction be­
tween arm and time (7,=0.001) (Figure 4).
There was no significant difference in the recovery of 
FMD post versus recov between the coated and uncoated 
conditions in the catheterized arm, with a 2-way ANOVA 
demonstrating a significant effect of time (7,=0.005) but no 
interaction of time and coating (/,=0.52). There was also no 
significant difference in the recovery of the GTN post versus 
recov between the coated and the uncoated conditions in the 
catheterized arm, with 2-way ANOVA demonstrating a 
significant effect of time (7’=0.000) but no interaction 
between time and coating (P=0.58). Baseline arterial diam­
eters, time to peak, and shear rate area under the curve are 
presented in Table 3.
Discussion
The aim of this study was to determine the impact of coating 
of sheaths used during radial artery catheterization on vascu­
lar function in vivo. Catheterization may have implications 
for long-term artery health, as endothelial damage leads to the
development of atherosclerotic plaques.1112 We assessed 
endothelial-dependent and -independent function in a section 
of the artery subjected to sheath placement. Measures were 
collected before and after catheterization and, in a subgroup, 
=“3 months postcatheterization to determine whether arterial 
function recovered. Within-subject control measures were 
also collected from the contralateral, noncatheterized limb. 
Our findings indicate that FMD and GTN decreased as a 
result of catheterization, impairment that largely resolved 
after months of recovery. There was no difference 
between the hydrophilic-coated versus uncoated groups in 
terms of the acute impact of catheterization or recovery. No 
changes in arterial function were observed in the noncath­
eterized arm at any time point. These data indicate that a 
hydrophilic coating does not ameliorate the dysfunction 
associated with catheter sheath insertion in vivo.
FMD is an in vivo bioassay of NO-mediated endothelial 
function.1819 Depressed FMD is an independent prognostic 
index of cardiovascular events, particularly in patients with 
cardiovascular disease.20-21 There are, however, few data 
examining the impact of catheterization of vascular function 
in vivo. One previous study found that FMD was impaired 
immediately after procedure and up to 9 weeks after sur­
gery.22 Our data largely reinforce this finding and indicate 
recovery in endothelial-dependent and -independent function 
months after procedure, whereas Burstein et al22 reported 
depressed function at 9 weeks. These findings suggest that 3 
months may be the minimum required for arterial function to 
normalize after sheath insertion.
The question of relative impact of sheath placement on the 
endothelium versus smooth muscle is difficult to definitively 
resolve from our data. Although impaired GTN responses 
indicate that the endothelium is not solely affected, a finding of
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Figure 3. Changes in FMD (%) in the catheterized and noncatheterized arms post and recov. Top panel shows coated sheath data, 
and bottom shows uncoated sheath data. Data are presented as mean±SD. ’Significantly different from pre P<0.05.
impaired FMD and GTN function nonetheless allows for the 
possibility that both endothelial and smooth muscle function 
were affected. We favor the latter interpretation because we 
believe that impairment in the function of the middle layer of the 
wall as a result of the introduction of a sheath, which is of similar 
outer diameter to that of the artery lumen, is likely to have 
resulted in endothelial denudation or dysfunction. Although we 
have no direct evidence of endothelial denudation or damage, it 
is important to consider that animal studies that established a role 
for the endothelial function in FMD did so by placing a balloon 
inside an artery to denude the inner layer.23-24 We would contend 
that sheath placement in this study represents a similar, or 
perhaps even more robust, intervention, which is supported by 
the significantly larger diameter postprocedure in the catheter­
ized but not in the noncatheterized arm. Therefore, it seems 
likely that both endothelial and smooth muscle function were 
affected by sheath placement.
The recovery of endothelial-dependent and -independent 
function in the catheterized arm indicates that transradial 
catheterization should not be considered an absolute contra­
indication to subsequent use of the radial artery as a donor 
graft. Some caution is warranted; however, as cannulation of 
the radial artery has been shown to reduce arterial lumen size 
and result in intima-medial thickening.25-27 Damage of the 
smooth muscle also may be associated with intimal hyper­
plasia, cell proliferation, collagen synthesis,28 and inward 
remodeling.26-29 Furthermore, transradial catheterization has 
been shown to induce intimal hyperplasia, medial inflamma­
tion, and tissue necrosis at the puncture site.30 Despite good 
clinical outcomes,31 caution in using the radial artery as a 
graft is advocated by several groups due to its propensity to 
spasm, an increased likelihood of development of atheroscle­
rosis, and damage induced by catheterization.25-26-32-34 
A unique aspect of this study was examination of the 
impact of sheath coating on vascular function. The develop­
ment of hydrophilic coating purportedly leads to reduction in 
the force required to remove the sheath and the likelihood of 
damage during removal.13 There is some evidence that sheath 
coating has beneficial clinical effects, including reduced 
spasm and pain.4-13-14-35 We therefore hypothesized that 
sheath coating would limit impacts on vessel function and 
that diminished impact on the endothelium may preserve its 
well-established antiatherogenic properties. However, our 
data show that there was no difference between hydrophilic- 
coated and uncoated sheaths in terms of endothelium- 
dependent or -independent function after sheath placement. 
Furthermore, we observed no evidence of a beneficial effect 
of sheath coating on the recovery of the artery after sheath 
removal. These data indicate that if clinical and outcome 
benefits from coating sheaths do exist, then the mechanisms
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Figure 4. Changes in GTN (%) in the catheterized and noncatheterized arms post to recov. Top panel shows coated sheath data, and 
bottom shows uncoated sheath. Data are presented as mean±SD. ‘Significantly different from pre P<0.05.
responsible are unlikely to be attributable to preserved endo­
thelial or vascular smooth muscle function. In addition, 
several recent articles have suggested that patients can de­
velop a granulomatous inflammation due to shedding of some 
of the hydrophilic coating into the artery.36-43 These findings, 
in combination with our data, support the suggestion of 
Tharmaratnam et al39 that the increased cost of the 
hydrophilic-coated sheaths, the cost of treatment of inflam­
mation, and the apparent lack of difference in spasm and 
depressed function need to be carefully balanced against the 
putative benefits of reduced spasm and pain on removal.
This study had a number of limitations. There were a 
relatively small number of patients in each group, and we could 
not get all to return at 3 months. This limitation is somewhat 
mitigated by our within-subject design and analysis. We did not 
control for age, preexisting vascular disease, history of smoking, 
or drug treatment; however, the use of the contralateral arm as an 
internal control negated this limitation, and our data set has the 
advantage of representing responses in typical unselected pa­
tients. Finally, sheath insertion increased baseline artery diame­
ter before our postprocedural measures of FMD and GTN. It has 
been suggested that baseline diameter is an important determi­
nant of the dilator response magnitude, at least between individ­
uals or between arteries, when large differences can exist in the 
resting diameter.44 However, the change in diameter we ob­
served is unlikely to explain the magnitude of impairment in
FMD. For example, on the basis of our recent article,44 an FMD 
difference of 0.2% to l.5% would be expected for a 0.3-mm 
change in baseline radial artery diameter. In addition, FMD data 
collected 3 months after catheterization (Table 3) remained 
impaired, despite return of the resting diameter to values below 
that observed before catheterization. Of course, the impact of 
baseline diameter change per se on FMD and GTN responses is 
not relevant to the issue of sheath coating because both types of 
sheath have similar effects on baseline artery diameter. Although 
our findings are clear and consistent, with a large number of 
tests, we cannot rule out the possibility of a type I error.
In conclusion, transradial catheterization results in revers­
ible depression in NO-mediated vasodilator function in the 
catheterized arm. This effect is not mitigated in patients who 
received a hydrophilic-coated sheath. The purported benefits 
of hydrophilic-sheath coating need to be weighed against the 
increased cost, possible increased risk of inflammation, and 
lack of reduction in arterial function. Future research and 
technological development should seek to minimize the 
effects of the catheter and the sheath on the vasculature. It is 
also possible that optimizing the function and size of the 
artery before its cannulation may improve the outcome and 
recovery of the artery and reduce the chance of graft failure if the 
artery is removed for coronary artery bypass.43 To this end, 
exercise training has been shown to improve arterial fiinction 
and induce outward remodeling,46-30 both of which might 
improve the health and recovery of the artery after the procedure.
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Table 3. Baseline Diameter, Time to Peak, and Shear Rate Area Under the Curve Preprocedure, the Day 
After the Procedure, and -3 Months After Procedure in the Catheterized and Noncatheterized Arms
Baseline Diameter, mm Time to Peak, s SRauc S-1X103
Pre Post Recov Pre Post Recov Pre Post Recov
FMD protocol
Cath
Coated 2.6±0.5 2.9±0.4 2.7 ±0.6 94 ±49 100±54 113±27 25.2±19.2 28.5±17.3 27.2±13.8
Uncoated 2.9±0.4 3.2±0.4 2.7±0.4t 109±46 86 ±44 90 ±56 31.7±17.9 20.6±14.0 33.2±23.8
Contr
Coated 2.6±0.5 2.4±0.4 2.6±0.5 67 ±50 66 ±25 81 ±45 17.2±8.6 24.8±10.9 32.5±22.3
Uncoated 2.6±0.4 2.9±0.4* 2.8±0.4t 87 ±24 103±68 89 ±48 23.0±7.1 27.3±15.7 26.8 ±16.9
GIN Protocol
Cath
Coated 2.7±0.5 2.9±0.5 2.5±0.3 316±110 372 ±63 343±100
Uncoated 3.0±0.5 3.2±0.2 2.7±0.3t 353 ±84 250±128 278±104t
Contr
Coated 2.7±0.2 2.9±0.5 2.8±0.3 323±148 303±103 293±131
Uncoated 2.9 ±0.3 2.9±0.3 3.1±0.4| 245±105 297±109 266±114f
Data are presented as mean±SD. Coated group, n=6 for FMD and GIN. Uncoated group, n=13 for FMD and n=12 for GIN. 
Endothelium-dependent (FMD) and endothelial-independent function (GIN) was assessed in both groups. Cath indicates catheterized 
arm; Contr, noncatheterized control arm; SRAUC, shear rate area under the curve.
•Significantly different from pre P<0.05. 
fSignificantly different from post.
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CLINICAL PERSPECTIVE
Since its introduction in 1989, transradial catheterization has gained popularity as an alternate approach for coronary 
diagnostic and interventional procedures. Recent advances in catheter sheaths include hydrophilic coatings, the aim of 
which is to reduce friction during sheath insertion and removal. The integrity of this artery is important because it might 
be harvested as a graft during coronary artery bypass surgery. Although there is evidence of reduced spasm with 
hydrophilic coating, there is no evidence regarding its impact on vascular function. Our study shows that vascular 
endothelial and smooth muscle function are reduced after radial artery sheath insertion. This effect is not mitigated by a 
hydrophilic-coated sheath. The potential benefits of hydrophilic-sheath coating need to be compared with increased cost, 
risk of inflammation, and reduction in endothelial function.
